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Summary 
Within the context of the establishment of a virosomal-based subunit malaria vaccine 
including synthetic peptides derived from Plasmodium falciparum antigens 
demonstrated that it is possible to improve immunogenic properties of synthetic 
peptides in a medicinal chemistry type optimization process. A close to natural 
conformation of peptides appears to be crucial for the induction of parasite-binding 
and inhibitory antibodies. In the case of a circumsporozoite protein (CSP) derived 
synthetic peptide we showed that this is achieved by conformational restriction of the 
peptide. In a phase Ia clinical trial of the virosomally formulated apical membrane 
antigen 1 (AMA-1) -derived 49 amino acid long phosphatidylethanolamin peptide 
conjugate AMA49-CPE, we measured both vaccine induced humoral and cellular 
responses. In 50% of the volunteers a peripheral blood mononuclear cells (PBMC) 
lymphoproliferative response specific for AMA49-CPE was elicited. Moreover, all 
volunteers who developed high titers of parasite cross-reactive IgG in 
immunofluorescence assay (IFA) and Western blot analysis, were positive in the anti-
synthetic peptide lymphoproliferation. No interference was found between the 
magnitude of the pre-existing influenza specific T cell response and the vaccination-
induced AMA49-CPE specific humoral and cellular immune response. We 
demonstrate that the virosomal antigen delivery platform combined with surface-
anchored synthetic peptides is suitable to elicit specific human CD4 T cell responses.  
 
Mycobacterium ulcerans infection (Buruli ulcer) is unique among mycobacteria in 
that much of the pathology and local immunosuppression appears to be mediated by 
the production of a cytopathic toxin called mycolactone. IFN-γ ELISpot was used to 
compare reactivity of PBMC of Buruli ulcer patients with complex antigens such as 
isopentenyl pyrophosphate (IPP), purified protein derivative (PPD) and influenza 
antigens prior to and after surgical treatment. The results demonstrated that M. 
ulcerans infection-associated systemic reduction in IFN-γ response is not confined to 
stimulation with mycobacterial antigens. Immunosuppression reversed after surgical 
treatment, indicating that this T cell anergy is not the consequence of a genetic defect 
but rather related to M. ulcerans infection. In the affected tissue we detected mRNA 
coding for innate immune system markers, even though the lack of inflammatory 
responses is a hallmark of Buruli ulcer disease. These were distributed within the 
Summary 
 
ii 
 
lesion in a very focal and heterogeneous way. IL-8, IL-6, and TNF-α mRNA was 
detectable by real time PCR in all lesions, whereas the expression of IFN-α, IL12p40, 
IL-10, and IFN-γ was only found in some lesions. Correlations of the distribution of 
mRNA encoding for the activation marker CD83 and the DC subset markers CD123 
and CD11c indicate that both activated plasmacytoid and myeloid DC were present in 
the lesions. These results suggest that adaptive M. ulcerans specific immune 
responses may develop once therapeutic interventions have limited the production of 
mycolactone.  
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Zusammenfassung 
Im Rahmen der Entwicklung eines auf der Virosomen-Technologie basierenden 
Malaria Subunit-Impfstoffes haben wir die immunogenen Eigenschaften von 
synthetisch hergestellten Peptiden in einem schrittweisen Optimierungsprozess 
systematisch verbessert. Dabei war es essentiell die 3-dimensionale Struktur der 
synthetischen Peptide der nativen Konformation des Zielantigens möglichst 
weitgehend anzunähern, um eine optimale Induktion von kreuzreaktiven und 
inhibitorischen Antikörpern zu erreichen. Im Falle der von Plasmodium falciparum 
Circumsporozoite Protein (CSP) abgeleiteten synthetischen Peptide UK39 und BP66, 
haben wir dies durch Restriktion der konformationellen Dynamik der Peptide erreicht. 
In einem klinische Phase Ia Versuch haben wir die zellulären Immunantwort 
virosomaler Formulierungen von UK39 und AMA49-CPE untersucht. Gegen das von 
Apical Membrane Antigen-1 (AMA-1) abgeleitete Peptid AMA49-CPE, nicht aber 
gegen UK39, zeigte die Hälfte der Probanden eine spezifische lymphoproliferative 
Antwort der peripheren mononukleären Zellen des Blutes (PBMC). Die Probanden, 
bei welchen hohe Titer von Parasiten-bindenden IgG-Antikörpern in 
Immunfluoreszenz-Anfärbung und Western Blotting gemessen wurden, wiesen auch 
eine positive zelluläre Immunantwort im Lymphoproliferations-Test auf. Die 
Intensität der bereits vorhandener Influenza-spezifischen T-Zell-Antworten hatte 
keinen Einfluss auf die Impfstoff-induzierten AMA49-CPE spezifischen humoralen 
und zelluläre Immunantworten. Mit unseren Ergebnissen haben wir aufzeigen können, 
dass die Virosomen-Technologie, kombiniert mit auf der Oberfläche verankerten 
synthetischen Peptid-Phospholipid Konjugaten, benutzt werden kann, um eine 
spezifische CD4 T-Zell Immunantwort auszulösen. 
 
Der von Mycobacterium ulcerans hervorgerufene Buruli Ulkus ist einzigartig unter 
den mykobakteriellen Infektionen, in dem ein vom Bakterium produziertes Toxin 
namens Mycolakton entscheidend an der Pathogenese und lokalen Immunsuppression 
beteiligt ist. Die IFN-γ ELISpot Technik wurde verwendet, um die Immunantworten 
von PBMC verschiedener Buruli Ulkus Patienten zu vergleichen, welche mit 
Isopentenyl-pyrophosphate (IPP), ‘Purified Protein Derivative’ (PPD) oder Influenza-
Antigenen stimuliert wurden. Unsere Ergebnisse mit PBMC, die vor oder nach 
chirurgischer Entfernung der Läsionen präpariert wurden, zeigten, dass eine mit der 
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Infektion einhergehende systemische Reduktion der IFN-γ Produktion nicht auf die 
Stimulation mit mycobakteriellen Antigenen beschränkt ist. Im erkrankten Gewebe 
haben wir mit real-time PCR mRNAs detektiert, welche für Marker des angeborenen 
Immunsystems kodieren, selbst wenn in Buruli Ulkus eine massive 
Entzündungsreaktion fehlt. Infiltrate scheinen in einer fokalen und heterogenen Weise 
innerhalb der Läsion verteilt zu sein. Während die mRNA von IL-8, IL-6, and TNF-α 
in allen untersuchten Läsionen detektierbar war, wurde IFN-α, IL12p40, IL-10 und 
IFN-γ nur in einigen Läsionen gefunden. Die positive Korrelation der Verteilung von 
mRNA des Aktivierungsmarkers CD83 und von Markern für verschiedene 
Untergruppen von dendritischen Zellen (CD123 und CD11c) weist auf die 
Anwesenheit von aktivierten plasmazytoiden und myeloiden dendritischen Zellen in 
den Läsionen hin. Unsere Ergebnisse lassen vermuten, dass eine Antwort des 
adaptiven Immunsystems in M. ulcerans Läsionen aufkommen kann, sobald 
therapeutische Interventionen die Produktion des Toxins Mykolakton beschränkt 
haben.  
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AA    Amino acid 
Ab    Antibody 
AFB    Acid fast bacilli 
Ag    Antigen 
APC    Antigen presenting cell/s 
APL    Altered peptide ligand/s 
BCG    Bacillus Calmette-Guérin 
BU    Buruli ulcer 
CCR    Chemokine (C-C motif) receptor 
CD    Cluster of Differentiation 
cDNA    Complementary Deoxyribonucleic acid 
Ci    Curie 
CpG    Cytosin phosphatidyl Guanosin 
cpm    Counts per minute 
CFSE    Carboxy-fluorescein diacetate, succinimidyl ester 
CTL    Cytotoxic T lymphocyte 
DC    Dendritic cell/s 
DNA    Deoxyribonucleic acid 
DNase    Deoxyribonuclease 
dNTP    deoxyribonucleoside triphosphate 
ELISA    Enzyme-linked immunosorbent assay 
ELISpot   Enzyme-linked immune spot assay 
FACS    Fluorescence activated cell scanning 
FCS    Fetal calf serum 
FITC    Fluorescin isothiocyanat 
HA    Hemagglutinin 
HAV    Hepatitis A virus/es 
HBSS    Hanks balanced salt solution 
HIV    Human immunodeficiency virus 
HLA    Human leukocyte antigen 
Ig    Immunoglobulin 
IL    Interleukin 
IFA    Immunofluorescence assay 
IFN    Interferon 
IPP    Isopentenyl pyrophosphate 
IRIV    Immunopotentiated reconstituted influenza virosome 
IS    Insertion Sequence 
mAb    Monoclonal Antibody  
M-DC    Myeloid dendritic cells 
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MHC    Mayor histocompatibility complex 
mRNA    Messenger ribonucleic acid 
MyD88   Myeloid differentiation primary response gene 88 
NA    Neuraminidase 
NF-κB    Nuclear factor kappa B 
NMR    Nuclear magnetic resonance 
NO    Nitric oxide 
NPNA    Asparagine-Proline-Asparagine-Alanine  
OD    Optical density 
ODN    Oligodeoxynucleotides 
PBC    Peripheral blood compartment  
PBMC    Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
P-DC    Plasmacytoid dendritic cells 
PE    Phosphatidylethanolamin 
PHA    Phytohemagglutinin 
PPD    Purified protein derivative 
RBC    Red blood cell/s 
SFU    Spot forming unit 
SI    Stimulation index 
spp.    Species 
TCR    T cell receptor 
Th    T helper cell 
TLR    Toll-like receptor 
TNF    Tumor necrosis factor 
TT    Tetanus toxoid 
WHO    World Health Organisation 
ZN    Ziehl-Neelsen staining 
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1.1 Host-pathogen interactions in chronic infectious diseases 
History shows that vaccines and successful treatments are most easily developed for 
those pathogens that induce natural, sterile immunity after a single infection [1]. 
Infectious agents can cause recurrent or persistent disease by avoiding normal host 
defense mechanisms or by subverting them to promote their own replication. Antigen 
variation, latency and suppression of immune effector mechanisms all contribute to 
persistent and medically important infections. Some pathogens use immune activation 
to spread the infection, and some others strongly activate the immune system which is 
in the end the actual cause of the disease. Each of these mechanisms has to be 
characterized and often requires a different medical approach to prevent or to treat the 
caused infection.  
Malaria remains one of the world’s greatest public health challenges. Although first 
visualized by Laveran more than 120 years ago, the parasite has resisted all efforts to 
control it. Today, an estimated 40% of the world’s population remains at risk of 
malaria, with 500 million of cases estimated annually, resulting in 1-2 million deaths, 
mostly young children [2]. Partial immunity against malaria develops only after 
several years of endemic exposure and for its maintenance repeated infections over 
the lifetime of the individual is required [3,4]. Immunity seems to be lost (or becomes 
less effective) when a previously immune person moves away from an endemic area 
[4,5]. Antigenic variation, high polymorphism and life stage specific antigen-
expression are considered important evasion mechanisms of Plasmodium falciparum 
parasite.  
Buruli ulcer is a disease of skin and soft tissue caused by an environmental pathogen, 
Mycobacterium ulcerans. It has been first described by Sir Robert Cook in 1897 in 
northeast Congo [6] and definitively characterized by MacCallum in 1948 in Australia 
[7].  In the last decade, the incidence in West African countries increased 
dramatically. In Southern Benin, a recent study has reported detection rates of 
21.5/100’000 per year, exceeding that of leprosy and tuberculosis [8]. Worldwide, it 
represents the third most common mycobacterial disease in immune-competent 
people, after tuberculosis and leprosy [9]. In Buruli ulcer affected people, spontaneous 
healing might occur in late stages after a chronic phase of variable length and relapse 
events can occur. The length of incubation time, the presence of dormant forms in 
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healthy people and the mechanisms by which the host may eventually overcomes 
immune suppression and develop a protective immune response are still open 
questions in Buruli ulcer infections. The toxin elaborated by M. ulcerans plays an 
important role in the development of Buruli ulcer disease, but other virulence factors 
may also contribute to the observed systemic immunosuppression in Buruli ulcer 
patients [10].  
Understanding immune responses to chronic infectious diseases like malaria and 
Buruli ulcer is crucial for the effective design and implementation of urgently needed 
vaccines, drugs and treatments. The present thesis is focusing on monitoring specific 
immune responses to malaria antigens, within the context of clinical malaria vaccine 
Phase Ia trial, and on the characterization of systemic and local immune status of 
Buruli ulcer patients. 
The objectives of this thesis are fully illustrated in Chapter 2.  
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1.2 Plasmodium falciparum malaria 
Malaria tropica is caused by P. falciparum and is responsible for about 90% of the 
malaria morbidity and mortality worldwide [3]. The pre-erythrocytic stage 
(sporozoite/liver) represents the body’s first encounter with the parasite and the 
erythrocytic stage is responsible for all symptoms and pathology of malaria. 
Exponential growth of parasites in the erythrocytes, modification of infected red cells 
in terms of parasite proteins expressed on the cell surface and the concomitant 
immune response to the parasite ultimately result in the disease manifestations of 
malaria. In recent years, the burden and mortality of the disease has increased 
substantially in malaria-endemic countries [11], and its transmission has spread to 
new areas [12]. The major causes are the development of resistance to drugs [13] and 
insecticides [14], the deterioration of national control programs, the increased human 
migration, and tourism [15-17]. 
 
Figure 1 Life cycle of Plasmodium falciparum. Stevenson et al., Nature Immunology, 2004 
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1.2.1 Natural Immunity 
Natural immunity to malaria is complex and varies with the levels of endemicity, 
genetic makeup, age of the host and parasite species. Generally in high endemic areas, 
maternal antibodies protect infants until 6 month of age. When this protection is lost 
infants become susceptible to severe forms of the disease with high mortality until 
about 3 years of age. The parasite is then controlled by the host, rather than eliminated 
or prevented: in clinically immune individuals asymptomatic re-infection, low-density 
parasitemia, and carriage of infective gametocytes continue [4,18]. The marked 
reduction in parasite density (104 to 106-fold lower than in naïve individuals [19]) and 
the decline in the prevalence and severity of symptoms are the indicators of valuable 
anti-parasitic and anti-disease effectors mechanisms by the human host. The natural 
immunity against malaria is still poorly understood but there is evidence that humoral 
as well as cellular mediated immunity are involved with a clear participation of the 
innate immunity. There is general agreement that antibodies, specific for the surface 
of parasitized erythrocytes and for the free merozoites (asexual blood-stages), are 
largely responsible for the semi-immune status providing direct protection against the 
pathological consequences of blood-stage re-infection [20-22]. Unfortunately the 
majority of the elicited antibodies do not recognize a common epitope found on all 
infected red blood cells, but mainly epitopes that are strain specific [23,24] requiring 
multiple infections to acquire immunity. The natural immunity against the sporozoites 
and liver stage (pre-erythrocytic stages) is comparatively more limited and does not 
appear to markedly hinder development of parasites in blood stages [5]. A lower 
prevalence of antibodies to liver stage antigen-1 (LSA-1) and circumsporozoite 
protein (CSP) than to blood-stage associated antigens (apical membrane antigen-1, 
AMA-1 and merozoite surface protein-2, MSP-2) has been reported [25,26]. The level 
of immunity to gametocytes and gamete antigens is variable and transmission-
blocking antibodies are present in only a minority of sera from immune adults [27-
29]. Hence, clinically immune adults provide a reservoir of infection for mosquitoes 
and consequently for transmission of malaria within the population. The investigation 
of immune mechanisms and pathogenesis of malaria is supported by the work with 
rodent Plasmodium species (spp.): P. chabaudi, P. berghei, P. yoelii and P. vinckei 
[30,31]. However, it has to be mentioned that no single rodent model replicates all of 
the features of human malaria infections [31]. Based on ongoing animal studies, 
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Figure 2 illustrates a possible regulation of adaptive immunity to blood-stage malaria 
by cytokines produced by the innate immune system.  
In humans, low levels of plasma IL-12 [32-34] and IL-18 [35] are associated with 
severe malaria pathology. Prospective epidemiological studies suggest that IL-12 
production is inversely associated with risk of infection and positively associated with 
hemoglobin concentration, IFN-γ and TNF-α production [36]. Recently studies 
propose possible mechanisms of dendritic cells (DC) regulation in malaria disease. 
Purified P. falciparum hemozoin, the insoluble residue of hemoglobin that 
accumulates in phagocytes, activate mice bone marrow DC through TLR9: TLR9-/- 
and MyD88-/- mice or DC, but not TLR2-4-/- or TLR7-/- showed an impaired 
production of cytokines and chemokines after hemozoin stimulation [37]. On the 
other hand, in vitro studies show that parasite infected erythrocytes bind to CD36 
expressed on human DC activating the release IL-12 and IL-18 [38]. The exact 
relevance of these mechanisms for P. falciparum host immunomodulation is debated 
[38,39]. Summarizing, naturally acquired immunity to malaria is not sterile and 
appears largely due to the acquisition of mechanisms to control blood-stages, 
allowing co-existence of host and pathogen. Survival and immune-evasion 
mechanisms of the parasite, requirement of frequent parasite-exposure by the host to 
maintain a good semi-immune status (pre-munition) and lack of long lasting memory 
are sentinels of non-sterile immunity. In which extent these problems are malaria-
specific rather than generic (i.e. result from inherent limitations of the vertebrate 
immune system) is not yet clear [4]. Previously immune adults revisiting endemic 
areas are at risk of developing symptomatic malaria. However, case fatality rates are 
significantly higher among non-immune travelers [40-42]. These observations suggest 
that a limited memory against malaria is present, but somehow incomplete. The 
development and maintenance of malaria specific memory are still open questions. 
Some experiments in mice models point out that malaria parasites can to some extent 
modulate memory T and B cells: newly P. berghei infected mice can selectively 
delete by apoptosis adoptive transferred CD4 T cells specific for the parasite [43]. 
Vaccines usually induce sterilizing or complete transmission-blocking immunity by 
means of antibody and T cell responses to one or a few antigens. For malaria, the 
absence of such immunity in the vast majority of exposed individuals suggest that for 
an effective vaccine the response should be of greater magnitude, duration and strain-
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transcendence than in naturally acquired immunity. An alternative, ambitious, long-
term approach is to use a cocktail of many antigens to elicit a better focused and more 
effective response [22,44].  
 
Figure 2 Link between innate and adaptive immunity to blood-stage malaria based on 
mice models. In response to parasite ligands, DC mature and migrate to the spleen. Released 
IL-12 activate the production of IFN-γ by natural killer cells (NK) and induce the 
differentiation of T helper (Th) 1 cells and further maturation of DC. These processes 
facilitate the clonal expansion of CD4 T cells and activation of macrophages, allowing the 
amplification of the adaptive immune response. [nitric oxide (NO)]. Stevenson et al., Nature 
Immunology, 2004 
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1.2.2 Vaccine development 
The concept for the development of a malaria vaccine arose in 1967 from 
experimental immunization studies with irradiated sporozoites in mice [45]. In 1975, 
human volunteers immunized with irradiated attenuated P. falciparum sporozoites 
developed a short term protective immune response against subsequent malaria 
infections [46-48]. The cloning of the first Plasmodium spp. antigen in 1983 and the 
publication of the complete P. falciparum genome in 2002 further encouraged the 
malaria vaccine research [49]. However, the vaccine still appears to be a long way off, 
scientific community estimate that its development will take not less than 10 years 
[21,50]. Nowadays malaria drug development is the research priority and vaccine 
development is one aspect of efforts to control the disease. However, an effective 
vaccine still represents the most cost-effective way to protect humans against 
infectious diseases. There are three intermediate goals of malaria vaccine research: (i) 
induction of strong, strain transcending, durable immune responses; (ii) identification 
of protective antigens for stage specific immunity, and (iii) successful combination of 
immunogenic candidates [22]. Meanwhile, the WHO Roll Back Malaria program is 
coordinating other strategies to control the disease: improved case management; 
promote insecticide-treated bed-nets to reduce malaria mortality [51]. 
1.2.2.1 Hurdles 
Many immunodominant malaria antigens contain highly polymorphic regions (AMA-
1, MSP-1, MSP-2) [52-58]. Furthermore, some P. falciparum antigens present 
irrelevant but immunodominant epitopes, which induce non-protective immune 
response of the host. On the other hand, some potentially protective conserved target 
epitopes/antigens appear to be cryptic and are consequently not able to induce 
effective immunity following natural malaria exposure [21]. These mechanisms have 
to be considered by the design of good vaccine candidates [21,59]. Infants and very 
young children represent the principal target of a malaria vaccine, many of them will 
carry maternal antibodies specific for the parasite. These antibodies may be important 
in providing protection against malaria [60,61], but it is well documented that the 
presence of specific maternally derived antibodies at the time of immunization may 
interfere with the development of the infant’s own active immune response by 
blocking access to critical B cell epitopes [62,63]. Delayed immunization, until levels 
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of maternally antibodies decrease, or the use of alternate epitopes for infant vaccines 
are proposed solutions [63]. On the other hand the adult population receiving the 
vaccine is already infected, therefore there may be a boost of preexisting memory T 
and B cells. In this respect the potential ability of the malaria parasite to modulate 
host memory immune responses has to be considered and further investigated. Some 
studies in mice show that new malaria infections can lead to anergy and deletion of 
parasite pre-existing memory CD4 T cells [43]. Anergy can be the consequence of the 
presentation of closely related peptide variants which provide altered activation 
signals to the T cell, resulting in the inactivation of some of its effector functions [64]. 
In malaria, down-regulation of T cell responses by epitope variants that vary in only 
one or few amino acid (AA), so called altered peptide ligands (APL), has been 
classically described for T cell clones expressing a specific T cell receptor structure 
[65-69]. In this respect, allelic polymorphism of P. falciparum antigens has probably 
evolutionary been maintained because of a parasite survival advantage of cohabiting 
allelic types [70]. Studies with the CSP, show that simultaneous stimulation with 
certain naturally occurring T cell epitope variants turns off effector T cell immunity, 
resulting in enhanced parasite survival [67]. Allelic MSP-1 epitopes with low T cell 
reactivity to dominant alleles have the capacity to turn off polyclonal T cell responses 
in both naïve and malaria exposed individuals [71]. The consequence of allelic 
interference with T cell priming is the induction of a state of partial activation of CD4 
T cells independently described with both anergic and suppressor cell functions. The 
lack of priming of fully functional CD45RO memory T cells from naïve precursors is 
likely to lead to ‘holes’ in the effector T cell repertoire [70,72]. Depletion of 
CD4+CD25+ regulatory T cells has been shown to protect mice from death when 
infected with a lethal strain of P.  yoelii [73]. 
1.2.2.2  Strategies 
An anti malaria vaccine could act at different stages of the parasite life cycle and 
infectious mechanisms: (i) block sporozoites from invading or developing within 
hepatocytes (pre-erythrocytic anti-infection vaccine) [74-76]; (ii) prevent the 
merozoite invasion of red blood cells or inhibit development of schizonts (anti-disease 
vaccine) [77,78]; (iii) obstruct the pathology inducing effects of cytokines, parasite 
sequestration and parasite toxin release (disease-modifying vaccine) [79]; (iv) block 
human-mosquito transmission by immunization against the sexual stages of the 
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parasite (transmission-blocking vaccine) [80,81]. The design of a malaria-vaccine 
ranges from a subunit to a whole parasite approach. The traditional whole-organism 
approach was considered till now the most protective but also least achievable, due to 
cost and safety problems. However some recent works and projects awaked the 
interest for this approach. Hoffman has raised the ambitious project to produce a 
vaccine with irradiated sporozoites dissected out from infected mosquitoes by keeping 
the production costs as low as possible [82]. Furthermore, results obtained with mice 
immunized with genetically modified P. berghei sporozoites, that do not develop 
beyond the liver stage, showed good challenge protection [83]. Concerning the 
asexual blood stages experiments with naïve volunteers infected with an ultra-low 
dose of malaria parasites (thirty P. falciparum-infected red blood cells, RBC) showed 
a good humoral and cellular immune response [84]. Mice vaccinated with crude 
preparation of parasitized red blood cells combined with the adjuvant IL-12 or CpG 
were protected against P. chabaudi challenge [85].  
Most malaria vaccine projects are focused on subunit vaccine technologies. The 
combination of conserved epitopes representing the different stages of the parasite life 
cycle [78], should diminish the impact of antigen polymorphism. An appropriate 
adjuvant as well as cost problems of producing a multi-component vaccine are 
important obstacles for this approach. In this respect the use of DNA vaccines [86-
89], or more effective adjuvants, like the virosomal delivery systems and, the 
application of CpG and IL-12 as immunostimulators are approaches under assessment 
[85,90-93].  
1.2.2.3 Synthetic peptides 
The advantages of synthetic peptides over conventional protein-based vaccines 
include, ease of handling and storage due to their higher stability, ease of synthesis 
and avoidance of problems associated with materials produced in cells. A further 
appeal is that the ideal subunit vaccine will induce immune responses only against 
determinants relevant for protection, thus minimizing the possibility of deleterious 
responses. Within the context of a malaria multi-component, multi-stage vaccine the 
criteria for epitope selection include sequence conservation, known induction of 
parasite inhibitory antibodies and identified secondary structure motifs indicating 
surface exposition. Based on these criteria in our malaria vaccine project a series of 
peptides vaccine candidates were developed, including CSP, MSP-1 and AMA-1 
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derived peptides. Starting from a lead structure, the peptide sequences and/or 
conformations were optimized in cycles and only the peptides with satisfactory 
immunological properties were selected for final preclinical profiling and clinical 
testing. In the case of CSP and MSP-1 derived peptides conformational restriction of 
the peptide was crucial for the induction of parasite-binding antibodies in mice 
[91,93]. Only correctly folded MSP-1 peptides with all three disulfide bonds in place 
induced parasite-binding antibodies but not peptides with blocked cysteins [94]. For 
the development of conformationally restricted synthetic peptide, parallel 3D 
structural studies were crucial [93,95,96]. In contrast, the AMA-1 derived peptide 
AMA49-C1 (loop I of AMA-1 domain III) seemed to have enough internal driving 
force to adopt a conformation suitable to elicit parasite cross-reactive antibodies 
recognizing a discontinuous epitopes. Indeed, the cyclized and the linear forms of this 
peptide had comparable immunogenic properties [83]. AMA-1 is an example of an 
antigen, where induction of parasite inhibitory antibodies has been reported without a 
detailed characterization and localization of the epitope. In such cases peptide 
libraries covering the whole protein sequence can help selecting an epitope inducing 
inhibitory antibodies. These examples underline the importance of a detailed 
preclinical profiling and optimization of every candidate antigen for inclusion into a 
malaria vaccine. Synthetic peptide chemistry strongly facilitates a medicinal 
chemistry approach for vaccine design, allowing rational stepwise peptide 
optimization based on structure-activity observations. 
1.2.2.4 Virosomal antigen delivery technology 
Peptide-based vaccines require efficacious and safe vaccine adjuvants. The virosomal 
technology is one of the approaches currently under evaluation. Immunopotentiating 
reconstituted influenza virosomes (IRIVs) are prepared by the detergent removal of 
influenza glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which are 
subsequently combined with natural and synthetic phospholipids. The resulting IRIVs 
are spherical, unilamellar vesicles with a mean diameter of approximately 150 nm 
[97-99]. The influenza HA plays a key role in the mode of action of the IRIVs. The 
HA globular head subunit (HA1) contain sialic acid site for HA and it is therefore 
assumed that the IRIVs bind to such receptors of antigen presenting cells (e.g. 
macrophages, DC, lymphocytes) initiating a successful immune response (adjuvant, 
immunepotentiator effect). The entry of influenza viruses into cells occurs through 
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receptor mediated endocytosis [100]. The HA2 subunit mediates the fusion of viral 
and endosomal membranes, which is required to initiate “infection” of cells. It is 
expected that this mediates the rapid release of the transported antigen into the 
membranes of the target cells [99,101]. There are currently two vaccines on the 
market exploiting, the IRIV delivery system: Hepatitis A (Epaxal) and Influenza 
(Inflexal V) vaccines. Epaxal was licensed for human use in 1996. It contains 
formalin-inactivated and highly purified hepatitis A viruses (HAV) coupled to IRIV 
vesicles. 10 days after immunization 100% of seroconversion was measured [102] 
and the adverse effect are less than for the conventional, alum adsorbed, forms of 
vaccination [103]. The superior immunogenic and protective abilities of IRIVs in 
terms of antibodies titers were evidenced also by comparing alum and IRIV 
formulation of diphteria and tetanus toxoids [104]. The suitability of virosomes for a 
multi-epitope malaria peptide vaccine approach was shown in mice, which developed 
antibodies cross-reactive with the parasite [83,90,91,93].  
  A     B 
  
Figure 3 Representation of IRIV mode of action; A with antigen presented on surface, B 
with encapsuled antigen. Westerfeld and Zurbriggen, Journal of Peptide Science, 2005  
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1.3 Mycobacterium ulcerans infection (Buruli ulcer) 
Buruli ulcer, caused by an environmental pathogen M. ulcerans, is a chronic 
ulcerative disease of skin and soft tissue with the potential to leave massive scarring 
and deformities. The main burden of disease falls on children living in Sub-Saharan 
Africa but healthy people of all ages, races and socioeconomic classes are susceptible. 
M. ulcerans is the third most important mycobacterial pathogen in immuno-competent 
people, after M. tuberculosis and M. leprae [9]. The slowly growing M. ulcerans, with 
an in vitro generation time of 20 hours [105] belongs to a group of mycobacteria that 
are potentially pathogenic for humans and animals. These are sometimes called 
“occasional pathogens” to distinguish them from strict pathogens. Most species 
belonging to this group are widespread in the environment and may become 
pathogenic under specific circumstances [106]. Changes in the environment, such as 
the construction of irrigation systems and dams, seem to have played a role in the 
resurgence of Buruli ulcer disease [107]. The exact mode of transmission to humans is 
still unclear, skin trauma or the bite of an infected water insect might be involved. 
Specific M. ulcerans DNA can be detected by PCR in some aquatic insects, as well as 
in aquatic snails, small fish, and the biofilm of aquatic plants [108,109]. M. ulcerans 
is found extracellularly in established Buruli ulcer lesions [110]. Recent studies 
showed that it proceeds through an initial phase where bacilli are internalized by 
phagocytic cells [111]. The transition to the extracellular phase occurs probably by 
the action of released toxins. M. ulcerans is unique among mycobacteria in that much 
of the pathology appears to be mediated by production of toxic macrolides that are 
required for virulence [110]. 
Figure 4 Countries reporting Buruli ulcer. Johnson et al., PLoS Med., 2005 
High endemic area
Low endemic area
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1.3.1 M. ulcerans toxins and mycolactone 
The pathogenesis of M. ulcerans and its extra-cellular localization are closely 
associated with the expression of plasmid-encoded enzymes that are involved in the 
synthesis of mycolactones. In 1965 Connor hypothesized the presence of toxins in 
early Buruli ulcer lesions: histopathological results evidenced that the necroses were 
more extended than the bacterial burden [112]. In 1999 this hypothesis was confirmed 
by the isolation of a macrolide toxin from bacteria culture filtrates called mycolactone 
(Figure 5). The name combines its mycobacterial source and chemical structure. 
Possibly other toxins, e.g. phospholipase C also play a role in the pathology of M. 
ulcerans [113]. The culture-isolated mycolactone has immunosuppressive and 
cytotoxic effects in vitro, inhibition of cytokine production and NF-κB function has 
been observed in human monocytes cultures [114]. When injected into healthy guinea 
pigs, histopathological changes comparable to Buruli ulcer lesions were induced 
[115]. Comparison of animal models infected with mycolactone producing and 
mycolactone negative M. ulcerans strains suggests that inflammatory cells are rapidly 
killed by necrosis when they encounter high concentrations of the toxin. Inflammatory 
cells more distant from the necrotic centre are killed via apoptosis [114]. Until now, 
no cell receptor has been found to explain the cascade of effects induced by 
mycolactone [116]. In contrast, in animals experimentally infected with mycolactone-
negative mutants, granulomatous lesions with strong self-healing tendencies are 
observed. Additionally, mycolactone negative mutants fail to colonize the salivary 
glands of water insects, suggesting that this molecule may also play a role in the 
ability of M. ulcerans to colonize potential reservoir species [110,117]. 
 
 
Figure 5 Mycolactone core structure: 12-membered ring to which two polyketide-derived 
side chains (R1 and R2) are attached. George et al., Science, 1999 
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1.3.2 Clinical presentation and histopathology 
A painless papule or firm nodule indicates the first stage of Buruli ulcer (Figure 6a-b). 
A papule is defined as a painless, raised skin lesion surrounded by reddened skin 
(Figure 6b). The nodule is characterized as an extended lesion from the skin into the 
subcutaneous tissue. Occasionally, some patients develop extensive indurate lesions 
or plaques that present irregular edges (Figure 6c). These first stages of the disease are 
characterized by coagulative necrosis of the lower dermis and subcutaneous fat. The 
bacteria are present in clumps or in smaller microcolonies in the centre of the lesion 
and there is little or no evidence of an inflammatory response or the development of 
granuloma formation [118]. In the second stage, ulceration takes place at the base of 
the small origin ulcer, which displays a white cotton wool-like appearance in the 
necrotic slough (Figure 6d). Many acid fast bacilli (AFB) are present in the slough, 
and the necrosis can extent away from the site where M. ulcerans is located (Figure 
6e). As the disease progresses all elements of the skin are affected including nerves 
and blood vessels. At this stage granulomas containing epithelioid macrophages and 
Langerhans giant cells may be seen [118]. The host may somehow overcome the 
immunosuppressive effects of the toxin, usually only after extended periods of 
progressing ulceration, and a healing process can start (Figure 6f).  This process may 
delay or never take place with consequent heavy complications for the host, including 
affection of the bone (osteomyelitis), the loss of organs such as the eye and breast, the 
amputation of limbs or other permanent disabilities [119,120]. 
Figure 6 Clinical forms of Buruli ulcer. a: nodule, b: papule, c: plaque, d: early ulcer, e: late 
ulcer, f: crippling deformity after self healing. Asiedu et al., WHO 2000; Portaels et al., WHO 
2001 
a cb
d e f
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1.3.3 Diagnosis and treatment 
Early treatment of M. ulcerans disease provides a better outcome than extensive 
surgical treatment of the ulcerative forms. In a known endemic area, an experienced 
person can diagnose an advanced M. ulcerans infection on clinical grounds: painless 
ulcer with undermined edges and a necrotic slough, no clinically detectable 
lymphadenitis and no systemic symptoms such a fever or malaise suggesting 
staphylococcal or streptococcal infection. Since, in particular, early and healing 
lesions may be confused with other skin diseases, laboratory confirmation of 
clinically diagnosed cases is desirable. The commonly used diagnostic laboratory tests 
are: (i) detection of mycobacteria by Ziehl-Nielsen (ZN) staining, a technique that 
lacks sensitivity and specificity, (ii) culture of M. ulcerans, which may take several 
months, (iii) detection of characteristic histopathological changes in excised tissue 
and (iv) detection of M. ulcerans DNA by PCR. PCR represents a rapid and sensitive 
diagnostic method but requires advanced technical expertise and high laboratory 
standards that are not always available in developing countries. While swabs can be 
taken to test the undefined edges of ulcerative lesions, it is much more problematic to 
take punch biopsies from pre-ulcerative lesions, since this technique may promote the 
spread of the mycobacteria. The WHO global Buruli ulcer initiative has asked the 
research community to develop a simple rapid diagnostic test in order to improve the 
detection rate of Buruli ulcer patients and to implement preventive therapy and early 
treatments [121]. Traditionally, the mainstay of treatment has been surgical excision 
of early lesions. Unfortunately many patients do not present until there is extensive 
and disfiguring ulceration, when there is no alternative but wide excision followed by 
skin-grafting, and sometimes even amputation [122]. Currently it is not clear how 
extensive surgeries should be performed and it is largely left to the individual 
judgment of the surgeon to find the right balance between an oversized excision and 
an incomplete removal of pathogen, thus increasing the risk of recurrence [123]. 
Relapse after surgery may occur in 15-47% of the cases [8,124]. For a long time, 
treatment of M. ulcerans infections with antimycobacterial agents has generally been 
disappointing, probably partly due to the suboptimal penetration of drugs to the 
necrotic lesions. In vitro, the bacteria are susceptible to several antimycobacterial 
drugs. The most promising combination in the mouse footpad model is rifampicin 
with amikacin [125]. A human trial has recently shown that early nodular lesions may 
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be rendered culture negative after a minimum of 4 weeks therapy with rifampicin plus 
streptomycin [126]. These results have encouraged WHO to recommend the use of 
this antibiotic combination to support surgical treatment [127].  
1.3.4 Immune response 
The mechanism of immune protection in M. ulcerans remains unclear. The 
predominant pattern in the pathology of this bacterial disease is that in early, pre-
ulcerative and ulcerative lesions, large numbers of extra-cellular mycobacteria are 
seen, with extensive necrosis and very little inflammatory response, and no granuloma 
formation. In surgical specimens of later stages during healing, bacilli are scanty or 
even absent usually accompanied by granuloma formation [7,128,129]. Several 
research groups, using different models, have observed that in early stages of the 
disease, specific immune protection seems to be lost. Almost 30 years ago, studies of 
the delayed hypersensitivity response in patients with Buruli ulcer after intradermal 
injection of a crude preparation of M. ulcerans sonicate (burulin) showed that patients 
with early M. ulcerans disease do not react, whereas a positive response is found in 
most patients with healing lesions, who were initially non-reactive, indicating a 
degree of T cell sensitization [130]. Burulin has not been prepared to the standard 
required for in vivo work with human beings since that time.  
Evidence from genetic defects in the IFN-γ signaling pathway supports the role of 
IFN-γ in protection against a range of non-tuberculous mycobacterial disease, 
including M. ulcerans [131]. Many healthy individuals in Buruli ulcer-endemic areas 
show specific immune responses to M. ulcerans [132,133], suggesting that, in analogy 
with leprosy and tuberculosis, the disease develops only in a limited proportion of 
those infected [134]. Gooding et al. describe the case of an unaffected household 
contact, the mother of an infected child with Buruli ulcer disease, which during the 
study developed an ulcerative M. ulcerans disease. A resulting shift from Th1 to Th2 
cytokines production was monitored by stimulating peripheral blood mononuclear 
cells (PBMC) with M. ulcerans [135,136]. Further evidence that a cellular immune 
response may protect individuals with Buruli ulcer is provided by a case reports that 
describes aggressive, disseminated M. ulcerans disease in patients co-infected with 
HIV [137]. However, unlike tuberculosis, the emergence of Buruli ulcer has not been 
linked with co-infection by the human immunodeficiency virus [138]. Host 
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susceptibility factors need to be explored to understand mechanisms explaining the 
development of BU once individuals have been infected with M. ulcerans [138-140]. 
In vitro immune analysis have confirmed the notion of a systemic T cell anergy in 
Buruli ulcer affected people: PBMC from patients showed significantly reduced 
lymphoproliferation and IFN-γ production in response to stimulation with M. bovis, 
Bacillus Calmette-Guérin (BCG) or M. ulcerans, and a Th2 type (IL-4, IL-5) cytokine 
mRNA pattern was present [135,141] suggesting Th2 mediated Th1 down-regulation. 
Prevot et al., tried to link systemic and local immune responses. By semi-quantitative 
PCR analysis he suggests that the systemic Th1 down modulation is mirrored by 
local, intralesional cytokine profiles. High IFN-γ with low IL-10 mRNA levels were 
present in early, nodular lesions and low IFN-γ mRNA levels were detected in late 
ulcerative lesions [142]. Hence, in active M. ulcerans disease, the Th1 response seems 
to be down-regulated both locally and systemically. A mouse model has been used to 
analyze the primary immune response against M. ulcerans [139]: histopathological 
analysis of the lesions induced by the infection showed comparable necrosis and 
changes in vasculature and collagen degeneration as in the patients. In the model an 
initial phase, where bacilli are internalized by macorphages was observed. This 
complies with most mycobacterial species. The transition to an extracellular phase is 
probably owing to the presence of mycolactone, which induces host cell death within 
days of infection in vitro. Several lines of evidence suggest that this transient 
intracellular step may contribute to the successful establishment of a chronic 
extracellular infection [111,143]. There is no specific vaccine against M. ulcerans 
infection, but M. bovis BCG offers some protection, albeit short lived [143,144]. 
Current prospects for better vaccines include improved BCG vaccination, 
development of a live vaccine based on an attenuated M. ulcerans isolate, and subunit 
vaccines aimed at immunodominant protein antigens or the toxin itself [145,146]. 
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Goals of the thesis 
 
 
2.1 Plasmodium falciparum malaria 
The underlying challenge of developing an effective malaria vaccine is that natural 
immunity to malaria is slow to develop, unstable and not complete even after years of 
endemic parasite exposure. Today, vaccine development against P. falciparum and 
other infectious diseases is focusing largely on subunit vaccines technology. A 
delivery system highly suitable for subunit vaccines is based on immuno-potentiating 
reconstituted influenza virosomes (IRIVs). The aim of the project was to prove that 
IRIVs are an appropriate delivery system for synthetic peptides hooked to the 
virosomal surface via a phospholipid anchor. In particular we wanted to demonstrate 
that peptide-specific T cell responses can be induced by virosomal formulations. 
 
Specific objectives 
1. To optimize the structure of an IRIV-anchored synthetic peptide eliciting P. 
falciparum sporozoite inhibitory antibodies   
2. To demonstrate that malaria peptide specific CD4 T cell responses can be 
generated by virosomally-anchored synthetic peptides 
3. To evaluate whether the magnitude of a pre-existing influenza specific T cell 
response affects the immune response elicites by virosomally formulated 
malaria peptides 
4. To characterize TLR9 of Aotus nancymaae as a potential model to evaluate 
TLR9 ligands as immunostimulator components for a malaria subunit vaccine 
formulation 
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2.2 Mycobacterium ulcerans infection (Buruli ulcer) 
 
A better understanding of the immunopathology of M. ulcerans disease in the human 
and of the immunomodulatory mechanisms of the bacterium may help to improve 
treatment modalities and to support the development of a vaccine and of new 
laboratory diagnostic methods. 
 
Specific objectives 
5. To study the extent of systemic immunosuppression in Buruli ulcer and to 
monitor recovery of the immunoresponsiveness after surgical treatment  
6. To analyze whether elements of the adaptive and non-adaptive immune system 
are locally present in active Buruli ulcer lesions 
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Summary 
The circumsporozoite protein (CSP) of Plasmodium falciparum is a leading candidate 
antigen for inclusion in a malaria subunit vaccine. We describe here the design of a 
conformationally constrained synthetic peptide, designated UK39, which has 
structural and antigenic similarity to the NPNA-repeat region of native CSP. NMR 
studies on the antigen support the presence of helical turn-like structures within 
consecutive NPNA motifs in aqueous solution. Intramuscular delivery of UK39 to 
mice and rabbits on the surface of immunopotentiating reconstituted influenza virus-
like particles (IRIV) elicited high titers of sporozoite cross-reactive antibodies. 
Influenza virus proteins were crucially important for the immunostimulatory activity 
of the IRIV-based antigen delivery system, since a liposomal formulation of UK39 
was not immunogenic. IgG antibodies elicited by UK39 loaded virosomes inhibited 
invasion of hepatocytes by P. falciparum sporozoites, but not by antigenically distinct 
P. yoelii sporozoites. This approach to optimized IRIV-formulated synthetic peptide 
vaccines should be generally applicable and amenable for other infectious and non-
infectious diseases. 
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Introduction 
Malaria is the most important parasitic disease in people and may cause as many as 
2.5 million deaths per annum [1]. Vaccine development against both Plasmodium 
falciparum and P. vivax is ongoing [2] and one candidate vaccine, RTS,S/AS02A 
demonstrated 30% protection against the first episode of malaria and 58% protection 
against severe malaria in a clinical trial in Mozambican children [3]. Nevertheless, it 
is assumed that it will take at least another decade until a malaria vaccine will be 
available that is more effective and more cost effective than current malaria control 
tools, such as insecticide treated bed nets and intermittent preventive treatment in 
infants [4-6]. 
Apart from plans to develop a radiation-attenuated sporozoite vaccine [7], vaccine 
development against malaria is focusing largely on subunit vaccine technologies [8]. 
It is thought that an effective malaria subunit vaccine will have to incorporate 
antigens against several developmental stages of the parasite. A combination of 
actions against sporozoites, infected liver cells, merozoites and infected red blood 
cells may be required to achieve substantial protective activity [8]. The fact that most 
vaccines currently available are based on attenuated or inactivated whole pathogens or 
material derived directly from them demonstrates that the technological problems 
associated with peptide and protein subunit vaccine design are still incompletely 
solved. Major obstacles include difficulties to retain the native conformation of key 
antibody epitopes and the need for an effective but safe human-compatible exogenous 
adjuvant in order to achieve efficient immune responses [9]. 
We are addressing the problem of protein subunit vaccine design by developing 
synthetic peptide structures that elicit antibodies against surface epitopes of native 
malaria antigens [10-12], and coupling them to the surface of immunopotentiating 
reconstituted influenza virosomes (IRIVs) as a liposomal carrier system [12, 13]. 
IRIVs are spherical, unilammelar vesicles, prepared by detergent removal from a 
mixture of natural and synthetic phospholipids and influenza surface glycoproteins. 
The hemagglutinin membrane glycoprotein of the influenza virus is a fusion-inducing 
component, which facilitates antigen delivery to immunocompetent cells. IRIVs 
represent a universal antigen-delivery system for multi-component subunit vaccines, 
since antigens can be either attached to their surface to elicit antibody responses or 
Chapter 3.1 
 
 
38 
 
encapsulated in their lumen to elicit CD8 T cell responses. They have an excellent 
safety profile and are already registered for human use [14]. 
Sequential rounds of optimization of synthetic peptide structures, as typically applied 
in drug research, may ideally lead to vaccine candidate antigens, which elicit 
primarily or exclusively antibodies that contribute to immune protection. In the case 
of the central repeat region (NPNA)≈37 of the circumsporozoite protein (CSP) of P. 
falciparum sporozoites, results of clinical trials with a linear (NANP)3 peptide 
conjugated to tetanus toxin in alum [15, 16] were disappointing. We have previously 
described the synthesis and immunological properties of template-bound NPNA 
peptides, which were superior to their linear counterparts in eliciting sporozoite-
binding antibodies [10-12]. Building on NMR and modeling studies we designed and 
synthesized an improved cyclic NPNA-repeat region peptide (designated BP65), 
which has been shown to efficiently elicit anti-sporozoite antibody responses in mice 
[11]. Here we describe functional properties of monoclonal antibodies (mAbs) elicited 
by BP65, and the properties and preclinical profiling of a synthetically more 
accessible derivative (UK39). An IRIV-based formulation of this peptide, designated 
PEV302, is currently being tested in human clinical trials. 
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Results 
Sporozoite-inhibitory activity of anti-BP65 mAbs 
Two mAbs (designated EP3 and EP9) specific for the synthetic compound BP65 
(Figure 1) were generated from spleen cells of mice immunized with BP65-loaded 
IRIVs. Both mAbs bind to sporozoites in IFA, and functional inhibitory activity was 
assessed by performing in vitro invasion inhibition assays with P. falciparum 
sporozoites and primary human hepatocytes. At a concentration of 200 µg/ml mAb 
EP3 caused 82% and mAb EP9 100% invasion inhibition (Figure 2A). The inhibitory 
activity decreased in a dose dependent manner, when increasing concentrations of 
BP66 were added to the antibody-parasite mixture (Figure 2B) confirming the 
specificity of the inhibitory activity of the mAbs. 
 
Design of UK40 and its phosphatidylethanolamine (PE)-conjugate UK39 
In an attempt to minimize the size of the synthetic vaccine antigen, a derivative of 
BP65, called BP-125, without the C-terminal PNA  and N-terminal NPNA portions 
was produced and tested for reactivity with the sporozoite-inhibitory anti-BP65 mAbs 
EP3 and EP9. Only a strongly diminished reactivity was observed (Figure S1), 
indicating that BP65 represents the minimal essential structure. 
In BP65 the folded conformation of the peptide is stabilized by cross-linking an 
amino group at the ß-position of Pro6 to a spatially adjacent side chain carboxyl of 
Glu as a replacement for Ala16 [11]. Since limited availability of orthogonally 
protected (2S,3R)-3-aminoproline required for the synthesis of BP65 represented an 
obstacle for up-scaling of the synthesis for clinical grade material, we synthesized 
derivatives of BP65 designated UK40 and UK39 (PE- conjugate of UK40), in which 
this building block is replaced by (2S,4S)-4-aminoproline (Figure 1). The required 
orthogonally protected N( )-Fmoc(2S,4S)-4-(Boc)aminoproline ((2S,4S)-Boc-4-
amino-1-Fmoc-pyrrolidine-2-carboxylic acid) is commercially available. 
 
NMR studies of UK40 
The solution structure of UK40 was investigated in water (90% H2O, 10% D2O, pH 
5.0, 293 K) by 1H NMR spectroscopy. The 1H NMR spectrum of UK40 indicated the 
existence of a major and two minor forms in a ratio of 14:3:1, which interconvert 
slowly on the NMR timescale, caused by cis-trans isomerism at Asn-Pro peptide 
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bonds. Similar cis-trans rotamers were found in BP66 in earlier work [11], and in 
linear peptides containing multiple NPNA-repeats [17]. The major form can be 
assigned the all trans conformation on the basis of observed NOE connectivities. 
Resonance overlap prevented an assignment of the minor forms to specific peptide 
bond rotamers. Chemical shift assignments for the major rotamer (Table S1) were 
made using standard 2D NMR methods [18]. Side chain proton frequencies in UK40 
exhibited major spectral overlap, although this problem was not as severe as seen in 
linear peptides containing multiple tandem NPNA-repeats. This is illustrated in Figure 
S2, where HN-C( )H cross peaks from 2D DQF-COSY spectra are shown for UK40 
and the peptide Ac-(NPNA)3-NH2. Notable in the spectrum of UK40 are the 
significantly upfield shifted amide HN resonances of Asn9 and Ala12. The amide 
proton chemical shift temperature coefficients were measured and are given in Figure 
S3. Notable are the low values for both Ala8 and Asn9, suggesting that both these 
amide NHs are involved in intramolecular hydrogen bonding. A low value is also seen 
for Ala12, but not for Asn13. 
2D NOESY spectra of UK40 showed dNN (i, i+1) NOE connectivities between amide 
protons of Asni+3, Alai+4 and Asni+5 within each NAN motif, as shown in Figure S3 and 
Figure S4. The same pattern of NOE interactions was also found earlier in BP66 [11]. 
Furthermore, characteristic medium range d N (i, i+2) NOEs were found between 
Asn7 and Asn9, Asn9 and Asn11, Pro10 and Ala12, Pro14 and Glu16 in UK40. Weak NOE 
contacts between side chains of the first Asn and the Ala of each NPNA motif are also 
seen, as predicted in the structure model of an NPNA motif in a helical turn 
conformation (vide infra) (Figure 3A). No other medium/long range NOEs were 
observed in NOESY spectra. 
Using the available short and medium range NOE connectivities, average solution 
structures for UK40 were calculated using DYANA. The final ensemble of 20 
structures (see Table S2) is shown in Figure 3B. The backbone atoms of residues 6-16 
enclosed within the macrocyclic ring can be superimposed with an rmsd of 1.6 Å, 
whereas the remaining residues at the N- and C-termini show much greater 
conformational diversity. When each tetrapeptide motif within the macrocycle is 
considered, the highest structural similarity both to the ANPNA crystal structure and 
to a model helical turn conformation is seen in the first (N5-A8) and in particular the 
central (N9-A12) tetrapeptide motifs (Figure 4), suggesting that helical turns are 
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significantly populated in this portion of the molecule. Within the third unit N13-E16, 
however, the helical turn conformations are adopted much less frequently, or not at 
all, in the 20 lowest energy DYANA structures, suggesting either that the turn is not 
significantly populated or, as seems more likely, that the average NMR structures do 
not represent accurately these regions of the macrocycle due to the presence of 
multiple rapidly interconverting helical and extended conformations. The low number 
and weak intensity of many NOEs are indicative of significant backbone flexibility. 
Moreover, the occurrence of significant restraint violations, such as from the Glu16 
C( )H to Asn17 HN  NOE, indicate also the presence of extended (ß) chain forms. 
 
Antigenic properties 
The antigenic properties of virosomally formulated UK39 were compared to those of 
BP65 and two previously described [12] template-bound peptides (JL934 and 
JL1036) (see Figure 1). Panels of CSP repeat region specific sporozoite-binding 
mAbs obtained after immunization of mice with either NPNA peptides or with P. 
falciparum sporozoites were tested in ELISA for cross-reactivity with the first to 
fourth generation compounds (Table 1). The results demonstrate that antibodies with a 
range of different fine-specificities can bind to native CSP on the sporozoite surface. 
Thus mAb 1.26 the only sporozoite cross-reactive mAb elicited by the antigen JL934 
[12] did not bind to the other peptide antigens and only three of the four sporozoite-
binding mAbs elicited by the peptide antigen JL1036 [12] cross-reacted with the  
antigens BP65 and UK39. The two mAbs elicited by virosomal formulations of BP65 
both recognized sporozoites and UK39, while only one mAb (EP9) recognized 
JL1036 and none JL934. Cross-reactivity analysis with a set of twelve CSP repeat 
region specific mAbs raised against P. falciparum sporozoites demonstrated that only 
two of these mAbs cross-reacted with JL934, five with JL1036 and all 12 with BP65 
and UK39. While cross-reactivity of mAbs Sp4-7H1 and Sp4-1B4 with the antigen 
BP65 was only weak, all twelve anti-sporozoite mAbs cross-reacted strongly with 
UK39, indicating that this compound better reflects the native structure of the CSP 
repeat region. 
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Immunogenicity of virosomally formulated UK39  
Already one immunization of BALB/c mice with UK39-loaded IRIVs elicited 
detectable titers of anti-UK39 IgG in ELISA (Figure 5A) and sporozoite cross-
reactive IgG in IFA (Figure 5B). While a second immunization led to a strong titer 
increase, a third immunization had only a moderate further booster effect. In Western 
blots with a lysate of P. falciparum salivary gland sporozoites, anti-UK39 IgG stained 
a characteristic CSP double-band of 50-55 kDa (not shown).  
Comparison of immune responses elicited by a liposomal and an IRIV-based 
formulation of UK39 demonstrated the importance of influenza virus proteins for the 
immunopotentiating activity of IRIVs (Figure 5C). The strong immunogenicity of 
virosomally formulated UK39 is virtually abolished when the peptide is presented on 
liposomes, lacking influenza derived hemagglutinin and neuraminidase. Also, no 
parasite cross-reactive IgG was detected in IFA (not shown). Already one dose of 
IRIV formulated UK39 elicited high ELISA and IFA IgG titers in rabbits (Figure S5). 
Additional immunizations had only a minor booster effect. IgG from immunized 
animals stained the CSP double-band in Western blots (not shown). 
 
Generation of sporozoite inhibitory antibodies by UK39 
Total IgG (final concentration 1mg/ml) purified from UK39-immunized rabbits 
showed inhibitory activity in sporozoite in vitro invasion inhibition assays (Figure 
6A). Inhibition decreased in a dose dependent manner. Control IgG preparations from 
rabbits immunized with empty IRIVs had no inhibitory activity. Sera inhibiting 
invasion of P. falciparum sporozoites did not inhibit invasion of P. yoelii into murine 
hepatocytes (not shown), demonstrating specificity of the inhibitory activity. 
Purified IgG from rabbits immunized with UK39 inhibited parasite gliding motility, 
as demonstrated by immunofluorescence analysis of the trails of CSP shed by P. 
falciparum sporozoites gliding on glass slides [19]. At a concentration of 1 mg/ml of 
total IgG, traces were reduced (Figure 6B). Furthermore, CSP was precipitated at the 
apical ends of the sporozoites as described [20] and sporozoites were agglutinated. 
Serum of rabbits immunized with empty IRIVs had no effect on gliding motility or on 
parasite morphology. 
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Discussion 
An important goal here was the design of a conformationally constrained 
peptidomimetic of the immunodominant NPNA repeat region of CSP, which could be 
delivered to the immune system on the surface of immunopotentiating reconstituted 
influenza virosomes (IRIVs). Linear peptides are generally unsuitable as 
immunogens, due to their inherent conformational flexibility. As a result, there are 
many different ways that linear peptides can be recognized (by B-cell receptors), 
correlating with the number of accessible conformational states available to the 
peptide chain. Only a small subset of these will be relevant for cross-recognition of 
the cognate folded protein. A peptide chain restrained into the biologically relevant 
backbone conformation, on the other hand, should be a more effective immunogen, 
since it should be recognized preferentially in a conformation that promotes cross-
reaction with the folded protein. There is the further advantage that linear peptides are 
usually degraded by proteolysis within minutes in biological fluids, which limits the 
window of accessibility to B-cell receptors. 
Our strategy for the design of a multi-stage multi-component subunit malaria vaccine 
is to focus immune responses onto protection-relevant structural elements of key 
parasite proteins. Moreover, synthetic peptides and proteins with native-like folds can 
be presented to the immune system on IRIVs, thereby bypassing many of the 
problems associated with the production of stable recombinant protein-based vaccine 
formulations. A key parameter used for selecting vaccine candidates was the cross-
reactivity of elicited antibodies with the native target antigen on the cell surface of the 
parasite. IRIV formulations of the peptide antigens evaluated here were immunogenic 
in mice and rabbits. The optimized structure, UK39, has remarkable structural and 
antigenic similarity with the native repeat region of the key sporozoite vaccine antigen 
CSP and is suitable for large scale GMP production.  
Key structural information used to guide the design of UK39 came from earlier NMR 
and modeling studies [11]. Already NMR studies on linear peptides containing one or 
several tandemly linked NPNA motifs suggested the presence of turn-like structures 
based on the NPNA cadence, stabilized by hydrogen bonding, but in rapid dynamic 
equilibrium with extended chain forms [17]. Recently, an X-ray crystal structure was 
reported of the pentapeptide Ac-ANPNA-NH2, which confirmed that the NPNA unit 
adopts a type-I ß-turn conformation in aqueous solution [21]. Nevertheless, a key 
Chapter 3.1 
 
 
44 
 
question remains how individual ß-turns in a longer (NPNA)n oligomer might be 
interconnected to form a repeat structure. In earlier work, we were strongly influenced 
by the observation in NOESY spectra of various (NPNA)n-containing cyclic and 
linear peptides, of strong sequential backbone NH-NH NOEs between both Asni+2 and 
Alai+3 as well as Alai+3 and Asni+4. This led us to consider backbone conformations of 
extended (NPNA)n oligomeric peptides, in which Proi+1, Asni+2 and Alai+3 are in the  -
helical region, leaving only Asni in the ß-region of     space; a combination called 
here a helical-turn. A computer model of such a turn is shown in Figure 3A, where the 
close approach of the backbone amide NHs of Asni+2 and Alai+3 as well as Alai+3 and 
Asni+4 can be seen. With these     angles for each NPNA motif, and assuming trans 
peptide bonds, a cross-linked peptidomimetic was designed using a computer model 
of an extended (NPNA)n-oligomer, as described earlier [11]. In our first effort, 
(2S,3R)-3-aminoproline was used to synthesize the mimetic BP66, and its 
phospholipid conjugate BP65. Here, we have investigated the related peptidomimetics 
UK39 and UK40 (Figure 1), which use instead the synthetically more accessible 
(2S,4S)-4-aminoproline. 
NMR studies on UK40 in aqueous solution provide insights into the preferred 
backbone conformations of this mimetic, and confirm a close similarity to those 
deduced earlier for BP66 [11]. As expected, the residues contained within the 
macrocyclic ring of UK40 are more restrained in their conformation than the NPNA 
units outside the macrocycle at the N- and C-termini (Figure 3B). The Asn5-Ala8 and 
Asn9-Ala12 motifs, in particular, appear to populate helical turns, as seen in the 
average solution structures calculated using NOE-derived distance restraints (Figure 
4). However, especially the Asn13-Glu16 motif within the macrocycle appears to be 
more disordered and to exist in dynamic equilibrium with extended forms. It is less 
clear what role (if any) the observed minor cis-(Asn-Pro) peptide bond conformers 
might play in eliciting antibodies cross-reactive with the CSP. 
As far as the antigenic properties are concerned, UK39 was recognized by all tested 
CSP repeat region specific mAbs elicited by sporozoite-immunization of mice, and by 
the majority of sera from human donors living in malaria endemic regions (data not 
shown). One major limitation in using peptide antigens as vaccine components is their 
poor immunogenicity. We demonstrate here that presentation of UK39 on the surface 
of virus-like particles elicited a strong parasite cross-reactive antibody response both 
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in mice and in rabbits. Lack of immunogenicity of a liposomal formulation 
demonstrated the importance of influenza protein antigens for the immunopotentiating 
activity of IRIVs. We have observed better immune responses with liposomal 
formulations of PE-conjugates of larger peptides, but also in these cases IRIV 
formulations were far superior (unpublished results). While two immunizations were 
needed to reach high IgG titers in mice, one immunization was sufficient in rabbits. 
Seroconversion was not only observed in all inbred mice, but also in all rabbits with 
diverse immunogenetic backgrounds. Genetic restriction of the response in humans 
may therefore not represent a serious limitation for IRIV-based peptide vaccines. As 
previously observed for other antigens [13, 22], pre-immunization of animals with an 
influenza vaccine improved the titers of antibodies elicited by the IRIV formulation 
(data not shown). Possible explanations for this phenomenon are (i) opsonization of 
IRIVs with pre-existing anti-influenza antibodies, leading to enhanced uptake by 
antigen presenting cells and (ii) activation of influenza-specific memory T cells, 
providing T cell help to UK39-specific B cells. The presence of antibodies against 
influenza are not a prerequisite for the induction of a good immune response but 
optimize the adjuvant effect of virosomes [13]. Widespread outbreaks of influenza 
have been reported for Africa [23], making the virosomal antigen delivery system 
applicable in malaria endemic areas of Africa. Results of the animal immunogenicity 
studies described here suggested that two immunizations with a 10 µg dose of UK39 
will elicit a potent antibody response in influenza pre-exposed humans, irrespective of 
their immunogenetic background. Preliminary immunogenicity data of clinical trials 
with two IRIV-based malaria vaccine components, UK39 and a peptide loop derived 
from the P. falciparum Apical Membrane Antigen-1 [10, 22] support this assumption 
and the general concept of delivering peptides as IRIV-bound 
phosphatidylethanolamine (PE)-conjugates to the human immune system.  
Antibodies against BP65 and its easier to synthesize derivative UK39 inhibited 
sporozoite invasion into hepatocytes in vitro. Inhibition with mAbs against BP65 was 
up to 100% whereas only lower levels of inhibition were observed with purified IgG 
from UK39-immunized rabbits. This reduced effect can be explained by the fact that 
we used total IgG from immunized animals. Thus, despite using high concentrations 
of IgG (1 mg/ml), only a minor fraction of the antibodies is specific for the NPNA 
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repeats. Additionally, physiological serum IgG concentrations of rabbits are higher 
than 1 mg/ml, pointing towards an increased inhibitory effect in vivo. 
The mechanism of this inhibition is not clearly understood. The observed inhibition of 
gliding motility suggests interference with parasite motility, which is necessary to 
invade the target cell, as described before [24]. Whether gliding inhibition is based on 
a specific block of the mechanism promoting movement or just the result of steric 
hindrance remains to be elucidated as the involvement of CSP in the process of 
gliding motility is still controversial [25]. The protective potential of anti-CSP repeat 
antibodies has been shown in vivo by passive transfer of anti-CSP repeat antibodies, 
which can protect mice from experimental sporozoite challenge [26]. The mechanism 
of this protection is at least in part due to antibody-mediated immobilization of 
sporozoites in the skin after injection by the mosquito [27].  
It is not likely that antibodies against UK39 alone would result in complete protection 
against malaria. However, in the context of a multi-stage vaccine, they may reduce the 
number of sporozoites entering liver cells and thus support immune protection elicited 
by components directed against the liver and blood stages of the malaria parasite. 
Moreover it is thought that reduction of the number of merozoites released from the 
liver by anti-pre-erythrocytic vaccination [3] or reduction of the sporozoite inoculum 
by the use of insecticide treated bed-nets [28] can reduce the incidence of severe 
malaria.  
The universal IRIV-based antigen delivery platform described in this report is highly 
suitable for combining antigens specific for the different development stages of the 
parasite into a multi-component malaria subunit vaccine. 
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Significance 
With increasing global prevalence of malaria and emerging resistance of P. 
falciparum to drug treatment, the need for an efficient malaria vaccine is greater than 
ever. Although it was shown more than 30 years ago that man can be protected 
against malaria by vaccination [29], a safe, effective and affordable vaccine is still 
many years away [4]. Especially the lack of safe and potent adjuvant/delivery systems 
and the technical and regulatory problems associated with recombinant protein 
production has hampered vaccine development. We have developed a technology 
platform based on the design of conformationally constrained synthetic peptides and 
the IRIV delivery system, which allows for the rational development of a malaria 
vaccine. The parasite-binding capacity of antibodies elicited by immunization of mice 
with virosomally-formulated peptides was used as a key indicator for the optimization 
of peptide antigens. The universal IRIV-based antigen delivery platform is highly 
suitable for combining antigens specific for the different development stages of the 
parasite into a multi-component malaria subunit vaccine. As the IRIV system is 
already registered for use in humans, this platform can contribute to the rapid 
development of a safe, efficient and cost-effective malaria vaccine. 
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Experimental procedures 
Synthesis of peptides 
Synthesis of JL934, JL1036 and BP65 has been described previously [11, 12, 30]. For 
UK40, a linear peptide was first assembled on Rink Amide MBHA resin (0.73 mM/g) 
(Novabiochem) using an Applied Biosystems ABI433A peptide synthesizer, and Fmoc-
protected amino acids (Fmoc-Asn(Mtt)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-
Glu(tBu)-OH and Fmoc-(4S,2S)-4-aminoproline(Boc)-OH) and HBTU/HOBt (4 eq.) 
for activation. After cleavage of the linear peptide from the resin with 95% TFA, 
2.5% TIS and 2.5% water over 3 h, the peptide was precipitated using iPr2O and 
dried. The linear peptide was then stirred overnight with HATU (4eq.) and HOAt (4 
eq.) in DMF with 1 % v/v iPr2EtN (2 mg/ml peptide). After drying in vacuo the 
peptide was stirred in 20 % piperidine in DMF for 15 min. The solvent was 
evaporated and peptide was precipitated using iPr2O, dried in vacuo, and then purified 
by reverse phase HPLC (C18 column using a gradient of MeCN/H2O (+0.1% TFA; 5 
to 95% MeCN ; tR = 11 min). ES-MS m/z: 2276 (M+H)+.  
The cyclic peptide (40 mg) was coupled to PE-CO-(CH2)2-COOH (PE-succinate; 4 
eq.) in DMF (5 ml), CH2Cl2 (5 ml) and 1% iPr2EtN using HATU and HOAt with 
stirring overnight at rt. The solvent was then removed and the product purified by 
reverse phase HPLC (C4 column Vydac 214 TP 1010, 25cmx10mm) using a gradient 
of 50 % ethanol in water to 100 % ethanol (+0.1% TFA) over 15 min. UK39 appears 
as a broad peak at about 90 % ethanol. ES-MS m/z: 1427 (M+2H)2+. Alternatively, the 
cyclic peptide was acetylated with acetic anhydride in MeOH and NH4HCO3 buffer 
and UK40 was purified by reverse phase HPLC (C18 column Vydac) using a gradient 
of 0 to 100% MeCN in water. ES-MS m/z: 1049 (M+2H)2+. 
 
NMR studies 
For NMR studies, UK40 was dissolved in 90%H2O/10%D2O, pH 5.0, at a 
concentration of ca. 10 mg/ml. 1D and 2D 1H NMR spectra were recorded at 600 
MHz (Bruker AV-600 spectrometer). Water suppression was by presaturation. The 
sequential resonance assignments were based on DQF-COSY, TOCSY and NOESY 
spectra. Distance restraints were obtained from NOESY spectra with mixing times of 
80 and 250 ms. Spectra were collected with 1024 x 256 complex data points zero-
filled prior to Fourier transformation to 2048 x 1024, and transformed with a cosine-
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bell weighting function. Data processing was carried out with XWINNMR (Bruker) 
and XEASY. [31] 
The structure calculations were performed by restrained molecular dynamics in 
torsion angle space by applying the simulated annealing protocol implemented in the 
program DYANA. [32] Starting from 100 randomized conformations a bundle of 20 
conformations were selected with the lowest DYANA target energy function. The 
program MOLMOL [33] was used for structure analysis and visualization of the 
molecular models. 
 
Preparation of peptide-loaded virosomes 
For the preparation of IRIVs loaded with phosphatidylethanolamine (PE)-peptide 
conjugates, a solution of purified Influenza A/Singapore hemagglutinin (4 mg) in 
phosphate buffered saline (PBS) was centrifuged for 30 min at 100,000 g and the 
pellet was dissolved in PBS (1.33 ml) containing 100 mM 
octaethyleneglycolmonodecylether (PBS-OEG). Peptide-PE conjugates (4 mg), 
phosphatidylcholine (32 mg; Lipoid, Ludwigshafen, Germany) and PE (6 mg) were 
dissolved in a total volume of 2.66 ml of PBS-OEG. The phospholipid and the 
hemagglutinin solutions were mixed and sonicated for 1 min. This solution was then 
centrifuged for 1 hour at 100,000 g and the supernatant was filtered (0.22 µm) under 
sterile conditions. Virosomes were then formed by detergent removal using BioRad 
SM BioBeads (BioRad, Glattbrugg, Switzerland). 
 
Mouse immunogenicity studies 
BALB/c mice were pre-immunized intramuscularly with 1  g of purified Influenza 
A/Singapore hemagglutinin in 0.1 ml PBS. . At least three weeks later they were 
immunized with PE-peptide conjugate-loaded IRIVs (containing 10  g PE-peptide) 
in intervals of at least two weeks. Blood was collected before each immunization and 
two weeks after the final injection. 
 
Generation of hybridomas and production of mAbs 
Hybridomas were generated from spleen cells of mice three days after a booster 
immunization with BP65 loaded IRIVs using PAI mouse myeloma cells as a fusion 
partner. Hybrids were selected in HAT medium and cells that secreted anti-BP65 
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mAbs were identified by ELISA. For large-scale mAb production, hybridoma cell 
lines were cultured in 175 cm2 flasks and mAbs were purified by protein A or G 
affinity chromatography (Protein A SepharoseTM CL4B or HiTrapTM Protein G HP, 
Piscataway, NJ). Purified mAbs were dialyzed against PBS, aliquoted and stored at -
80°C. Generation of anti-P. falciparum sporozoite mAbs has been described 
previously [34]. 
 
Rabbit immunogenicity studies 
Rabbits were pre-immunized intramuscularly 5  g of purified Influenza A/Singapore 
hemagglutinin in 0.1 ml PBS. . At least three weeks later they were immunized with 
peptide-loaded IRIVs (containing 10  g PE-peptide) in intervals of at least two 
weeks. Blood was collected before each immunization and two weeks after the final 
injection. Rabbit IgG was purified from immune sera by protein A affinity 
chromatography. 
 
ELISA 
ELISA analyses with peptide-PE conjugates were performed essentially as described 
before [10]. Briefly, PolysorpTM plates (Nunc, Fisher Scientific, Wohlen, Switzerland) 
were coated overnight at 4°C with 100 µl of a 10 µg/ml solution of UK39 in PBS (pH 
7.2). After three washings with PBS containing 0.05% Tween-20 wells were blocked 
with 5% milk powder in PBS for 30 min at 37°C and washed three times again. Plates 
were then incubated with serial dilutions of anti-peptide mouse or rabbit sera or anti-
peptide mAbs in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 
37°C. After washing, plates were incubated with alkaline phosphatase-conjugated 
goat anti-mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, Mo) for 1 h at 37°C. 
After washing again, phosphatase substrate solution (1 mg/ml p-nitrophenyl 
phosphate (Sigma, St. Louis, Mo) in a pH 9.8 buffer solution containing 10% 
[vol/vol] diethanolamine and 0.02% MgCl2) was added and the plates were incubated 
in the dark at room temperature until the colorimetric reaction had progressed 
sufficiently. The optical density was measured at 405 nm on a Titertek Multiscan 
MCC/340 reader (Labsystems, Helsinki, Finland). For experiments with rabbit sera, 
horseradish peroxidase-conjugated goat anti-rabbit IgG heavy and light chain 
antibodies (Bio-Rad Laboratories, Hercules, CA) were used as secondary antibody. 
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The TMB microwell peroxidase substrate system (KPL, Gaithersburg, MD) was used 
according to the manufacturer and optical density was measured at 650 nm. After 
stopping the reaction by addition of 50 µl 1N HCl per well OD was measured at 
450nm.  
 
Indirect immunofluorescence assay (IFA) 
Air-dried unfixed P. falciparum (strain NF54) salivary gland sporozoites attached to 
microscope glass slides were incubated for 15 min at room temperature with 25 µl 
blocking solution containing 1% fatty acid-free bovine serum albumin (BSA) in PBS. 
Immunostaining was performed by incubating the wells with 25 µl of an appropriate 
serum dilution in blocking solution in a humid chamber for 1 h at room temperature. 
After five washes with blocking solution 25 µl of 5 µg/ml cyanine dye (Cy3)-
conjugated affinity-pure F(ab´)2 fragment goat anti-mouse IgG (Fc-specific) 
antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) or Cy3-
conjugated donkey anti-rabbit IgG heavy and light chain antibody (Jackson Immuno 
Research Laboratories, West Grove, PA), diluted in blocking solution containing 0.01 
mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, Mo) were added to the wells and 
incubated for 1 h at room temperature. Finally, wells were washed five times with 
PBS, mounted with mounting solution (90% [vol/vol] glycerol containing 0.1 M Tris-
Cl, pH 8.0 and 2 mg/ml o-phenylenediamine) and covered with a coverslip. Antibody 
binding and DNA staining were assessed by fluorescence microscopy on a Leitz 
Dialux 20 fluorescence microscope and documented with a Leica DC200 digital 
camera system. 
 
SDS-PAGE and immunoblotting 
100 µl of an Anopheles stephensi salivary gland lysate containing about 100’000 P. 
falciparum sporozoites were diluted with an equal volume of 2x loading buffer 
(1.7ml, 0.5M Tris-HCl pH 6.8, 2 ml glycerol, 4.5 ml 10% SDS, 1 ml β-
mercaptoethanol, 0.8 ml 0.3% w/v bromophenol blue) and heated to 95°C for 10 
minutes. Proteins were separated on a 10% SDS PAGE mini-gel. Separated proteins 
were electrophoretically transferred to a nitrocellulose filter (Protran® Nitrocellulose, 
BA85, Schleicher & Schuell) by semi-dry blotting. Blots were blocked with PBS 
containing 5% milk powder and 0.1% Tween-20 over night at 4°C. The filter was cut 
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into strips and incubated with appropriate dilutions of immune sera in blocking buffer 
for 2 h at room temperature. Filter strips were then washed three times for 10 minutes 
in blocking buffer and incubated at room temperature for 1 h with alkaline 
peroxidase-conjugated goat anti-mouse IgG (Fc-specific) antibodies (Sigma, St. 
Louis, Mo) diluted 1:30’000 in blocking buffer or horseradish peroxidase-conjugated 
goat anti-rabbit IgG heavy and light chain antibodies (Bio-Rad Laboratories, 
Hercules, CA) diluted 1:6’000 in blocking buffer. After washing again, blots were 
finally developed using ECLTM Western blotting detection (Amersham Biosciences, 
Buckinghamshire, England) reagents to visualize bands.  
 
P. falciparum and P. yoelii in vitro invasion inhibition assay 
Inhibition assays were performed as described before [35, 36]. Briefly, primary 
human or mouse hepatocytes were isolated as described [37, 38], and inoculated with 
P. falciparum (NF54 strain) or P. yoelii (265BY strain) sporozoites (1 x 105/Labtek 
well) obtained from salivary glands of infected Anopheles stephensi mosquitoes. After 
3 h at 37°C, the cultures were washed, further incubated in fresh medium for 3 days 
(P. falciparum) or 2 days (P. yoelii) before fixation in methanol. Quantification of 
exoerythrocytic forms was done by immunofluorescence. To determine the effects of 
anti-CSP antibodies on sporozoite infectivity, sporozoites were incubated with 
hepatocytes in the presence of increasing concentrations of mAbs or purified 
polyclonal rabbit IgG from immunized animals. The percentage of inhibition was 
determined in comparison to PBS control. 
 
Gliding inhibition 
To analyze sporozoite motility, 30,000 sporozoites were deposited on multispot glass 
slide wells precoated with anti-P. falciparum CSP (PfCSP) mAb E9 (100 µg/ml 1 h at 
37 °C) and incubated at 37 °C for 1 h. The slides were then washed, and the deposited 
CSP trails were fixed with 4% paraformaldehyde for 15 min. The trails were then 
labeled using the anti-PfCSP mAb E9 conjugated to Alexa Fluor® 488 and visualized 
under a fluorescence microscope. 
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Figure 1. Structures of peptidomimetics discussed in the text. 
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Figure 2. Hepatocyte invasion inhibition by anti-BP65 mAbs. A: Inhibition of parasite 
invasion into primary human hepatocytes by mAb EP3 and mAb EP9. Shown is the mean 
percentage of inhibition compared to PBS control ± SD deviation for duplicates. B: 
Competition of invasion inhibition by increasing concentrations of BP66 peptide (BP65 
without PE). Inhibitory mAbs were used at a constant concentration of 20  g/ml. 
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Figure 3. A: An NPNA motif is depicted in a helical turn conformation (see text). N-atoms 
dark blue, O-atoms red, C-atoms grey, amide H-atoms light white, H-bonds pale blue broken 
line. Here the first Asn has     angles in the ß-region, and the following Pro, Asn and Ala 
in the  -region. A green ribbon traces the backbone. B: Superimposition of the final 20 
DYANA structures for UK40. The backbone only is represented, superimposed using all 
heavy atoms from Apro6 to Glu16 (region in blue). 
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A   (res. 5-8)    B  (res. 9-12)   C  (res. 13-16) 
 
D   (res. 5-8)    E  (res. 9-12)   F  (res. 13-16) 
 
 
 
Figure 4. Backbone superimposition of the 20 DYANA structures of UK40 with a helical turn 
conformation (red, A - C), and with the ANPNA crystal structure (green, D - F). In A and D 
only residues 5-8 in UK40 were used for the superimposition, for B and E only residues 9-12, 
and for C and F only residues 13-16. 
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Figure 5. Immunogenicity of virosomal and liposomal formulations of UK39 in mice. A: 
Anti-UK39 IgG response in ELISA after immunization with IRIV-formulated UK39. Shown 
are mean ELISA readouts ± SD obtained with serial dilutions of mouse sera taken pre-
immune and two weeks after the first, second and third immunization. Sera from 10 animals 
were analyzed at every time point. B: Induction of P. falciparum sporozoite cross-reactive 
IgG upon immunization with UK39. Shown are IFA endpoint titers of 10 individual mice. 
Sera have been taken pre-immune and two weeks after first, second and third immunization. 
C: Anti-UK39 IgG response in ELISA of mice immunized with UK39 presented either on 
liposomes or on virosomes. Shown are the means ± SD of 5 animals per group. Sera have 
been taken 2 weeks after the third immunization. 
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Figure 6. Inhibitory capacity of anti-UK39 antibodies. Sporozoite invasion inhibition by 
purified IgG from rabbits immunized with UK39. A: P. falciparum sporozoites have been 
cultured with primary human hepatocytes in the presence of purified polyclonal rabbit IgG at 
different concentrations. Shown is the mean percentage of inhibition compared to PBS control 
± SD of 3 experiments for two animals immunized with IRIV-formulated UK39 (D1 and D3) 
and one control animal immunized with empty IRIVs (IRIV). B: Fluorescence microscopy of 
CSP trails deposited by P. falciparum sporozoites upon gliding on a glass slide. Left panel: 
Trails of sporozoites incubated with purified IgG from a rabbit immunized with empty IRIVs. 
Middle panel: Reduced trails of sporozoites incubated with purified IgG from an UK39-
immunized animal. Right panel: Agglutination of sporozoites incubated with purified IgG 
from a rabbit immunized with UK39. 
Chapter 3.1 
 
 
60 
 
 
Table 1. Cross-reactivity of anti-NPNA mAbs. 
amice were immunized with IRIVs loaded with the respective peptide 
bmice were immunized with P. falciparum sporozoites from A. stephensi salivary glands in 
Freund’s adjuvant  
cELISA reactivity to the peptides 
dIFA reactivity to P. falciparum sporozoites 
eDescribed by Moreno et al. 2001 
Cross-reactivity with
mab Immunogen
JL934c JL1036c BP-65c UK-39c Sporozoitesd
1.26e + - - ND +
1.7e + - ND ND -
1.15e
JL934a
+ - ND ND -
2.1e - + + + +
3.1e - + + + +
3.2e - + - - +
3.3e - + + + +
3.4e - + ND ND -
3.5e
JL1036a
- + ND ND -
EP3 - - + + +
EP9
BP-65a
- + + + +
Sp4-5F2 (+) + + + +
Sp4-2H1 (+) + + + +
Sp3-E6 - + + + +
Sp3-C6 - (+) + + +
Sp3-E9 - (+) + + +
Sp4-4B6 - - + + +
Sp4-7C2 - - + + +
Sp4-7E4 - - + + +
Sp4-7H1 - - (+) + +
Sp4-4D7 - - + + +
Sp3-B4-C12 - - + + +
Sp4-1B4
Pf sporozoitesb
- - (+) + +
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Supplementary material 
 
 
 
 
 
 
Figure S1. BP-125 a shortened version of BP65. ELISA with anti-BP65 mAbs EP3 and EP9 
on CSP mimetics BP65 and the shortened version BP-125. Shown are serial dilutions of the 
mAbs on constant concentrations of the two peptides. 
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A      B 
 
 
 
Figure S2. Sections from 2D DQF-COSY spectra in aqueous solution for: A, UK40; and B, 
the linear peptide Ac-(NPNA)3-NH2. Cross-peaks for HN-C( )H 3J couplings are indicated. 
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Figure S3. Results from 2D COESY spectra of UK40. NOE connectivities from NOESY 
spectra, and temperature coefficients (    / T ppb/K) of peptide amide NH resonances 
from 2D TOCSY spectra of UK40 measured in the range 279 -314 K. The thickness of the 
lines for the sequential distances dNN (i,i+1), d N (i,i+1) and d N (i,i+1) is inversely 
proportional to the squared upper distance restraint. 
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Figure S4. Backbone amide HN-HN cross peaks in a NOESY spectrum of UK40 in aqueous 
solution. The residue assignments are shown for each cross peak. 
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Figure S5. Immunogenicity of UK39 in rabbits. A: Anti-UK39 IgG levels measured 
in ELISA. Shown are the means ± SD of 3 rabbits. Sera have been taken pre-immune 
and two weeks after first, second and third immunization. B: Cross-reactivity of 
UK39 induced IgG with P. falciparum sporozoites. Shown are IFA endpoint titers of 
3 individual animals pre-immune and two weeks after first, second and third 
immunization. Arrows indicate immunizations with IRIV-formulated UK39. 
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Table S1. 1H Chemical shift assignments for UK40 in 90% H2O/10% D2O, pH 5, 293 
K. 
Residue NH H-C(a) H-C(b) Others
 UK-40
Asn1 8.43 4.97 2.86, 2.71 NH(d)a
Pro2 - 4.43 2.31, 1.98 CH(g) 2.04 – 1.98; CH2(d) 3.81, 3.81
Asn3 8.38 4.67 2.85, 2.74 NH(d)aa
Ala4 8.02 4.28 1.39
Asn5 8.41 4.91 2.87, 2.74 NH(d)a
Apro6 8.21b 4.51 2.66, 2.00 CH(g) 4.45; CH2(d) 4.24, 3.62
Asn7 8.44 4.54 2.80, 2.80 NH(d) 7.63, 6.95
Ala8 8.07 4.29 1.40
Asn9 7.95 5.009 2.92, 2.74 NH(d) 7.71, 7.08
Pro10 - 4.40 2.33, 1.96 CH2(g) 2.04 – 1.98; CH2(d) 3.81, 3.81
Asn11 8.33 4.68 2.88, 2.76 NH(d)a
Ala12 7.76 4.31 1.40
Asn13 8.42 4.92 2.87, 2.76 NH(d)a
Pro14 - 4.43 2.31, 1.99 CH2(g) 2.04 – 1.98; CH2(d) 3.80, 3.80
Asn15 8.34 4.68 2.84, 2.74 NH(d) 7.66, 6.98
Glu16 8.13 4.27 2.12, 1.99 CH2(g) 2.34, 2.34
Asn17 8.47 4.97 2.88, 2.74 a(d)a
Pro18 - 4.43 2.30, 1.99 CH2(g) 2.04 – 1.98; CH2(d) 3.80, 3.80
Asn19 8.42 4.69 2.87, 2.75 NH(d)a
Ala20 8.04 4.25 1.41
 a Overlapping resonances. Range H(d) (Z) 7.75-7.65 and H(d)E 7.11-6.96
 b The C(g)-NH proton, Apro6 = (2S,4S)-4-aminoproline
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Table S2.  Experimental distance restraints and statistics for the final 20 NMR 
structures calculated for UK40. 
UK-40
NOE upper-distance limits
Intraresidue
Sequential
Medium- and longe-range
99
27
60
12
Residual target function value (Å2)
0.16 ± 0.05
Mean rmsd values (Å)
All backbone atoms
Backbone atoms of residue 6-16
3.74 ± 1.02
1.59 ± 0.54
Residual NOE violation
Number > 0.2  Å
Maximum (Å)
13
0.34
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Abstract 
Peptide vaccines containing surface loops of protective antigens provide the 
advantages of low cost, safety, and stability while focusing host responses on relevant 
targets of protective immunity. However, the limited diversity of the elicited immune 
response raises questions regarding their equivalence to immune responses elicited by 
recombinant protein vaccines or whole inactivated parasite vaccines. Here we have 
addressed the question whether a virosomally formulated peptide, optimized for 
generating parasite-binding antibodies can also elicit CD4 T cells specific for the 
malaria antigen apical membrane antigen-1 (AMA-1) derived sequence stretch used 
for vaccination. In a phase Ia clinical trial of the virosomally formulated 49 amino 
acid long phosphatidylethanolamin peptide conjugate AMA49-CPE, we measured 
both vaccine induced humoral and cellular responses. In 50% of the volunteers (8/16) 
peripheral blood mononuclear cells lymphoproliferative response specific for the 
AMA49-CPE was elicited. Moreover, all four volunteers who developed high titers 
(>1000) of parasite cross-reactive IgG in immunofluorescence assay and Western blot 
analysis, were positive in the anti-synthetic peptide lymphoproliferation assay. No 
interference was found between the magnitude of the pre-existing influenza specific T 
cell response and the vaccination-induced AMA49-CPE specific humoral and cellular 
immune response. These studies demonstrate that the virosomal antigen delivery 
platform combined with surface-anchored synthetic peptides is suitable to elicit 
specific human CD4 T cell responses. These responses are not essential for eliciting 
target peptide specific IgG, but may improve the quality of the humoral immune 
response. 
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Introduction 
The use of synthetic peptide for the design of subunit vaccines represents an 
alternative approach to recombinant proteins and pathogen-purified components, 
which bypasses many of the problems related to antigen production and handling. 
However, the poor immunogenicity of the synthetic peptides, principally due to their 
small size (1), is hampering their use as vaccines. An optimal presentation of the 
synthetic peptides to the immune system is therefore essential. The suitability of 
immnopotentiating reconstituted influenza virosomes (IRIVs) as peptide carrier and 
immunopotentiator system has already been proven in preclinical studies (2-6). The 
repetitive arrangement of the antigen on the virosomal surface enables a good 
crosslinking of the B cell receptors and therefore, an optimal B cell stimulation (7). 
On the other side, the influenza hemagglutinin (HA) binds to sialic acid on antigen 
presenting cells (APC), e.g. macrophages, dendritic cells (DC) or B lymphocytes, 
enabling a receptor-mediated endocytosis of the virosomes. The HA2 subunit 
mediates the fusion of viral and endosomal membranes. Subsequently, virosomal 
surface particles and synthetic peptides can be degraded within the 
endosomal/lysosomal compartment (8) and the generated peptides might associate 
with MHC class II molecules giving access to the T helper pathway. There are two 
commercially available virosome-based vaccines licensed for human use: Inflexal to 
prevent the influenza-infection itself and Epaxal against Hepatitis A virus (HAV)-
infections. For the later one intact virions of inactivated HAV were associated to the 
surface of IRIV, and a vaccine induced seroconversion in 100% of the vaccinated 
people with long lasting antibody-mediated immunity was obtained (9). At present, 
our research on IRIVs is focused on their use for the design of synthetic peptide based 
vaccines, containing either encapsulated peptides or surface exposed peptide-
phospholipid conjugates. A first phase Ia clinical trial combining the virosomal 
technology with synthetic peptides anchored on the virosome surfaces was conducted 
in 2003-2005 within the context of a multi-stage malaria subunit vaccine project. The 
two peptide-phosphatidylethanolamin (PE) conjugate included in the vaccine 
formulations represented optimized B cell antigens derived from the leading malaria 
vaccine candidates circumsporozoite protein (CSP) and apical membrane antigen-1 
(AMA-1) (Genton et al. submitted, Okitsu et al. submitted) (5). The specific 
objectives of the trial have been completely fulfilled: the three immunizations of all 
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vaccine formulations were safe, well tolerated and at appropriate antigen doses 
seroconversion rates of 100% were achieved, attesting the concept that virosomal 
technology is suitable to elicit high titers of antibodies also against small synthetic 
peptides (Genton et al. submitted). Here we addressed the question whether such 
formulation can also be used to elicit peptide specific CD4 T cells. It is assumed that 
influenza antigen specific CD4 T cells provide T cell help for the malaria peptide 
specific B cells, assure the antibody class switching and development of memory B 
cells (8, 10). But an extra priming of CD4 T cells against the synthetic peptides may 
further enhance humoral immunity to the malaria peptide. To investigate the cellular 
immune responses against the AMA-1 derived synthetic was monitored in 30 
vaccinated volunteers by lymphoproliferation analysis and ex vivo IFN-γ ELISpot.  
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Materials and Methods: 
Subjects and study design 
The prospective phase Ia, single blind, randomized, placebo controlled, dose-
escalating study was conducted in 46 healthy adult volunteers (Genton et al., 
submitted). 30 male and female volunteers, aged 18-45 years randomized into four 
groups were selected for cellular analysis: PEV301 50 µg (n = 8; Group 3), PEV302 
50 µg (n = 8; Group 4), PEV301 50 µg + PEV302 50 µg (n = 8; Group 5) or 
unmodified virosomes (IRIVs) serving as controls (n = 6; Group 6) (Table I, Figure 
1). 
Vaccine 
Two virosome-formulated Plasmodium falciparum malaria vaccines PEV301 
(incorporating the AMA-1 derived PE-peptide conjugate AMA49-CPE) and PEV302 
(incorporating the CSP derived PE-peptide conjugate UK39) were produced 
according to the rules of good manufacturing practice (GMP). Tests for sterility, 
pyrogenicity, immunogenicity in animals, stability and chemical composition were 
performed on the vaccine lots used in this trial. Each dose was composed of 50 µg 
AMA49-CPE or UK39, 10 µg influenza HA, 100 µg phospholipids and 0.5 ml PBS.  
Immunological analyses 
Volunteers were immunized with the different vaccine combinations on days 0, 30 
and 180. Blood samples for cellular analysis were taken during the screening visit, 21 
days after each vaccination. 25 ml of venous blood were obtained in BD vacutainer 
covered with EDTA and peripheral blood mononuclear cells (PBMC) were isolated 
by Ficoll-Paque gradient centrifugation. Cells were analyzed the same day by ex vivo 
IFN-γ ELISpot analysis and lymphoproliferation assay. PBMC were resuspended in 
cell culture medium consisting of RPMI 1640 supplemented with 10 % heat-
inactivated non-immune pooled human AB serum (Milan Analytica AG, La Roche, 
Switzerland), 2 mM glutamine and antibiotics (100 U/ml penicillin, 100  g/ml 
streptomycin).  
Ex vivo IFN-γ  ELISpot  
PBMC were adjusted to 2 x 106 cells/ml and incubated for 24 h in 5 ml polypropylene 
round-bottom tube (Falcon BD) at 37 °C, 5 % CO2 humidified atmosphere with 
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medium alone, influenza antigens (H1N1 A/Singapore/6/86) (40 µg/ml), UK40 (40 
µg/ml) or AMA-C1 (40 µg/ml). Ex vivo INF-γ ELISpot assays were performed to 
detect antigen-specific effector T cells from freshly isolated PBMC. The anti-IFN-γ 
monoclonal antibody (mAb, 1-D1K) and the biotinylated anti-IFN-γ monoclonal 
antibody (mAb, 7-B6-1) (Mabtech, Stockholm, Sweden) were used according to the 
manufacturer’s instructions. Nitrocellulose-backed 96-well plates MultiScreenIP 
plates (Millipore AG, Volketswil, Switzerland) were coated with 10 µg/ml of capture 
antibody (1-DIK) overnight at 4 °C. The plates were then washed five times with PBS 
and blocked with cell culture medium for 1 h. Medium was decanted and cells were 
distributed in triplicate wells at a concentration of 1 x 10 5 cells/well for influenza 
antigens stimulation and at 2 x 105 cells/well for the AMA-C1 and UK40 stimulation 
for a further 20 h incubation period. After six times washing with PBS, secondary 
mAb 7-B6-1 was applied at 1 µg/ml concentration for 2 h at room temperature. Plates 
were washed six times with PBS before application of streptavidine-alkaline 
phosphatase (1:1000 dilution in PBS, 0,5 % FCS, 100 ml/well) for 1 h at room 
temperature. Wells were washed seven times with PBS and spots were revealed by 
incubation for 4 to 10 min until distinct spots emerged with developing buffer 
(BCIP/NBT, diluted 1:100). Development was stopped by washing the plates with tap 
water. Plates were evaluated using the automated ELISpot Reader system (AID, 
Germany) using the same settings throughout the whole study for better comparability 
of the results. Results are expressed as numbers of spot forming units (SFU) per 106 
PBMC. 
Lymphoproliferation assays 
Fresh PBMC were distributed in triplicates (4 x 105 cells/well) in 96 well round 
bottomed plates in 200 ml final volume and incubated for 5 days at 37 °C in a 
humified atmosphere containing 5 % CO2. During the last 16 h of incubation, 1 
µCi/well of [3H]-Thymidine (Moravek Biochemicals, CA) was present. Antigens 
tested included the AMA49-C1 (40 µg/ml), UK40 (40 µg/ml) and influenza antigens 
(40 µg/ml). Data were expressed as stimulation index (SI), calculated as: SI = 
arithmetic mean experimental count per minutes (cpm) with antigen / arithmetic mean 
control cpm without antigen. A SI > 2 was regarded as positive response. 
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Immunogenetic analysis 
The HLA-DRB gene expression of the volunteers vaccinated with AMA49-CPE 
(group 3 and group 5) were analyzed by IMGM Laboratories GmbH (Martinsried, 
Germany, http://www.imgm.de/hla_typing.php).  
In silico analysis 
AMA49-C1 peptide sequence was analyzed with the software TEPITOPE that predict 
promiscuous HLA class II ligands on the basis of virtual matrices (threshold used: 
3%) (www.imtech.res.in/raghava/propred/) (11) 
Statistical analysis 
Linear regression was applied for ex vivo IFN-γ ELISpot assay on the SFU/106 PBMC 
and for lymphoproliferation assay on SI values to compare the follow up times (1st, 2nd 
and 3rd immunizations) with the pre-immunization time for each vaccination group. 
Random effect was taken into account at individual level in order to consider 
correlations due to the repeated measurement on the same individual. 
 
Immunofluorescence analysis (IFA), Western blot and ELISA 
The procedures have been described elsewhere (Gentom et al. submitted, Mueller at 
al. submitted) 
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Results 
Cellular immune response to the virosomally formulated peptide-PE conjugate 
AMA49-CPE 
Freshly isolated PBMC of volunteers vaccinated with 50 µg of a virosomal 
formulation of the peptide-PE conjugate AMA49-CPE either alone (vaccination group 
3) or in combination with the CSP-derived peptide-PE conjugate UK39 (group 5) 
were analyzed three weeks after each of the three immunizations by ex vivo IFN-γ 
ELISpot assay and lymphoproliferation analysis. In both test systems cells were 
stimulated with the 49-mer peptide, AMA49-C1 (AMA49-CPE without lipid anchor; 
Table I, Figure 1) or influenza antigens.  
In the ex vivo IFN-γ ELISpot analysis, the reference baseline in all tested vaccination 
groups (1-6), i.e. PBMC incubated without any stimulus, was oscillating between 0 
and 140 SFU/106 with an average of 10 SFU/106 PBMC per well. The cut-off 
frequency was set at 100 SFU/106 PBMC with a minimal difference of 75 SFU/106 
PBMC from the baseline. Based on these criteria, none of the PBMC preparations 
tested contained a significant number of AMA49-C1 SFU (0 to 75 SFU/106 PBMC, 
Figure 2A). The validity of the ELISpot assay was proven by parallel PBMC 
stimulation with influenza antigens, where a high frequency of SFUs was observed 
with all PBMC preparations (ranging from 110 to 1080). The geometric mean 
frequency of influenza SFUs was already considerably high prior to the first 
vaccination (>400 SFU/106 PBMC) and did not further increase significantly in the 
course of the vaccinations (Figure 2B). 
While none of the 16 PBMC samples taken prior to the first immunization with 
AMA49-CPE (groups 3 and 5) had a SI > 2 in the lymphoproliferation assay with 
AMA49-C1, altogether 13 of the 46 post-immunization samples tested yielded a value 
above this threshold (Table 2). In contrast, only one post-immunization PBMC 
sample from the 14 volunteers receiving empty virosomes (group 6) or a virosomal 
formulation of the unrelated peptide-PE conjugate UK39 alone (group 4) showed a 
AMA49-C1 SI slightly above the threshold (SI = 2.1). While the response rate after 
the first and after the second AMA49-CPE immunization was comparable (37.5% 
[6/16] and 40% [6/15], respectively) it had dropped considerably after the third 
immunization (6.7% [1/15]). Only one volunteers (#41) responded after all three 
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immunizations, but altogether 50% (8/16) of the volunteers had a positive readout 
with at least one of the three post-immunization samples (Table 2). These eight 
volunteers were associated with a diverse spectrum of HLA-DR haplotypes (Table 3). 
In the lymphoproliferation assay with influenza antigens the mean SI of PBMC 
preparations taken prior to the first immunization was 24, with a wide range between 
3 and 118. After the first, second and third vaccination no significantly increase of the 
anti-influenza geometric means (SI = 19, 34 and 33, respectively) was found. 
Correlation between the generation of parasite-binding antibodies, AMA49-C1 
specific lymphoproliferative response and HLA-DRB1  
While all volunteers vaccinated with 50 µg of AMA49-CPE (vaccination groups 3 
and 5) developed an anti-AMA49-CPE IgG-response in peptide ELISA (Genton et al. 
submitted), only some of them (Table 2) developed titers of parasite cross-reactive 
IgG that were above the detection limit of P. falciparum blood stage parasite IFA and 
Western blotting assays (Müller et al. submitted). Only borderline correlations (r = 
0.34, p = 0.059) between the elicited anti-peptide IgG ELISA titers and the SI values 
in the AMA49-C1 lymphoproliferation assay after the first and second immunization 
was observed (Figure 3). However, the four volunteers (#27, #30, #39, #46) who had 
developed both high (>1000) IFA and Western blotting titers with blood stage 
parasites were all positive in the AMA49-C1-lymphoproliferation assay (Table 2). 
Three of them (#30, #39 and #46) had positive values both after the first and after the 
second immunization, one (#27) only after the second. 
Using the TEPITOPE software (http://www.imtech.res.in/raghava/propred)(11),  
we searched for predicted HLA class-II ligands within the AMA49-C1 peptide 
sequence. The thirteen best scoring epitope/HLA-DR allele combinations are listed in 
Table 4. The only volunteers expressing one of these predicted high affinity binding 
HLA-DRB1 alleles were volunteers #27, #30 and #46. Strikingly, all three belonged 
to the group of four volunteers which were both positive in the AMA49-C1 
lymphoproliferation assay and in the IFA and Western blotting assays for parasite 
cross-reactive IgG (Table 2). All three expressed HLA-DRB1*0301 which yielded a 
high score with the predicted AMA49-C1 derived epitope FISDDKDSL. Of the HLA-
DR alleles expressed by the fourth volunteer (#39) of the lymphoproliferation and 
IFA/Western blotting double positive group, the HLA-DRB5*0101/peptide 
Chapter 3.2 
 
 
82 
 
IERESKRIK combination yielded the best score, when the TEPITOPE analysis was 
performed at lower stringency.  
General lack of correlation between the pre-existing influenza specific T cell 
response and the vaccination-induced AMA49-C1 specific humoral and cellular 
immune responses  
No correlation between the magnitude of the pre-existing anti-influenza 
lymphoproliferative response and the elicited AMA49-C1 specific 
lymphoproliferative responses induced by the first or second immunization was 
observed (Table 5). Similarly the pre-existing anti-influenza ex vivo frequency given 
in SFU/106 PBMC did not show any association with the AMA49-C1 specific 
lymphoproliferative responses after the second immunization. On the contrary, a 
negative correlation with the anti-AMA49-C1 SI values after the 1st immunization 
might indicate some interference of high pre-existing anti-influenza CD4+ T cell 
frequency (Table 5). A general lack of correlation was observed also between the 
magnitude of the ELISA anti-peptide (AMA49-CPE) IgG titers after each 
immunization and the two measured pre-existing anti-influenza cellular compartments 
(SI, SFU).  The only exception was the negative correlation between the anti-
influenza pre-existing lymphoproliferation and the anti-AMA49-CPE IgG titers after 
the second immunization (Table 5). To this concern it has to be mentioned that 
volunteers #27 and #28 presented extremely high IgG titers after the second 
immunization (1:102’400) which ‘regularized’ again after the third immunization 
(data not shown, Genton et al.).  
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Discussion 
This is the first analysis of the cellular immune response against a synthetic peptides 
anchored to the surface of IRIVs. The results obtained here with the AMA-1 derived 
synthetic peptide AMA49-C1 prove the feasibility to elicit a proliferative CD4 T cell 
response against the synthetic peptide. Generally, the issue of T-cell monitoring 
during a clinical trial is complex and always requires a multifaceted decision which 
type of assays to use. Both standardization and validation of the various monitoring 
tools for cellular responses is insufficient and difficult (12). Enormous limitations are 
specimen availability since responding specific T-cell subsets may not always be 
present in peripheral blood compartment (PBC) (13, 14). Only few studies monitored 
T cell responses in vaccine site draining lymph node (13). In this trial we analyzed 
fresh isolated human PBMC using lymphoproliferation and ex vivo IFN-γ ELISpot 
assays. The first assay measures the T helper function at the level of the entire cell 
population, thus requiring prior in vitro expansion, the second one measures ex vivo T 
cell IFN-γ functionality at a single cell level. No significant increase in SFU beyond 
the pre-immune background has been detected for AMA49-C1 ex vivo ELISpot, 
whereas 50% of the volunteers were positive in AMA49-C1 lymphoproliferation after 
at least one of the three immunizations. The discrepancy between the two assays may 
be explained by various factors. (i) The two assays measure different T cell 
subpopulations as suggested by natural immunity analyses in adults from malaria 
endemic regions. PBMC stimulation with different CSP T cell epitopes gave for all 
donors different reactivity patterns according to the assay employed 
(lymphoproliferation, ex vivo ELISpot and 14-days cultured ELISpot, respectively). 
Thus, depending on the assay different protein regions emerged as immunodominant 
and the peptide reactivity pattern for each donor was unique (15). (ii) Detection limits 
of ex vivo ELISpot technology have been observed with tumor-specific T cells. 
ELISpot was less sensitive than IFN-γ intracellular flow cytometry in detecting T 
cells producing low amount of IFN-γ (16, 17). (iii) On the other side, in malaria 
exposed adults, T cell responses with different liver-stage antigen 1 (LSA-1) and 
thrombospondin-related adhesive protein (TRAP) peptides were detected with 5-days 
cultured IFN-γ ELISpot but not with ex vivo ELISpot (18). Moreover, the 5-days 
cultured ELISpot was less sensitive compared to ELISA proposing, in naturally 
exposed population, low frequency of high IFN-γ producing T cells specific for 
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malaria epitopes (18). The data we present here suggest that the in vitro expansion 
step of the lymphoproliferation assay increased the frequency of AMA49-C1 specific 
T cells sufficiently to yield SI ranging from 2 to 4.5 after the 1st and 2nd immunization. 
A decrease of response after the third inoculation (lymphoproliferative and ex vivo 
ELISpot values) has also been reported after immunization with the recombinant P. 
falciparum MSP142 delivered with AS02A adjuvant (19). This decrease is probably 
mainly attributable to the limitations of the peripheral blood-sampling compartment. 
The low frequency of AMA49-C1 specific T cells may be explained by paucity of 
promiscuous immnuodominant T cell eptitopes. The thirteen predicted best scoring 
AMA49-C1-epitope/HLA-DR allele combinations comprise only one (DRB1*0301) 
of the twelve HLA-DR molecules most prevalent throughout the world (11, 20). All 
three volunteers expressing DRB1*0301 were positive both for AMA49-C1 
lymphoproliferation and for parasite cross-reactive IgG in IFA and Western blotting 
assays. Inclusion of promiscuous CD4 T cell epitopes thus may represent an option to 
extend the T cell immunogenicity of virosomally formulated peptide vaccines. 
In children living in regions endemic for malaria, a malaria vaccine may boost pre-
existing anti-malaria T cell responses. More importantly, malaria antigen specific T 
cells elicited by natural exposure are expected to provide T cell help for vaccine 
induced B cells upon reinfection. Several lines of evidence indicate that influenza 
antigen specific immune responses enhance immunogenicity of IRIV-associated 
peptides. In mice a substantial increase in antibodies responses against IRIV-coupled 
antigens (diphtheria toxoid, tetanus toxoid, malaria peptides) was observed when pre-
immunized with influenza vaccine (2, 21) Furtheremore, influenza antigen CD4 
specific T cells enhanced the induction of melanoma peptide specific cytotoxic T 
lymphocytes (CTLs) in vitro. The spike protein hemagglutinin (HA), comprised in the 
virosomal formulation is described as good CD4 T cell activator (22). Our 
lymphoproliferation and ex vivo ELISpot data reconfirm that healthy adult Caucasian 
have usually developed a solid anti-influenza T cell response (23-25). When using 
IRIV for antigen delivery, the influence of pre-existing immunity to the viral 
components is an important issue, because of possible interference and impairment 
problems among the different responses. HA-specific CD4+CD25+ T regulatory cells 
capable of nonspecific bystander suppression have been described in vitro (26). A 
general lack of correlation between the magnitude of the pre-existing influenza 
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specific T cell response and the vaccination-induced AMA49-C1 specific humoral 
and cellular immune responses was found indicating that the different responses are 
not interfering among each other.  
Furthermore, we have shown that the combination of influenza virosomes carrying 
two different malaria-antigen-peptides did not negatively influence the immune 
response directed against AMA49-C1 peptide, because AMA-C1 lymphoproliferative 
responders are equally represented in the two considered vaccine formulation groups. 
Thus, IRIV appear to be a platform for the inclusion of several malaria-antigens in 
one vaccine-application targeting either the humoral immune response as well as CD4 
T cells. The inclusion of CD8 T cell epitopes is possible as well, as IRIV have 
demonstrated to induce CTLs if the peptide to be loaded onto MHC class I was 
encapsulated in the lumen of the virosomal particle (27, 28).  
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Table 1. Vaccine formulation groups analysed with IFN-γ ex vivo ELISpot and 
lymphoproliferation assay  
 
 
 
 
 
 
 
 
 
 
vaccine
formualtion
group
synthetic peptide
synthetic
peptide dose
total IRIV
amount
vaccine
formulation
name
group 3 AMA49-CPE 50 µg 10 µg influenza HA
100 µg phospholipids
PEV301
group 4 UK40 50 µg
10 µg influenza HA
100 µg phospholipids
PEV302
group 5 AMA49-CPE &
UK40
50 µg
20 µg influenza HA
200 µg phospholipids
PEV301&302
group 6 none -
10 µg influenza HA
100 µg phospholipids
IRIV
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Table 2. Comparison of AMA49-C1 lymphoproliferative response with anti-parasite 
antibodies.  
Bold indicates a positive response: for lymphoroliferation assay a stimulation index (SI) > 2; 
for IFA or Western blot analysis a titer > 100, + 100-1000,  ++ >1000. Frame indicates a 
positive response in all three assays. 0-Pre: pre-immunization blood sample, 1-st: 1st 
immunization blood sample, 2-nd: 2nd immunization blood sample, 3-rd: 3rd immunization 
blood sample.  
Lymphoproliferation assay were run in triplicate; SI = arithmetic mean cpm of AMA49-C1 
stimulated PBMC / arithmetic mean cpm of unstimulated PBMC 
 
 
 
 
 
 
 
 
 
 
Lymphoproliferation/SI
Abs
specificity/titers
Vaccine
formulation
Volunteers 0-Pre 1-st 2-nd 3-rd IFA/3-rd
Western
blot/
3-rd
group 3 21 0.8 0.4 0.3 0.4 - -
PEV301 24 0.9 0.3 0.1 0.6 - -
AMA49-CPE 50
µg
26 0.4 0.4 0.4 0.6 - -
27 0.1 1.2 2.4 0.3 ++ ++
28 0.3 0.4 1.6 1.4 - ++
29 0.3 0.9 3.6 0.1 - -
30 0.6 2.0 4.0 0.6 ++ ++
32 0.3 0.2 0.7 0.7 - ++
group 5 37 0.4 4.0 0.9 0.9 - -
PEV301&PEV302 38 1.2 0.7 1.6 0.9 - ++
AMA49-CPE 50
µg
39 1.2 4.4 2.8 1.9 ++ ++
UK39 50 µg 41 1.5 4.1 2.7 2.5 - ++
43 1.0 3.6 drop
out
44 0.9 0.9 1.1 1.3 + -
45 1.1 0.7 1.7 1.6 + -
46 0.5 2.4 4.5 1.3 ++ ++
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Table 3. Overview of HLA-DRB typing results of AMA49-CPE vaccinated volunteers 
Dash indicates a negative result. Bold indicates volunteers with a SI > 2 in 
lymphoproliferation assay. Frame indicates a positive response in the three assays 
(lymphoproliferation, IFA and Western blot analysis). Underlined indicates the best scoring 
HLADRB/AMA49-C1 epitopes. Italic indicates the next best scoring HLADRB/AMA49-C1 
epitopes obtained with TEPITOPE software 
(www.imtech.res.in/raghava/propred/) 
  HLA-DRB locus
Vaccine
formulation
Volunteers HLA-DRB1 HLA-DRB3 HLA-DRB4 HLA-DRB5
group 3 21 *0101/*1301 *0101 - -
PEV301 24 *0103/*0701 *0101 - -
AMA49-CPE 26 *0801/*1101 *0202 - -
27 *0101/*0301 *0101 -
28 *0701/*1104 *0202 *0103 -
29 *0801/*1501 *0101 - -
30 *0301/*1201 *0101/*0202 - -
32 *0101/*1001 - - -
group 5 37 *0405/*1101 *0202 *0103 -
PEV301&PEV302 38 *1104/*1501 *0202 *0101 -
AMA49-CPE 39 *1302/*1501 *0301 - *0101
UK39 41 *0404/*1401 *0202 *0103 -
43 drop out - - -
44 *0701/*1501 *0103 *0101 -
45 *1501 *0101 - -
46 *0301/*1502 *0101 - *0102
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Table 4. In silico results of the AMA49-C1 peptide with the software TEPITOPE using a 
threshold of 3% (www.imtech.res.in/raghava/propred/). Underlined indicates the predicted T 
cell epitope nonamers. 
 
 
 
 
 
 
 
 
 
 
 
HLA
DRB1-locus
AMA49-C1 peptide
DRB1_0301 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0305 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0306 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0307 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0308 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0309 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0311 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0410 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_0421 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_1102 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
DRB1_1107 GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG
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Table 5. Sperman’s correlation between the pre-existing anti-influenza T cell responses and 
the vaccine induced AMA49-CPE peptide specific immune responses. Spearman’s 
correlations with an r ranging from 0.3 to 0.6 and a p < 0.05 are low to moderate positive; 
with an r > 0.6 and a p < 0.05 are positive to strong positive. On the other side, Sperman’s 
correlations with an r ranging from - 0.3 to – 0.6 and a p < 0.05 are low to moderate negative; 
with an r < - 0.6 and a p < 0.05 are negative to strong negative. Other results than the one just 
described indicate lack of correlation. 
 
 
 
 
 
 
pre-existing anti-
influenza
responses
anti-AMA49 peptide
responses
Immunization
(anti-peptide
responses)
Spearman
correlation
Lymphoproliferation/SI Lymphoproliferation/SI 1-st r = 0.22
p = 0.40
(AMA49-C1) 2-nd r = -0.22
p = 0.44
IFN-! ex-vivo Elispot/
SFU/106 PBMC
Lymphoproliferation/SI 1-st r = -0.64
p = 0.007
(AMA49-C1) 2-nd r = -0.41
p = 0.13
Lymphoproliferation/SI ELISA/titers 1-st r = -0.04
p = 0.9
(AMA49-CPE) 2-nd r = -0.59
p = 0.02
3-rd r = -0.49
p = 0.07
IFN-! ex-vivo Elispot/
SFU/106 PBMC
ELISA/titers 1-st r = 0.33
p = 0.21
(AMA49-CPE) 2-nd r = 0.23
p = 0.4
3-rd r = 0.18
p = 0.53
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FIGURE 1. Structures of synthetic peptides discussed in the text.  
Synthetic peptides without R1 conjugate (phosphatidylethanolamin, PE): AMA49-C1 and 
UK40 
 
NH-GGCYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCG-CONH2
S S
R1
AMA49-CPE
AMA49-C1, UK40
without R1
UK39
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FIGURE 2. Summary of ex vivo IFN-γ ELISpot results. All the assays were run in triplicates. 
A) fresh isolated PBMC of group 3 and group 5 were stimulated for 24 h with AMA49-C1. 
B) fresh isolated PBMC of group 3-6 were stimulated for 24 h with influenza antigens.  
Spot forming unit (SFU) = arithmetic mean of spots of stimulated PBMC – arithmetic mean 
of spots of unstimulated PBMC. The obtained results were multiplied (x 5) for AMA49-C1 
stimulated PBMC (A) and (x 10) for influenza antigen stimulated cells (B) in order to get 
SFU/106 PBMC. The cut-off frequency was set at 100 SFU/106 PBMC with a minimal 
difference of 75 SFU/106 from the baseline. 
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FIGURE 3.  Sperman’s correlation between AMA-C1 lymphoproliferation SI and AMA-
CPE specific antibody titers (r = 0.34, p = 0.059). SI: Stimulation index. Spearman’s 
correlations with an r ranging from 0.3 to 0.6 and a p value of < 0.05 are low to moderate 
positive; with an r > 0.6 and a p < 0.05 are positive to strong positive 
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Figure 2: Association between AMA49-C1 lymphoproliferation and AMA49-CPE specific IgG-titer
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 Abstract 
In the absence of suitable rodent animal models for P. falciparum malaria, efficacy 
testing of asexual blood-stage vaccine candidates in Aotus nancymaae represents a 
tool to select between different formulations before conducting expensive human 
clinical trials. CpG oligo-nucleotides (ODN) specifically promote the production of 
pro-inflammatory and Th1-type cytokines and they enhance immunogenicity of co-
administered antigens. Toll like receptor 9 (TLR-9) binds directly and sequence-
specifically to single-stranded un-methylated CpG-DNA mediating the biological 
effects of CpG ODN. We cloned and characterized functionally the TLR-9 cDNA of 
A. nancymaae. The cDNA encompassed 3099 base pairs predicted to code for 1032 
amino acid residues. Results of homology searches to human TLR-9 suggested that 
the receptor is 93 and 94 % identical at the nucleotide and amino acid sequence level, 
respectively. Stimulation of splenocytes of A. nancymaae with CpG ODN resulted in 
proliferative responses in all animals analyzed. The B cell marker CD20 was up-
regulated after incubation of cultures with CpG ODN as assessed in FACS analysis 
consistent with B cell activation by CpG ODN. The high level of sequence 
conservation of Aona-TLR-9 reinforces the suitability of A. nancymaae as animal 
model for malaria sub-unit vaccine development. 
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The development of a safe and effective malaria vaccine remains an urgent medical 
need for human populations living in malaria-endemic regions (Malaney et al. 2004; 
Richie and Saul 2002). A. nancymaae is one of the few permissive hosts for asexual 
forms of two major human malaria parasites, Plasmodium falciparum and P. vivax 
(Gysin 1998). Immunisation and parasite challenge studies in A. nancymaae can 
rationally support decisions concerning further development of sub-unit malaria 
vaccines based on distinct antigens, antigen-combinations and antigen delivery 
systems (Chang et al. 1996). We have carried out immuno-genetic studies to 
characterize the adaptive immune system of this species in order to define at the 
molecular level its suitability as an experimental model in asexual blood-stage malaria 
vaccine development (Daubenberger et al. 2001; Diaz et al. 2000; Diaz et al. 2002; 
Diaz et al. 2000; Favre et al. 1998; Nino-Vasquez et al. 2000; Vecino et al. 1999).  
The vertebrate innate immune system recognizes conserved, pathogen-associated 
molecular patterns not present in the host, and responds through secretion and 
activation of a number of effector molecules (Klinman 2004). Recognition of un-
methylated CpG di-nucleotides within specific flanking bases has evolved as a pattern 
recognition mechanism used by the innate immune system to detect DNA of 
pathogens (Klinman 2004). The central involvement of the Toll like receptor 9 (TLR-
9) in responses to un-methylated CpG dinucleotides has been demonstrated using 
TLR-9-deficient mice (Hemmi et al. 2000) and CpG DNA is bound directly by the 
TLR-9 in the lysosomal compartment after cellular uptake (Cornelie et al. 2004; Latz 
et al. 2004). B cells and plasmacytoid dendritic cells are the main human cell types 
that express TLR-9 and respond directly to CpG ODN stimulation. Human memory B 
cells constitutively express high levels of TLR-9 and memory B cells proliferate and 
differentiate to immunoglobulin-secreting cells in response to CpG (Bernasconi et al. 
2003). At least three structurally distinct classes of CpG ODNs have been described in 
primates. K-type CpG ODN induce strong B- and NK-cell activation, D-type ODN 
provoke high levels of IFN-α secretion by plasmacytoid dendritic cells while C-type 
ODN combine properties of K- and D-type ODN (Vollmer el. 2004). Examples of K-
type include ODN 2006, an ODN with four “TCGT” motifs separated by polyT 
(Hartmann et al. 2000). K-type ODN rapidly activate CD19+ B cells in the peripheral 
blood to proliferate and secrete large amounts of IgM, IL-6 and IL-10 (Klinman et al. 
2004).  
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Addition of K-type ODN to vaccines against influenza virus, measles virus, hepatitis 
B virus surface antigen or tetanus toxoid increased antigen-specific antibody titres in 
mice by up to three orders of magnitude (Klinman 2004). Optimal immuno-
stimulatory CpG DNA motifs differ between mouse and human based on amino acid 
sequence variations between the extra-cellular regions of human and mouse TLR-9 
(Bauer et al. 2001). Therefore, experiments to determine whether a particular CpG 
ODN may be of therapeutic benefit in humans are initiated in rodents, followed by 
evaluations in non-human primates finally leading to phase I clinical trials (Cooper et 
al. 2004; Krieg et al. 2004).  
In the current study we analyzed at the molecular and functional level the TLR-9 of A. 
nancymaae (Aona-TLR-9). This study was motivated by the hypothesis that CpG 
ODN might have suitable adjuvant activity for induction of Th1-mediated immune 
responses in malaria vaccine development (Jones et al. 1999a). Additionally, a recent 
report demonstrated that schizont extracts of P. falciparum may contain a novel non-
CpG ODN ligand binding to human TLR-9 leading to possible novel insights into 
early events in host-parasite interactions in malaria (Pichyangkul et al. 2004).  
The animals analyzed were captured in the Colombian Amazon area close to Leticia 
and kept at the experimental primate station of the Fundacion Instituto de 
Immunologia de Colombia (FIDIC). The animals were kept in accordance with 
recommendations of the Committee on Care and Use of Laboratory Animals, US and 
the Colombian National Institute of Health guidelines for use of laboratory animals 
and supervised by the Colombian Wildlife Corporation (CORPOAMAZONIA). 
Mononuclear cells from three healthy monkeys numbered as 23964, 23967 and 23968 
were obtained by splenectomy followed by density gradient separation. Total RNA 
was isolated from spleen cells of monkey 23968 as described (Daubenberger et al. 
2001) using RNAeasy Mini Kit (Qiagen, Germany) according to the manufacturer's 
protocol. After reverse transcription using Superscript and random hexamer primers, 
the complete cDNA of TLR9 was amplified in overlapping fragments. The primer 
sequences used were designed according to human TLR-9 sequence (GenBank 
accession number NM017442) and are summarized in Table 1. The following 
temperature profile was employed: 3 min 94 C, and 30 cycles with a profile of 30 sec 
each at 94 °C, 58 °C and 72 °C. Amplicons were purified using a PCR product 
purification kit (Roche Molecular Biochemicals) according to manufacturer's protocol 
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and cloned into the pGEM5 T-vector (Promega, Catalys AG). After isolation of 
plasmids using the NucleoSpin kit (Macherey-Nagel AG), double stranded plasmid 
DNA was sequenced and analyzed employing an ABI PRISM 310 genetic analyzer 
(Perkin Elmer) on both strands. To exclude possible PCR errors, all products were 
amplified from two independently obtained cDNA and several independent plasmids 
of each amplification reaction were sequenced.  
Phylogenetic analysis 
Phylogenetic analysis was performed employing the PHYLIP 3.572 software package 
available under http://bioweb.pasteur.fr. The phylogenetic tree was constructed 
according to the neighbour-joining method based on Kimura two-parameter distances 
estimates (Saitou and Nei 1987).  
Oligodeoxynucleotides 
The CpG ODN used were designed with a phosphoro-thioate backbone, which 
confers nuclease resistance on the DNA protecting them from rapid degradation 
within the cells. The CpG sequences were chosen on the basis of the studies of 
Hartmann et al (Hartmann et al. 2000a) demonstrating that ODN 2006 (5´-
TCGTCGTTTTGTCGTTTTGTCGTT -3´) is an optimal sequence for stimulation of 
human B cells. Control ODN IMT022 (5´-TGCTGCAAAAGAGCAAAAGAGCAA-
3´) has been described (Elias et al. 2003). Desalted phosphoro-thioate 
oligonucleotides (ODN), HPLC purified, were purchased from Metabion GmbH 
(Germany). Purity was assessed by HPLC assays. ODN were suspended in HBSS 
buffer (Sigma) and kept at -20 °C until used.  
Lymphocyte proliferation assay 
Spleen cells derived from A. nancymaae were isolated by Ficoll-Hypaque (Amersham 
Pharmacia Biotech, Switzerland) density gradient centrifugation and were used after 
preservation in liquid nitrogen. Cells were cultured in cell culture medium composed 
of RPMI 1640 supplemented with 10 % heat-inactivated human AB serum (Milan 
AG, Switzerland), 2mM L-glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (Sigma). A. nancymaee spleen cells (1 x 105 cells/well) were stimulated 
for 72 h with phosphoro-thioate ODN 2006 and control ODN IMT022 at 6 µg/ml in 
96-well round bottomed plates (Nunc) or with medium alone. 16 h before harvest, 
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[3H]thymidine  was added (1 µCi/well), the cultures harvested onto glass-fibre filters 
and the incorporated radioactivity measured by scintillation counting.  
FACS analysis of in vitro B cell stimulation 
Briefly, spleen cells of A. nancymaae were cultivated at 3 x 105 cells/ml in cell culture 
medium in 48-well plates (Nunc) for 96 hours in the presence of medium alone or the 
ODN 2006 and IMT022. Cells were recovered, resuspended in HBSS buffer 
containing 1% human serum albumin and 0.01 % NaN3 (FACS buffer), transferred to 
FACS tubes and stained for flow cytometry with the B cell specific anti-CD20 mAb 
B-Ly1 (Daubenberger et al. 2001c).  Cells were gated using forward and side scatter 
parameters for dead cell exclusion. In each sample, 10 000 events were measured and 
data analyzed using the CellQuest software (BD Biosciences) to determine mean 
fluorescence intensities.  
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Results 
Using primer pairs designed according to the human TLR-9 sequence (GenBank 
accession number NM017442), a set of RT-PCR products were obtained which 
comprised the entire coding sequence of A. nancymaae TLR-9 cDNA (Aona-TLR-9). 
The total length of the Aona-TLR-9 open reading frame (ORF) was 3099 bp coding 
for a protein of 1032 amino acids. The nucleotide sequences and the amino acid 
sequences displayed 93 % and 94% identity, respectively, to the human TLR-9 
(Figure 1A). A comparison of structural features using the SMART architecture 
research program (http://www.smart.embl-heidelberg.de) demonstrated that the 
structure of Aona-TLR-9 is highly conserved to human TLR-9. Eighteen leucine-rich 
repeats (LRR) were identified by the program, followed by one leucine rich repeat C-
terminal domain and the toll - interleukin 1 – resistance domain (TIR) encompassing 
residues 869 to 1016 (Figure 1A). A single-nucleotide polymorphism of TLR-9 in 
human populations has been described (Lazarus et al. 2003). One of the allelic 
variants in humans carried at amino acid position 5 cysteine instead of arginine 
(R5C). Alignment of human and Aotus TLR-9 amino acid sequences demonstrated 
the same sequence polymorphism (R5C) between these two species. Phylogenetic 
analysis confirmed that the amino acid sequences of human and Aona-TLR-9 are 
closely related clustering together on a separate branch, separated from rodent and 
carnivora TLR-9 sequences (Figure 1B).  
Next we wanted to demonstrate that Aona-TLR9 bind to CpG ODN leading to cell 
activation. It is well established that K-type CpG ODN induce proliferative responses 
via TLR-9 binding in B cells (Krieg et al. 1995). Therefore, we measured proliferative 
responses of splenocytes upon incubation with ODN 2006 and control ODN IMT022. 
In splenocytes of all three Aotus animals tested, ODN 2006 induced significant 
proliferative responses. The [3H]thymidine uptake in cultures incubated with control 
ODN IMT022 was comparable to un-stimulated cultures demonstrating that the effect 
of ODN 2006 was dependent on a distinct ODN sequence (Figure 2).  
In order to confirm that Aotus B cells were activated by CpG ODN 2006, we analyzed 
changes in CD20 expression level. As demonstrated in Figure 3, incubation of spleen 
cells with ODN 2006 resulted in increase of mean fluorescence intensity. In cultures 
incubated with medium or control ODN IMT022, the values ranged between 180 and 
Chapter 3.3 
 
104 
 
141, respectively, while in ODN 2006 treated cultures the mean fluorescence intensity 
reached 202.   
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Discussion  
Aluminium compounds, the only adjuvant used widely in humans, do not support the 
development of Th1-type cell-mediated immune responses. Since this arm of the 
cellular immune response seems to play a central role in protection in a number of 
infectious diseases including malaria (Gupta 1998) novel approaches to develop 
vaccine formulations that induce Th1-type and cytotoxic T cell responses are needed.   
CpG ODN have potential to be developed as components in novel vaccine 
formulations (Klinman 2004e). CpG ODN trigger the production of chemokines, Th1-
type and pro-inflammatory cytokines (including IFN-γ, IL-6, IL-12, IL-18 and TNF-
α) and promote antigen-specific humoral immune responses by acting with B cells 
(Krieg et al., 1995). TLR-9 molecules expressed by different species have diverged 
over evolutionary periods and the precise sequence motif optimal for stimulating 
immune cells from one species frequently differs from those in other species (Bauer et 
al. 2001a). PBMC from humans, rhesus macaques, chimpanzees and orang utans 
respond to the same broad classes of CpG ODN while rodents respond poorly to some 
but not all CpG ODN that are highly active in primates. Thus efforts to determine 
whether CpG ODN may be of therapeutic benefit are typically initiated in mice and 
then followed by studies involving non-human primates (Klinman et al. 2004a).  
Introduction of double alanine mutations (D535A and Y537A) strongly diminished 
the CpG-sequence specific DNA binding supporting that the region containing D535 
and Y537 is involved in DNA binding (Rutz et al. 2004). These two amino acid 
residues of functional importance are conserved between all full length TLR-9 
sequences available in the GeneBank and also in Aona-TLR-9. The CD20 molecule, 
also known as Bp35, is expressed from the pre-B to mature B cell stages and while its 
precise functional role remains unknown, a role in B cell activation, proliferation and 
differentiation is suggested (Clark et al. 1985). We report here to our knowledge the 
first time that CD20 is up-regulated upon incubation of B-cells with CpG ODN 2006. 
Furthermore, the first TLR-9 cDNA sequence of a non-human primate is described 
here.  
Aotus monkeys immunized with a synthetic malaria peptide formulated in CpG ODN 
2006 responded with significantly higher antibody levels compared to animals treated 
with control ODN (Jones et al. 1999b). In summary, these results support the 
Chapter 3.3 
 
106 
 
suitability of Aotus monkeys to analyze CpG ODN as adjuvant compound for subunit 
based vaccines against P. falciparum and P. vivax.  
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Fig. 1 a Amino acid sequence comparison of TLR-9 of A. nancymaae and H. sapiens using 
the ClustalW program available under http://www.ebi.ac.uk/clustalw/.  
Symbols “*”,“:” and “.” indicate identical, conserved and semi-conserved amino acid 
residues, respectively. Both sequences were analyzed for its domain structure using the 
SMART program available under http://smart.embl-heidelberg.de/. The predicted signal 
sequence is given in italics, the leucine-rich repeat region (LRR) is underlined and the boxed 
sequences indicate the Toll – IL-1 - resistance domain (TIR).   
H. sapiens       MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA
60
A. nancymaae MGFCCSALHPLSLLVQAMMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSVAA 60
                 **** ************:***************************************:**
H. sapiens       PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL
120
A. nancymaae     PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLDLKWNCPPVGLSPMHFPCHMTIEPNTFL
120
                 ********************************:***********************.***
H. sapiens       AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY
180
A. nancymaae     AVPTLEELNLSYNSITAVPALPKSLVSLTLSRTNILVLDSASLAGLHALRFLFMDGNCYY
180
                 *************.* :********:**:**:****:***********************
H. sapiens       KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL
240
A. nancymaae     KNPCRRALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNHIIKLAPGDL
240
                 *****:********************************************:*:**** **
H. sapiens       ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN
300
A. nancymaae     ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPNTFSHLSRLEGLVLKDSSLSWLN
300
                 *************************************:**********************
H. sapiens       ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF
360
A. nancymaae     ASWFHGLGNLRVLDLSENFLYECITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF
360
                 ****:****************:**************************************
H. sapiens       GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV
420
A. nancymaae     GSLFSLEELDMHGIFFRSLDETTLRPLARLSRLQTLHLQMNFINQAQLGIFGAFPGLRHV
420
                 **.:*:***********************. ****:************** ******:*
H. sapiens       DLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLS
480
A. nancymaae     DLSDNRISGASELAATTGEADGGGRVWLQPGDLAPAPVDAPSSEDFTANCSTLNFTLDLS
480
                 *************:** ****** :**************:****** .************
H. sapiens       RNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHS
540
A. nancymaae     RNNLVTVRPEMFARLSHLQCLRLSHNCIMQAVNGSQFLPLTDLRVLDLSHNKLDLYHEHS
540
                 *******:*****:************** ************.*:****************
H. sapiens       FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL
600
A. nancymaae     FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRYLSLAHNNIHSRVSPQLRSTSL
600
                 **************************************:**********:** ** ****
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Fig. 1 b Unrooted phylogenetic tree established from deduced TLR-9 amino acid sequences 
of Canis familiaris (NP_001002998), Sus scrofa (NP_999123), Rattus norvegicus 
(NP_937764), Homo sapiens (NP_059138), Felis catus (AAN15751), Mus musculus 
(NP_112455) and A. nancymaae AY788894 using the neighbor-joining algorithm of the 
PHYLIP 3.572 program package available at http://bioweb.pasteur.fr. The numbers at the 
nodes indicate the percentage of recovery of that node in 1,000 bootstrap replications. 
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Fig. 2 Stimulation of spleen cells of A. nancymaae by ODN. A. nancymaae spleen cells were 
cultured in the presence of 6 µg/ml ODN for 72 h, pulsed during the last 16 h with [3H]-
thymidine and incorporated radioactivity was measured. Data represent mean cpm of 
triplicate cultures of three different animals.  
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Fig. 3 The B cell marker CD20 is up-regulated upon incubation with CpG ODN 2006. Spleen 
cells were incubated for 96 h with medium alone (dotted line), CpG ODN IMT022 (black 
line) and 2006 (filled graph) at 6 µg/ml. Then cells were removed from culture and stained 
with anti-CD20 mAb and analyzed by FACS analysis. 
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Abstract 
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is the third most common 
mycobacterial infection in immuno-competent humans besides tuberculosis and 
leprosy. We have compared by ex vivo ELISpot analysis interferon-gamma (IFN-γ) 
responses in peripheral blood mononuclear cells (PBMC) from BU patients, house-
hold contacts and individuals living in an adjacent M. ulcerans non-endemic region. 
PBMC were stimulated with PPD and non-mycobacterial antigens like reconstituted 
influenza virus particles and isopentenyl-pyrophosphate. With all three antigens the 
number of IFN-γ spot forming units was significantly reduced in BU patients 
compared to the controls from a non-endemic area. This demonstrates for the first 
time that M. ulcerans infection-associated systemic reduction in IFN-γ responses is 
not confined to stimulation with live or dead mycobacteria and their products, but 
extends to other antigens. IL-12 secretion by PPD stimulated PBMC was not reduced 
in BU patients, indicating that reduction in IFN-γ responses was not caused by 
diminished IL-12 production. Several months after surgical excision of BU lesions, 
IFN-γ responses of BU patients against all antigens used for stimulation recovered 
significantly, indicating that the measured systemic immuno-suppression was not the 
consequence of a genetic defect in T cell function predisposing for BU but is rather 
related to the presence of M. ulcerans bacteria.   
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Introduction 
BU caused by M. ulcerans is an infectious disease characterized by chronic, 
necrotizing ulceration of subcutaneous tissues and the overlying skin. The disease 
starts as a subcutaneous nodule, papule or plaque that eventually ulcerates and 
progresses over weeks to months until surgical excision or spontaneous healing 
occurs [1]. After tuberculosis and leprosy BU is the third most common 
mycobacterial infection in immuno-competent humans [2]. The main burden of 
disease falls on children living in sub-Saharan Africa but healthy people of all ages, 
races and socio-economic class are susceptible [3]. The effectiveness of anti-
mycobacterial drug therapy has not been proven [3]. Consequently, surgery is 
presently the recommended treatment option [4]. In BU lesions clumps of extra-
cellular acid-fast organisms surrounded by areas of necrosis are found particularly in 
subcutaneous fat tissue [5]. M. ulcerans produces a family of macrolide toxin 
molecules, the mycolactones, which are associated with tissue destruction and local 
immunosuppression [6]. In cell culture experiments mycolactones produce apoptosis 
and necrosis in many human cell types [7;8]. The toxin appears to play a role in 
inhibiting the recruitment of inflammatory cells to the site of infection, which 
explains at least in part why inflammatory responses are poor in BU lesions [5]. 
However, intra-lesional influx of leukocytes and granulomatous responses in the 
dermis and panniculus has been reported in late stages of the disease [9;10]. 
Spontaneous healing can occur and is often accompanied by a conversion of the 
Burulin (M. ulcerans sonicate) skin test from negative to positive. However, the 
immune mechanisms involved in protection against BU are largely unknown. 
The importance of IFN-γ for immunity against mycobacterial infections in humans is 
demonstrated by the increased susceptibility of children carrying complete IFN-γR1 
chain deficiency to environmental mycobacterial infection [11]. Apart from CD4+ T 
cells, γδ T cells, natural killer cells and CD8+ T cells are potent sources of IFN-γ. CD4 
T cells can be differentiated into Th1 and Th2, distinguished by their patterns of 
cytokine production after antigen activation. Apart from other cytokines, Th1 cells 
preferentially secrete IFN-γ, while Th2 cells preferentially secrete IL-4 and IL-5. Th1 
or Th2 development is determined by the cytokine environment during T cell 
activation in the primary response to antigen with IL-12 and IFN-γ implicated in the 
decision to adopt a Th1 phenotype [12]. IFN-γ binds to the IFN-γR1/IFN-γR2 receptor 
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complex and stimulates innate cell-mediated immunity through NK cells and 
activation of bactericidal mechanisms in macrophages. The central role of IFN-γ in 
MHC class I and class II restricted antigen processing and presentation is well 
documented [13]. At present, the contribution of IFN-γ in immunity to extra-cellular 
M. ulcerans remains to be established.  
Peripheral blood mononuclear cells (PBMC) of BU patients with active disease 
showed significantly reduced lympho-proliferation and IFN-γ secretion in response to 
stimulation with live or killed preparations of M. bovis, M. ulcerans, M. tuberculosis 
and the recombinant protein Ag85 of M. tuberculosis [14-18]. Here we have 
determined in a cross-sectional study the frequency of IFN-γ secreting cells in PBMC 
from BU patients, their household contacts and controls from BU non-endemic areas 
by ex vivo ELISpot analysis. The antigens used for stimulation included isopentenyl-
pyrophosphate (IPP), reconstituted influenza virus particles (virosomes) and 
tuberculin purified protein derivative (PPD) of M. tuberculosis, which stimulate 
distinct T cell subsets, like Vγ2Vδ2 T cells [19], CD4 T cells [20], CD4 and Vγ2Vδ2 
T cells [21], respectively. Results demonstrate that BU associated reductions in IFN-γ 
responses are not confined to stimulation with live or dead mycobacteria and 
mycobacterial antigens. Furthermore, it is shown for the first time that in individual 
BU patients this suppression in IFN-γ secretion improved in a time interval of 5 to 10 
months.  
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Materials and Methods 
Study population  
Thirteen BU patients, 19 clinically healthy household contacts that never had clinical 
BU and 18 healthy persons living in a M. ulcerans non-endemic districts in the 
Greater Accra region of Ghana were enrolled for the study (Table I). All BU patients 
enrolled were residents of the BU-endemic Ga District and presented with pre-
ulcerative or ulcerative lesions at the Amasaman Health Centre. Informed consent was 
obtained from study participants or their parents or guardians before enrollment. For 
ethical reasons, the age range of the non-exposed controls that were included into the 
analysis was higher than that of the BU patients. Ethical approval for the study was 
obtained from the local ethical review board of the Noguchi Memorial Institute for 
Medical Research, University of Ghana, Legon. Clinical diagnosis of BU was 
reconfirmed as described [22;23] by one or more laboratory verification tests (Table 
II) including culture of M. ulcerans, microscopic detection of Acid Fast Bacilli (AFB) 
or IS2404 PCR. The clinical pictures of the patients ranged from nodules or plaques 
to severe ulcerative forms (Table II). In the BU group nine persons and in the other 
two groups each 10 persons with a BCG scar were recruited (Table I). PBMC were 
isolated from venous peripheral blood using Ficoll-Hypaque gradient centrifugation 
following standard procedures and cryo-preserved prior to the analysis.  
Antigens 
After thawing PBMC were directly stimulated with 50 µM isopentenyl pyrophosphate 
(IPP; Sigma), 10 µg/ml tuberculin purified protein derivative of M. tuberculosis 
(PPD; Statens Seruminstitut, Denmark), 10 µg/ml PHA (Sigma) or 20 µg/ml 
reconstituted influenza virus particles (IRIV, Berna Biotech). These influenza 
virosomes are spherical uni-lamellar vesicles prepared by detergent removal from 
influenza surface glycoproteins and mixtures of natural and synthetic phospholipids 
containing H1N1 from influenza virus strain A/Singapore/6/86 [24]. Cell culture 
medium consisted of RPMI 1640, 10 % heat inactivated human AB serum, 2 mM 
glutamine, 100 U/ml penicillin, 100  g/ml streptomycin (Gibco-BRL). 
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Ex vivo IFN-γ  ELISpot analysis 
PBMC were thawed, washed and suspended at a concentration of 2 x 106 cells/ml in 
complete cell culture medium. The cells were then stimulated with the different 
antigens at the final concentrations indicated above and incubated for 24 h at 37°C, 5 
% CO2 humidified atmosphere. A 96-well nitrocellulose-bottomed plate (Millipore) 
was coated overnight at 4°C with 10 µg/ml anti-human-IFN-γ primary antibody 
(clone1-D1K; Mabtech, Sweden). The plates were then washed five times with PBS 
and blocked with cell culture medium for 1 h at room temperature. The medium was 
decanted and pre-incubated cells (2 x 105 or 1 x 105) were added to each well in 
triplicate and incubated at 37 °C for another 20 h. Assays were terminated by washing 
plates three times with PBS-Tween 80 (0.05 %) followed by PBS another three times. 
Secondary antibody (biotin-labeled anti-human-IFN-γ; clone 7-B6-1) was added to 
each well at 1 µg/ml and the plate incubated for 2 h at RT. Plates were washed again 
six times with PBS before application of streptavidine-alkaline phosphatase (1 : 1000 
dilution in PBS, 0,5 % FCS, 100  l/well) for 1 h at RT. After washing wells seven 
times with PBS, distinct spots were developed by the incubation of plates at RT for 4 
to 10 min following the addition of the developing buffer (BCIP/NBT, diluted 1 : 100, 
Bio-Rad). Spot development was stopped by washing the plates extensively with 
water and left to dry. Plates were later evaluated using the ELISpot Reader system 
(AID, Germany) to determine the number of spot forming units (SFU).  
ELISA quantification of IL-12 in cell culture supernatants  
Levels of total IL-12 in culture supernatant of PBMC incubated with PHA (10 µg/ml) 
and PPD (10 µg/ml) for 96 h were determined by ELISA employing a commercial kit 
(Mabtech, Sweden). Samples were analyzed in triplicates and results expressed as the 
average of the three readings in an ELISA reader at 450 nm with reference to curves 
generated using serially diluted recombinant human IL-12. The sensitivity of the 
assay was 30 pg/ml for total IL-12.  
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Statistical analysis 
Data were analyzed using the STATA program (Stata Corporation). Comparisons 
among the paired samples were performed using the Wilcoxon signed-rank test whilst 
the Wilcoxon rank-sum test was used to analyze the significance of observed 
difference in IL-12 secretion between patients and un-exposed controls. For 
comparing the frequencies of antigen specific IFN-γ secreting cells, the data was 
transformed to normality using Box-Cox transformation before analyzed by linear 
regression. Data were considered statistically significant when P< 0.05. 
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Results 
Frequency reduction of IFN-γ  secreting spot forming units in PBMC from BU 
patients 
Thirteen patients with laboratory-reconfirmed M. ulcerans infection, nineteen 
clinically healthy household contacts and eighteen individuals from a neighboring BU 
non-endemic area were enrolled for this study (Table I and Table II). The frequency 
of immediate IFN-γ secreting cells in PBMC upon stimulation with IPP, IRIV and 
PPD was analyzed using an ex vivo ELISpot assay. Fig. 1 shows that the mean of SFU 
upon stimulation with PPD, IPP and IRIV was significantly lower (p=0.0086, p=0.001 
and p=0.0002, respectively) in BU patients compared to non-exposed controls. In 
household contacts, the mean of SFU after IPP and IRIV stimulation was significantly 
higher compared to BU patients (p=0.005 and p=0.001, respectively) while in PPD 
stimulated cultures no significant difference was observed (p=0.82).  
Recovery from systemic immuno-suppression after surgical treatment 
All patients enrolled for the study were treated by wide surgical excision of the BU 
lesions. Blood samples were collected several months after the first sampling (Table 
2) and PBMC from both time points were analyzed in parallel using the same IFN-γ 
ELISpot assay as above. A 3.9, 3.7 and 3.6 fold median increase in cellular responses 
against IPP, IRIV and PPD stimulation, respectively, was observed when PBMC 
taken at the two time points were compared (Fig. 2A). Statistical analysis confirmed 
this increase of responses as highly significant with p-values of 0.021 and 0.003, 
respectively, after IPP and IRIV stimulation. PHA stimulated control wells showed 
only a slight (1.7 fold) median increase between the two different time points 
analyzed (p=0.17) and in PPD stimulated cultures the boost was not significant 
(p=0.09). One representative example of an ELISpot analysis is shown in Fig. 2B 
with the numbers of SFU detectable after IPP, IRIV and PPD stimulation rising 
between 1st and 2nd sampling. In contrast, medium and PHA control wells remained at 
a comparable level between the two analyses. 
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IL-12 production in PPD stimulated PBMC is not affected in BU patients 
Next we wanted to determine whether the systemic suppression of IFN-γ responses in 
BU patients is related to a diminished capacity to secrete IL-12. PBMC of nine 
patients and ten persons from BU non-endemic areas were stimulated with PHA or 
PPD and the total IL-12 concentration in cell culture supernatants was measured by 
ELISA (Fig. 3). Interestingly, the IL-12 concentrations in PPD stimulated PBMC of 
individuals living in M. ulcerans non-endemic regions were statistically lower 
compared to BU patients (p=0.011) while in PHA stimulated cultures no significant 
difference was observed (p=0.57) (Fig. 3). The mean IL-12 concentrations in 
supernatants of PPD and PHA stimulated cultures of PBMC obtained before or after 
surgical treatment showed no difference (Fig. 3).  
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Discussion 
An ex vivo ELISpot assay for detection of IFN-γ secretion permitting the direct 
detection of individual antigen-specific T cells at low frequencies was employed in 
the current study [25]. The 48 h antigen challenge of PBMC suffices to engage 
cytokine production in the memory/effector T lymphocyte but not in naïve T cells and 
allows determination of frequencies and cytokine signatures of re-circulating antigen-
specific T cells [25]. The frequencies of systemic IFN-γ producing SFU after 
stimulation with IPP, IRIV or PPD was significantly reduced in BU patients 
compared to individuals living in a neighboring BU non-endemic area. This result is 
consistent with other reports demonstrating that PBMC from subjects with past or 
current M. ulcerans disease had reduced IFN-γ production in response to PPD of M. 
tuberculosis and M. bovis or whole killed M. bovis BCG or M. ulcerans [14-18]. 
However, our data strongly indicate that reduced IFN-γ production is not confined to 
immune responses specific for mycobacterial antigens or whole mycobacteria but 
extends to CD4 T cell responses specific for influenza virus [20] and Vγ2Vδ2 T cells 
[19].  
Reduced IFN-γ production in BU patients could be the consequence of a genetic 
abnormality in T cell function predisposing for mycobacterial infections [11]. 
Therefore, we analyzed PBMC of BU patients sampled at two consecutive time 
points. When the paired PBMC samples were analyzed in parallel by ELISpot 
analysis, the numbers of IFN-γ secreting cells after IPP, IRIV and PPD stimulation 
increased significantly after surgical treatment. Comparable numbers of SFU in PHA 
stimulated PBMC in paired samples excluded a general suppression of cellular 
immune responses in BU and variations in quality of PBMC sample cryo-
preservation. To our knowledge, this is the first report demonstrating that antigen-
specific IFN-γ production in BU patients is coming back to normal levels after 
surgical treatment. Hence, confounding genetic defects do not seem to be responsible 
for the observed immuno-suppression. The question if IFN-γ production in patients 
undergoing spontaneous healing of BU will also improve over time is not addressed 
here.  
IL-12 induces T and NK cells to produce several cytokines, including IFN-γ [26]. 
Total IL-12 concentrations in culture supernatants of PPD stimulated PBMC were 
statistically higher in BU patients (treated and untreated) than in the controls. This 
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may reflect a compensatory mechanism of the immune system to restore IFN-γ 
production and indicates that the observed reduction in systemic IFN-γ responses is 
not caused by diminished IL-12 production. Different cytokine expression profiles in 
both PBMC and skin lesions were described in patients suffering from the nodular 
and ulcerative forms of BU. Nodules were associated with higher IFN-γ and lower IL-
10 production and BU with lower IFN-γ and higher IL-10 production [17]. Within the 
limited number of BU patients enrolled in our study, a relationship between different 
stages of BU disease and reduction of IFN-γ secretion was not observed.  
Vγ2Vδ2 T cells compose the majority of human γδ T cells in circulation and among 
their defined ligands is IPP, a metabolite found in prokaryotic and eukaryotic cells 
including mycobacteria [27]. Studies in rhesus monkeys provided evidence that 
Vγ2Vδ2 T cells contribute to adaptive immune responses in mycobacterial infections 
[28]. A correlation between the absence or loss of Vγ2Vδ2 T cells and the extent of 
M. tuberculosis disease has been described [29]. An impaired ability of Vγ2Vδ2 T 
cells to produce cytokines or proliferate in response to phosphorylated microbial 
metabolites was observed in active M. tuberculosis pulmonary disease [30-32]. 
Interestingly, in 10 out of 13 BU patients analyzed here, the ex vivo IFN-γ secretion of 
IPP-reactive Vγ2Vδ2 T cells increased significantly after surgical treatment.  
The diffusible macrolide toxins produced by M. ulcerans are considered as virulence 
factors responsible for pathogenicity of M. ulcerans and it has been hypothesized that 
lack of inflammatory responses in BU lesions are related to local immuno-suppressive 
activities of the mycolactones [6;33;34]. The treatment-associated reversal of immune 
suppression may indicate that mycolactones exert apart from local also systemic 
effects. Alternatively, additional other immune-suppressive mechanisms may be 
operative in chronic M. ulcerans disease. PBMC from healthy contacts of TB patients 
and TB patients with limited disease produce large quantities of IFN-γ in response to 
whole mycobacteria, PPD of M. tuberculosis, ESAT-6, 16-kDa and 38 kDa proteins 
[35-39]. In contrast, PBMC of active TB patients with advanced disease produce low 
quantities of IFN-γ after similar stimulation and following effective drug treatment the 
IFN-γ secretion improved [39;40]. Possible candidate structures mediating immune 
suppression in M. tuberculosis isolates like phenolic glycolipids have been described 
[41;42]. In leprosy induction of regulatory or suppressor T cells mediating immune 
suppression in affected hosts has been proposed [43;44]. Our findings, within their 
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limits due to the small number of BU patients analyzed and the timing of the blood 
samples drawn, may indicate that mycolactone-independent immunosuppressive 
mechanisms common to chronic mycobacterial infections contribute to the reduction 
of systemic IFN-γ responses in BU patients.  
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TABLE 1. Characteristics of BU patients, household contacts and controls from a BU non-
endemic area enrolled in the study. 
a % values calculated for 13 patients, 14 household contacts and 14 controls, respectively. 
Five household contacts and four non-exposed controls remained with uncertain scar status. 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Buruli
ulcer
patient
(n = 13)
Household
contacts
(n =19)
Controls from non-
endemic area
(n = 18)
Sex
Male 5 (39%) 6 (32%) 8 (44%)
Female 8 (61%) 13 (68%) 10 (56%)
Median age (years) 15 15 29.5
Age range (years) 6 - 45 6 - 56 24 - 65
BCG scar present
(%) a 69 52 55
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TABLE 2. Clinical data of patients presenting with lesions due to confirmed M. ulcerans 
infection. 
a clinical forms of BU disease were graded according to the WHO case definition [1]. 
b BCG status was determined by confirmation of the presence of a BCG scar by two persons. 
c Acid fast bacilli detection was performed by direct smearing of tissue exudates followed by 
Ziehl-Neelsen staining [1]. 
d Culture of M. ulcerans according to [22]. 
 
 
 
 
 
 
 
patient age gender clinical forma BCG
statusb
AFBc cultured PCRe 1st blood
sample f
2nd blood
sample f
P03 45 f ulcerative - + + + 3 mo 11 mo
P04 9 f plaque + - + + 0 8 mo
P05 10 m nodule + + + + 0 8 mo
P08 16 m ulcerative - + + + 4 mo 14 mo
P09 5 f ulcerative + + - + 3 mo 12 mo
P11 20 f ulcerative + + + + 7 d 7 mo
P12 16 m ulcerative + - - + 3 mo 12 mo
P13 11 f ulcerative - + + + 7 d 7 mo
P14 15 m plaque - - - + 7 d 8 mo
P15 7 f ulcerative + + + + 0 9 mo
P19 6 m nodule + + + + 0 6 mo
P21 17 f nodule + + - + 0 5 mo
P22 17 f nodule + + + - 0 5 mo
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Fig. 1. Quantification of ex vivo IFN-γ secreting cells by ELISpot analysis after stimulation of 
PBMC with IPP (◊), IRIV () and PPD (). PBMC derived from BU patients (BU), 
household contacts (HC) and controls from a BU non-endemic area (NC) were thawed into 
cell culture medium and kept overnight in the presence or absence of the different stimuli. For 
the detection of IFN-γ  producing cells, 2 x105 PBMC/well were plated in triplicate wells 
and spots were developed after 24 h. Delta SFU = mean of SFU of stimulated triplicate 
cultures – mean SFU of un-stimulated triplicate cultures. Data from each individual analyzed 
are shown separately. Mean SFU/106 PBMC were 26 (6 – 102), 137 (57 – 327) and 262 (157 
– 436) after stimulation with IPP in BU patients, HC and NC, respectively. In IRIV-
stimulated cells, the mean SFU/106 cells were 22 (7 – 70), 135 (83 – 221), 149 (56 – 394) in 
BU patients, HC and NC, respectively. After PPD stimulation, 88 (35 – 223), 39 (14 – 106) 
and 212 (100 – 445) SFU/106 PBMC were recorded in BU patients, HC and NC, respectively. 
The values given in brackets are the 95 % confidence intervals of the geometric means of 
SFU. Data of patients P03, P08, P09 and P12 are shaded in grey. 
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Fig. 2. (A) Frequency increase of antigen-specific ex vivo IFN-γ secreting cells in BU 
patients. PBMC of thirteen BU patients sampled at two time points (Table II) were thawed 
into cell culture medium and kept overnight in the presence or absence of IPP (◊), IRIV (), 
PPD () and PHA (). For the detection of IFN-γ producing cells, 2 x105 PBMC/well were 
plated in triplicate wells and spots were developed after 24 h. Delta SFU were calculated as 
described in Fig. 1. Given is the ratio of SFU obtained after 2nd sampling / 1st sampling. Data 
of patients P03, P08, P09 and P12 are shaded in grey. 
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Fig. 2. (B) Representative IFN-γ ELISpot patterns of BU patient P21. PBMC of BU patient 
P21 were obtained immediately before surgical excision of the BU lesion (1st sampling) and 5 
months later (2nd sampling). Parallel analysis of both samples was conducted in triplicates 
arranged horizontally with 2 x 105 cells/well plated. The different stimulators used are given 
on the right and the numbers of SFU/well are shown on the lower left corner.   
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Fig. 3. Total IL-12 concentrations in cell culture supernatants of PHA and PPD stimulated 
PBMC of nine BU patients obtained at the two different sampling time points (TABLE 2). 
Mean of total IL-12 concentration (given in pg/ml) in PPD stimulated cultures was 543 and 
750 after 1st and 2nd sampling, respectively, and in PHA stimulated cultures 348 and 472, 
respectively. PBMC of ten individuals living in a neighbouring M. ulcerans non-endemic 
region were treated similarly and the mean total IL-12 concentrations after PPD and PHA 
stimulation were 276 and 402, respectively.  
 
 
 
 
 
 
 
 
 
 
 
1000
500
1500
2000
2500
3000
PHA PHA PHAPPD PPD PPD
BU patients
(1st sampling)
BU patients
(2nd sampling)
Non-exposed
controls
Chapter 4.1 
 
136 
 
References 
 1.  Portaels,F., Johnson,P.D., Meyers,W.M. (2001) Buruli ulcer: Diagnosis of 
Mycobacterium ulcerans disease. World Health Organization. 
 2.  Asiedu,K., Scherpbier,R., Raviglione,M. (2000). Buruli ulcer: Mycobacterium 
ulcerans infection. World Health Organisation. 
 3.  Johnson,P.D., Stinear,T., Small,P.L., Pluschke,G., Merrit,R.W., Portaels,F., 
Huygen,K., Hayman,J.A., Asiedu,K. (2005) Buruli ulcer (Mycobacterium 
ulcerans infection): new insights, new hope for disease control. PLOSMedicine 
2, 0282-0286. 
 4.  Buntine,J., Crofts,K. (2001) Buruli ulcer: Management of Mycobacterium 
ulcerans disease. World Health Organization. 
 5.  Hayman,J., McQueen,A. (1985) The pathology of Mycobacterium ulcerans 
infection. Pathology 17, 594-600. 
 6.  George,K.M., Chatterjee,D., Gunawardana,G., Welty,D., Hayman,J., Lee,R., 
Small,P.L. (1999) Mycolactone: a polyketide toxin from Mycobacterium 
ulcerans required for virulence. Science 283, 854-857. 
 7.  George,K.M., Pascopella,L., Welty,D.M., Small,P.L. (2000) A Mycobacterium 
ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue 
culture cells. Infect. Immun. 68, 877-883. 
 8.  Dobos,K.M., Small,P.L., Deslauriers,M., Quinn,F.D., King,C.H. (2001) 
Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect. Immun. 
69, 7182-7186. 
 9.  Dodge,O.G. (1964) Mycobacterial skin ulcers in uganda: histopathological and 
experimental aspects. J. Pathol. Bacteriol. 88, 169-174. 
 10.  Hayman,J. (1993) Out of Africa: observations on the histopathology of 
Mycobacterium ulcerans infection. J. Clin.Pathol. 46, 5-9. 
 11.  van de Vosse,E., Hoeve,M.A., Ottenhoff,T.H. (2004) Human genetics of 
intracellular infectious diseases: molecular and cellular immunity against 
mycobacteria and salmonellae. Lancet Infect. Dis. 4, 739-749. 
 12.  Carmen,I. (1999) Th1/Th2 balance in infection. Springer Seminars in 
Immunopathology 21, 317-338. 
 13.  Boehm,U., Klamp,T., Groot,M., Howard,J.C. (1997) Cellular responses to 
interferon-gamma. Annu.Rev.Immunol. 15, 749-795. 
Systemic immunosuppression in Buruli ulcer patients 
 
137 
 
 14.  Gooding,T.M., Johnson,P.D., Smith,M., Kemp,A.S., Robins-Browne,R.M. 
(2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and 
unaffected household contacts. Infect. Immun. 70, 5562-5567. 
 15.  Gooding,T.M., Johnson,P.D., Campbell,D.E., Hayman,J.A., Hartland,E.L., 
Kemp,A.S., Robins-Browne,R.M. (2001) Immune response to infection with 
Mycobacterium ulcerans. Infect. Immun. 69, 1704-1707. 
 16.  Gooding,T.M., Kemp,A.S., Robins-Browne,R.M., Smith,M., Johnson,P.D. 
(2003) Acquired T-helper 1 lymphocyte anergy following infection with 
Mycobacterium ulcerans. Clin.Infect. Dis. 36, 1076-1077. 
 17.  Prevot,G., Bourreau,E., Pascalis,H., Pradinaud,R., Tanghe,A., Huygen,K., 
Launois,P. (2004) Differential production of systemic and intra-lesional gamma 
interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. 
Infect. Immun. 72, 958-965. 
 18.  Westenbrink,B.D., Stienstra,Y., Huitema,M.G., Thompson,W.A., Klutse,E.O., 
Ampadu,E.O., Boezen,H.M., Limburg,P.C., Van Der Werf,T.S. (2005) Cytokine 
responses to stimulation of whole blood from patients with buruli ulcer disease 
in Ghana. Clin.Diagn.Lab. Immunol. 12, 125-129. 
 19.  Wesch,D., Marx,S., Kabelitz,D. (1997) Comparative analysis of alpha beta and 
gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl 
pyrophosphate. Eur.J. Immunol. 27, 952-956. 
 20.  Schumacher,R., Adamina,M., Zurbriggen,R., Bolli,M., Padovan,E., Zajac,P., 
Heberer,M., Spagnoli,G.C. (2004) Influenza virosomes enhance class I 
restricted CTL induction through CD4+ T cell activation. Vaccine 22, 714-723. 
 21.  Green,A.E., Lissina,A., Hutchinson,S.L., Hewitt,R.E., Temple,B., James,D., 
Boulter,J.M., Price,D.A., Sewell,A.K. (2004) Recognition of non-peptide 
antigens by human V gamma 9V delta 2 T cells requires contact with cells of 
human origin. Clin.Exp.Immunol. 136, 472-482. 
 22.  Yeboah-Manu,D., Bodmer,T., Mensah-Quainoo,E., Owusu,S., Ofori-Adjei,D., 
Pluschke,G. (2004) Evaluation of decontamination methods and growth media 
for primary isolation of Mycobacterium ulcerans from surgical specimens. J. 
Clin.Microbiol. 42, 5875-5876. 
Chapter 4.1 
 
138 
 
 23.  Noeske,J., Kuaban,C., Rondini,S., Sorlin,P., Ciaffi,L., Mbuagbaw,J., Portaels,F., 
Pluschke,G. (2004) Buruli ulcer disease in Cameroon rediscovered. Am.J 
Trop.Med.Hyg. 70, 520-526. 
 24.  Zurbriggen,R., (2003) Immunostimulating reconstituted influenza virosomes. 
Vaccine 21, 921-924. 
 25.  Letsch,A., Scheibenbogen,C. (2003) Quantification and characterization of 
specific T-cells by antigen-specific cytokine production using ELISPOT assay 
or intracellular cytokine staining. Methods 31, 143-149. 
 26.  Trinchieri,G. (2003) Interleukin-12 and the regulation of innate resistance and 
adaptive immunity. Nat.Rev.Immunol. 3, 133-146. 
 27.  Bonneville,M., Fournie,J.J. (2005) Sensing cell stress and transformation 
through Vgamma9/Vdelta2 T cell-mediated recognition of the isoprenoid 
pathway metabolites. Microbes.Infect. 7, 503-509. 
 28.  Shen,Y., Zhou,D., Qiu,L., Lai,X., Simon,M., Shen,L., Kou,Z., Wang,Q., 
Jiang,L., Estep,J., Hunt,R., Clagett,M., Sehgal,P.K., Li,Y., Zeng,X., 
Morita,C.T., Brenner,M.B., Letvin,N.L., Chen,Z.W. (2002) Adaptive immune 
response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 
295, 2255-2258. 
 29.  Li,B., Rossman,M.D., Imir,T., Oner-Eyuboglu,A.F., Lee,C.W., Biancaniello,R., 
Carding,S.R. (1996). Disease-specific changes in gamma/delta T cell repertoire 
and function in patients with pulmonary tuberculosis. J. Immunol. 157, 4222-
4229. 
 30.  Gioia,C., Agrati,C., Casetti,R., Cairo,C., Borsellino,G., Battistini,L., 
Mancino,G., Goletti,D., Colizzi,V., Pucillo,L.P., Poccia,F. (2002) Lack of 
CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immuno-
compromised hosts and during active pulmonary tuberculosis. J. Immunol. 168, 
1484-1489. 
 31.  Boom,W.H., Canaday,D.H., Fulton,S.A., Gehring,A.J., Rojas,R.E., Torres,M. ( 
2003) Human immunity to Mycobacterium tuberculosis: T cell subsets and 
antigen processing. Tuberculosis 83, 98-106. 
 32.  Dieli,F., Sireci,G., Caccamo,N., Di Sano,C., Titone,L., Romano,A., Di Carlo,P., 
Barera,A., Accardo-Palumbo,A., Krensky,A.M., Salerno,A. (2002) Selective 
depression of interferon-gamma and granulysin production with increase of 
Systemic immunosuppression in Buruli ulcer patients 
 
139 
 
proliferative response by Vgamma9/Vdelta2 T cells in children with 
tuberculosis. J. Infect. Dis. 186, 1835-1839. 
 33.  Pahlevan,A.A., Wright,D.J., Andrews,C., George,K.M., Small,P.L., 
Foxwell,B.M.( 1999) The inhibitory action of Mycobacterium ulcerans soluble 
factor on monocyte/T cell cytokine production and NF-kappa B function. J. 
Immunol. 163, 3928-3935. 
 34.  Pimsler,M., Sponsler,T.A., Meyers,W.M. (1988) Immunosuppressive properties 
of the soluble toxin from Mycobacterium ulcerans. J. Infect. Dis. 157, 577-580. 
 35.  Al Attiyah,R., Mustafa,A.S., Abal,A.T., Madi,N.M., Andersen,P. (2003) 
Restoration of mycobacterial antigen-induced proliferation and interferon-
gamma responses in peripheral blood mononuclear cells of tuberculosis patients 
upon effective chemotherapy. FEMS Immunol.Med.Microbiol. 38, 249-256. 
 36.  Dlugovitzky,D., Bay,M.L., Rateni,L., Urizar,L., Rondelli,C.F., Largacha,C., 
Farroni,M.A., Molteni,O., Bottasso,O.A. (1999) In vitro synthesis of interferon-
gamma, interleukin-4, transforming growth factor-beta and interleukin-1 beta by 
peripheral blood mononuclear cells from tuberculosis patients: relationship with 
the severity of pulmonary involvement. Scand.J. Immunol. 49, 210-217. 
 37.  Dlugovitzky,D., Bay,M.L., Rateni,L., Fiorenza,G., Vietti,L., Farroni,M.A., 
Bottasso,O.A. (2000) Influence of disease severity on nitrite and cytokine 
production by peripheral blood mononuclear cells (PBMC) from patients with 
pulmonary tuberculosis (TB). Clin.Exp.Immunol. 122, 343-349. 
 38.  Lee,J.S., Song,C.H., Kim,C.H., Kong,S.J., Shon,M.H., Kim,H.J., Park,J.K., 
Paik,T.H., Jo,E.K. (2002) Profiles of IFN-gamma and its regulatory cytokines 
(IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients 
with multidrug-resistant tuberculosis. Clin.Exp.Immunol. 128, 516-524. 
 39.  Jo,E.K., Park,J.K., Dockrell,H.M. (2003) Dynamics of cytokine generation in 
patients with active pulmonary tuberculosis. Curr.Opin.Infect Dis. 16, 205-210. 
 40.  Dieli,F., Friscia,G., Di Sano,C., Ivanyi,J., Singh,M., Spallek,R., Sireci,G., 
Titone,L., Salerno,A. (1999) Sequestration of T lymphocytes to body fluids in 
tuberculosis: reversal of anergy following chemotherapy. J. Infect. Dis. 180, 
225-228. 
Chapter 4.1 
 
140 
 
 41.  Reed,M.B., Domenech,P., Manca,C., Su,H., Barczak,A.K., Kreiswirth,B.N., 
Kaplan,G., Barry,C.E., III, (2004) A glycolipid of hyper-virulent tuberculosis 
strains that inhibits the innate immune response. Nature 431, 84-87. 
 42.  Manca,C., Reed,M.B., Freeman,S., Mathema,B., Kreiswirth,B., Barry,C.E., III, 
Kaplan,G. (2004) Differential monocyte activation underlies strain-specific 
Mycobacterium tuberculosis pathogenesis. Infect. Immun. 72, 5511-5514. 
 43.  Mutis,T., Cornelisse,Y.E., Datema,G., van den Elsen,P.J., Ottenhoff,T.H., de 
Vries,R.R. (1994) Definition of a human suppressor T-cell epitope. 
Proc.Natl.Acad.Sci.U.S.A 91, 9456-9460. 
 44.  Belkaid,Y., Rouse,B.T. (2005) Natural regulatory T cells in infectious disease. 
Nat.Immunol. 6, 353-360. 
 
 
 
Chapter 4.2 
 
 
 
 
Local activation of the innate immune system in Buruli ulcer lesions 
 
 
Elisabetta Peduzzi 1*, Célia Groeper 2*, Daniela Schütte 1, Paul Zajac 2, Simona 
Rondini 1, Ernestina Mensah-Quainoo 3, Giulio Cesare Spagnoli 2, Gerd Pluschke 1, 
Claudia Andrea Daubenberger 1 
 
 
1 Swiss Tropical Institute, Department of Medical Parasitology and Molecular 
Infection Biology, Basel, Switzerland 
2 Institut für Chirurgische Forschung und Spitalmanagement, Basel University 
Hospital, Basel, Switzerland 
3 Ghana Health Service, Ministry of Health, Ghana 
 
*these two authors contributed equally 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article has been published in: 
Journal of Investigative Dermatology  
(2006 Oct, Epub ahead of print) 
 
 
Chapter 4.2 
 
142 
 
Abstract 
Buruli ulcer caused by Mycobacterium ulcerans is a chronic necrotising disease of the 
skin and the underlying soft tissue. Fat tissue necrosis accompanied by minimal 
inflammation is considered the most reliable histopathologic feature of Buruli ulcer. 
There may be a constant influx of inflammatory cells to the sites of active infection 
but these are thought to be killed by mycolactone, a polyketide toxin produced by M. 
ulcerans, through apoptosis and necrosis. Here we describe the spatial correlations 
between mycobacterial load and the expression of dendritic cell surface markers 
(CD83, CD11c, CD123), the Toll-like receptor (TLR) 9 and pro-inflammatory and 
anti-inflammatory cytokines (IL-8, IL-6, TNF-α, IFN-α, IL-12p40, IL-10 and IFN-γ) 
within Buruli ulcer lesions. While IL-8, IL-6, and TNF-α mRNA was detectable by 
real-time PCR in all lesions, the expression of the other cytokines was only found as 
small foci in some lesions. Correlations of the distribution of mRNA encoding the 
activation marker CD83 and the dendritic cell subset markers CD123 and CD11c 
indicate that both activated plasmacytoid and myeloid dendritic cells were present in 
the lesions. Results suggest that M. ulcerans specific immune responses may develop 
once therapeutic interventions have limited the production of mycolactone.  
 
 
Innate immunity activation in Buruli ulcer lesions 
 
143 
 
Introduction 
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a chronic necrotizing disease 
of skin and soft tissue. Generally it manifests initially as firm, non-tender, 
subcutaneous nodules, probably at the sites of penetrating skin trauma (pre-ulcerative 
stage). Subsequently, these areas become fluctuant, followed by the formation of an 
ulceration with undermined edges (ulcerative stage). Ulcers can be extensive, 
involving more than 10% of the patient's skin surface (Johnson et al., 2005). 
Subcutaneous fat is particularly affected, but underlying bone may also become 
involved in advanced cases. In BU lesions clumps of extra-cellular acid fast bacilli 
surrounded by areas of necrosis are found. Fat tissue necrosis accompanied by 
minimal inflammation is considered the most reliable histopathologic feature of BU 
(Guarner et al., 2003; Hayman, 1993; Hayman and McQueen, 1985). In late stages of 
the disease, intra-lesional influx of leukocytes and granulomatous responses in the 
dermis and panniculus has been described. If left untreated, spontaneous healing of 
BU lesions can occur after extended periods of progressive ulceration (Asiedu et al., 
2000). Traditionally, BU is treated by wide surgical excision, drug therapy has been 
considered ineffective, but recent data suggest that combinations of anti-
mycobacterial antibiotics can support or replace surgical treatment (Etuaful et al., 
2005). Provisional WHO guidelines now recommend the use of rifampicin and 
streptomycin for the treatment of BU (WHO, 2006). M. ulcerans is unique among 
mycobacterial pathogens in that it is mainly extra-cellular and produces a plasmid-
encoded toxin with a polyketide derived macrolide structure, named mycolactone 
(Stinear et al., 2004). Mycolactone is believed to play a central role in determining the 
extra-cellular localisation of the bacteria and modulation of immunological responses 
to M. ulcerans (Adusumilli et al., 2005). Observations in rodents experimentally 
infected with mycolactone producing and mycolactone negative M. ulcerans strains 
suggested that inflammatory cells are rapidly killed by necrosis when encountering 
high toxin concentrations. Inflammatory cells more distant from the necrotic centre 
are thought to be killed via apoptosis resulting in extra-cellular bacteria surrounded by 
an area of coagulation necrosis. In contrast, granulomatous lesions with strong self-
healing tendencies were observed with mycolactone-negative mutants (Oliveira et al., 
2005).  
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Intrigued by the described lack of inflammatory responses in BU lesions, we have 
analysed the impact of M. ulcerans infection on the activation of the skin innate 
immune system, including dendritic cells (DC). Here we describe the spatial 
correlations between bacterial load and the expression of DC surface markers (CD83, 
CD11c, CD123), the intracellular receptor TLR9 and pro-inflammatory and anti-
inflammatory cytokines (IL-8, IL-6, TNF- , IFN-α, IL-12p40, IL-10 and IFN-γ) 
within BU lesions.  
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Results 
Quantitative real-time PCR was used to determine the spatial distribution of mRNA 
encoding cytokines and cell-surface markers of the innate immune system within 
surgically excised early ulcerative BU lesions of three selected patients. Histo-
pathological changes and M. ulcerans DNA levels in the same tissue samples have 
been described previously (Rondini et al., 2006). A summary of these data is provided 
in Figures 1 and 2 for direct comparison with the distribution of cytokine and DC 
marker mRNA. 
Distribution of DC marker mRNA  
Figure 1 shows the spatial pattern of mRNA encoding the cell surface marker CD83, 
CD11c, CD123 and the intracellular receptor TLR9. Percent values normalised to β-
actin mRNA are provided. In all three patients CD83 (Figure 1, d–f) and CD123 
mRNA (Figure 1, j–l) was detectable along the entire lesions. Relative levels ranged 
from 0 to 4.2% (as compared to 0.2 ± 0.1% in normal skin) and from 0 to 7.4% (0.2 ± 
0.2% in normal skin), respectively. CD11c (Figure 1, g-i) and TLR9 mRNA (Figure 
1, m-o) showed a more focal distribution with relative levels ranging from 0 to 92% 
(0.4 ± 0.2% in normal skin) and 0 to 1.2% (< 0.01% in normal skin), respectively. For 
all four markers peak values were thus much higher than in normal skin. In many 
cases peaks were located close to foci of M. ulcerans DNA (sample G in patient A, 
samples D and F in patient B and samples D and E in patient C).  
Distribution of cytokine mRNA 
Expression of cytokines with pro-inflammatory or anti-inflammatory activity was 
analyzed (Figure 2). IL-8, IL-6 and TNF-α mRNA was detectable in all three BU 
lesions, albeit in different amounts and in markedly different spatial patterns. Peaks of 
the relative levels of IL-8 mRNA were associated with the ulcerations and the 
histological detection of neutrophils (Figure 2, a-c). In contrast, location of the 
relative peaks of IL-6 mRNA with respect to the location of ulcerations and peaks of 
M. ulcerans DNA varied markedly between lesions. In patient A, the relative IL-6 
mRNA levels were highest at the less affected borders of the excised tissue, in patient 
B it was peaking at the nodular pre-ulcerative lesion and in patient C at and around 
the ulceration (Figure 2, d-f). TNF-α mRNA was broadly distributed over the lesion. 
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Relative peak levels of IL-8, IL-6, and TNF-α mRNA (13’395%, 10% and 2.3%, 
respectively) were dramatically higher than the levels found in normal skin (4.7 ± 
5.1%, 0.1 ± 0.1% and 0.1 ± 0.1%, respectively).  
Like in normal skin, IL-12p40 mRNA levels were below the detection limit in all 
three BU lesions analysed (< 0.03%) (data not shown). In contrast, IFN-α, IFN-γ and 
IL-10 mRNA, also undetectable in normal skin, was found at least in one of the three 
analysed lesions in spatially highly restricted foci.  IL-10 and IFN-γ mRNA was 
detected only in patient B (Figure 2 n). While a peak of IL-10 mRNA was associated 
with the secondary non-ulcerated nodule (peak value 1.2%), IFN-γ mRNA was found 
in one sample close to the small ulceration and the associated granulomas (peak value 
0.2%) (Figure 2 n). Significant levels of IFN-α mRNA were primarily found in 
patient C (Figure 2, j-l), peaking towards the right margin of the excised tissue 
(Figure 2 l, peak value in sample I, 246%). 
Correlations of the spatial distribution of mRNA species 
The spatial mRNA distributions of the two DC subset markers CD11c and CD123 
were positively correlated with that of the cellular maturation marker CD83 (CD83 
vs. CD123: r = 0.63, p < 0.0001; CD83 vs. CD11c: r = 0.54, p = 0.001; Figure 3 a, b). 
Also strong positive correlations of the distribution of CD83 with IL-6 and TNF-α 
were observed (r = 0.67, p < 0.0001 and r = 0.80, p < 0.0001, respectively; Figure 3 c, 
d). Correlation of IL-6 expression with CD123 was tighter (r = 0.66, p < 0.001; Figure 
3 e) compared with CD11c (r = 0.41, p = 0.02; Figure 3 f). The correlation of both DC 
subset markers with TNF-α expression was moderate (CD11c vs. TNF-α: r = 0.50, p 
= 0.002; CD123 vs. TNF-α: r = 0.48, p = 0.004; data not shown). There was no 
indication of a correlation between IFN-α and CD123, CD83 or CD11c (data not 
shown). 
Immunohistochemical detection of CD123 positive DCs  
Results of quantitative real-time PCR and immunohistochemistry were highly 
associated, i.e. the relative numbers of CD123 and TLR9 positive cells were 
consistent with the mRNA levels detected by real-time PCR (Figure 4). In the thin 
sections of lesions positive for CD123 and TLR9 mRNA, CD123 and TLR9 
antibodies stained cells with plasmacytoid features (inset, Figure 4 b, d).  
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Discussion 
Under homeostatic conditions, cutaneous dendritic cells include epidermal 
Langerhans cells and interstitial/dermal dendritic cells that are of myeloid origin (M-
DC) (Kupper and Fuhlbrigge, 2004). Our real time PCR and immunostaining data 
indicate that in addition to the CD11c positive CD123 negative M-DC (Colonna et al., 
2004), CD123 positive plasmacytoid dendritic cells (P-DC), are present in early 
ulcerative lesions. P-DC are of lymphoid origin (Colonna et al., 2004), CD11c 
negative and known to be recruited to diseased skin in conditions such as systemic 
lupus erythematosus, atopic dermatitis, psoriasis vulgaris and contact dermatitis 
(Bangert et al., 2003; Nestle et al., 2005; Wollenberg et al., 2002).  
 
One of the surface molecules up-regulated upon DC activation and maturation is 
CD83 (Lechmann et al., 2002). Although CD83 is also expressed on activated human 
B and T cells and a subpopulation of activated monocytes (Lechmann et al., 2002), 
the observed correlations of mRNA expression between CD83 and CD123 or CD11c 
indicated, that both P-DC and M-DC were activated in the BU lesions. The 
distribution of mRNA encoding the highly expressed pro-inflammatory cytokines IL-
6 and TNF-α was also strongly correlated with the activation marker CD83. 
Expression of IL-6 was additionally strongly correlated with that of CD123, 
indicating that activated P-DC may represent the major source of IL-6 expression in 
the BU lesions. In contrast to M-DC, P-DC express TLR7 and TLR9 but lack TLR2, 
TLR3, TLR4 and TLR5. In the majority of patient samples analyzed, expression of 
TLR9 and CD123 mRNA was consistent, supporting the presence of P-DC in BU 
lesions (Figure 1). Signalling through TLR7 and TLR9 results in P-DC activation to 
secrete large amounts of type I IFN and moderate amounts of TNF-  and IL-6 
(Colonna et al., 2004). In contrast to IL-6, no correlation between CD123 and IFN-α 
mRNA was observed. IFN-α expression by P-DC seems to be variable; while P-DC 
activation by TLR9 in response to viruses results in secretion of large amounts of 
IFN-α  (Colonna et al., 2004), during the development of psoriatic phenotype IFN-α 
expression by P-DC seems to be only an early and transient event (Nestle et al., 
2005). Consistent with published data (Kiszewski et al., 2006; Phillips et al., 2006; 
Prevot et al., 2004), TNF-α and IL-8 mRNA levels were, like those of IL-6 and IFN-
α RNA, much higher in the BU lesions than in normal skin. Since moderate 
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correlation between DC markers and TNF-α mRNA was observed, TNF-α mRNA 
expression may be in part associated with other cell types, like monocytes, activated T 
cells or NK cells.  
The mechanism of immune protection in M. ulcerans remains unclear. Evidence from 
genetic defects in the IFN-γ signalling pathway supports the role of IFN-γ in 
protection against a range of non-tuberculous mycobacterial disease, including M. 
ulcerans (Ottenhoff et al., 2005). PBMC from BU patients with active disease showed 
significantly reduced lympho-proliferation and IFN-γ production in response to 
stimulation with live or dead M. bovis BCG, M. ulcerans, PPD of M. tuberculosis, 
isopentenyl pyrophosphate and non-mycobacterial antigens like reconstituted 
influenza virosomes (Gooding et al., 2001; Gooding et al., 2002; Gooding et al., 2003; 
Prevot et al., 2004; Yeboah-Manu et al., 2006). Prévot et al. showed with semi-
quantitative PCR analyses that the systemic Th1 down modulation was mirrored by 
local, intra-lesional cytokine profiles. High IFN-γ with low IL-10 mRNA levels were 
present in early, nodular lesions and low IFN-γ mRNA levels were detected in late 
ulcerative lesions (Prevot et al., 2004). Hence, in active M. ulcerans disease, the Th1 
response seemed to be down-regulated both locally and systemically. The presence of 
IL-6 during T cell priming may promote Th2 differentiation and simultaneously 
inhibit Th1 polarization (Diehl and Rincon, 2002). Therefore the close association of 
CD123 (P-DC) with IL-6 in conjunction with the lack of INF-α production may 
favour Th2 development and result in the observed Th1 down-modulation in BU. IL-6 
is a pleiotropic cytokine involved in the growth and differentiation of numerous cell 
types, including those of dermal and epidermal origin (Paquet and Pierard, 1996). In 
the skin, it is induced in a broad range of dermatotoxic reactions and may be involved 
in wound healing (Hernandez-Quintero et al., 2006). The presence of high numbers of 
P-DC in the lesions in the absence of IFN-α gene expression raises also the issue of a 
tolerogenic role of these cells, as suggested in primary cutaneous melanomas (Vermi 
et al., 2003).  
 
IL-10 and IFN-γ mRNA was detected in one of the three analysed BU lesions, where 
it was present only in highly focal areas. Phillips et al. showed wide variations in IL-
10 and IFN-γ mRNA expression among individual skin punch biopsies (Phillips et al., 
2006). Generally, our results demonstrate that expression of cytokines and cell surface 
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markers can vary considerably within a BU lesion. Therefore, results obtained with 
biopsies of BU lesions do not necessarily reflect the overall profile of a lesion. Our 
comparison of the spatial relationship between bacterial load, DC marker and pro-
inflammatory cytokine mRNA suggests that the presence of clusters of M. ulcerans 
does not exclude innate immune system recruitment to the site of infection. This 
conclusion is consistent with the hypothesis of Oliveira et al., suggesting a constant 
influx of neutrophils, monocytes/macrophages and lymphocytes to active M. ulcerans 
lesions (Oliveira et al., 2005). Potentially, M. ulcerans specific immune responses 
may therefore develop, once a therapeutic intervention, such as a successful antibiotic 
treatment, is limiting the production of mycolactone.  
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Materials and Methods 
Clinical specimens 
Three BU patients with ulcerative lesions, who received standard treatment at the 
Amasaman Health Centre in the Ga district in Ghana, were enrolled in this study. The 
standard treatment comprised wide surgical excision including margins of 
macroscopically healthy tissue followed by skin grafting. BU clinical diagnosis was 
reconfirmed by IS2404 PCR, microscopic detection of acid fast bacilli and 
observation of characteristic histopathological changes. The distribution of M. 
ulcerans DNA and histopathological examination within the excised tissue samples 
analyzed here, have been described elsewhere (Rondini et al., 2006). Patient A 
presented with an ulcerated plaque (ulcer size 4 x 5 cm) on the dorsal aspect of the 
left upper arm. The central necrotic slough was associated with typical inflammatory 
cells while no granulomas were seen in any zone of the excision. The highest 
mycobacterial DNA burden was present at the base of the ulcer and decreased 
towards the margins of the excision (Figure 1 a). Patient B presented with a small 
ulcerated lesion (∅ 1 cm) and a larger non-ulcerated nodule located about 3 cm apart 
on the dorsal aspect of the right elbow. The M. ulcerans DNA was present with high 
load within the non-ulcerated nodule and, with lower load, in the ulcerated region. 
Between these two lesions no bacterial DNA was detected. Granulomas were present 
across the tissue from nodule to ulcer till the right margin of the excision (Figure 1 b). 
Patient C presented with a small ulcer 5 cm away from a larger ulcer, which was 
surrounded by scar tissue and showed evidence of previous treatment. M. ulcerans 
DNA was only present at the base of the small ulcer and no granulomas were detected 
in the whole excision (Figure 1 c). Ethical approval for analysing patient specimens 
was obtained from the local ethical review board of the Noguchi Memorial Institute 
for Medical Research and participants gave their written informed consent. The study 
was conducted according to the Declaration of Helsinki Principles.  
RNA extraction, removal of genomic DNA and reverse transcription  
RNA was extracted from several samples of equal size, each comprising skin and fat 
tissue, which were obtained from BU patients’ excised lesions: patient A, 14 samples 
(A-N); patient B, 11 samples (A-K); patient C, 9 samples (A-I). Samples were 
disrupted by sonication for 2 min (Sonifer Branson 250, Branson Ultrasonics 
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Corporation, Danbury, CT) and centrifuged for 3 min at 10’000 x g. RNA was 
extracted from the tissue lysate using the RNeasy Mini Kit (Qiagen AG, Basel, CH) 
and treated with DNase I (Invitrogen, Paisley, UK) to remove genomic DNA. 
To synthesize complementary DNA (cDNA), total RNA was incubated with oligo 
d(T) for 10 min at 65°C, and put on ice. A reaction mixture containing dNTP mix 
(125 nM), DTT (10 mM) and reverse transcriptase M-MLV (200U) with 
corresponding first strand buffer was added (Invitrogen, Paisley, UK). The reaction 
mix was incubated for 60 min at 37°C before enzyme inactivation for 5 min at 94°C.  
Quantitative real time polymerase chain reaction 
Gene transcription was evaluated using the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). Primers and probes for 6 human 
cytokines (IL-6, IL-8, IL-10, IL-12p40, TNF-α, IFN-α, IFN-γ), cell surface proteins 
(CD11c, CD83, CD123, TLR9) were used to amplify specific cDNA in duplicate, 
according to the manufacturers instructions (Applied Biosystems, Foster City, CA). 
The β-actin gene was used as an internal house keeping gene reference. Primers and 
probes for β-actin, IL-8, IL-12p40, IFN-α, CD11c, CD83, CD123 and TLR9 were 
obtained from Applied Biosystems. Primer and probes for IL-6 (Hartwig et al., 2002), 
IL-10 (Giulietti et al., 2001), TNF-α (Razeghi et al., 2001) and IFN-γ (Kammula et 
al., 1999) were synthesised by Mycrosynth (Balgach, CH). Having verified that the 
amplification dynamic remains proportional at all tested dilutions, RNA expression of 
each surface marker and cytokine was presented as percentage relative to β-actin gene 
expression. The assays were run in duplicates and the results with a standard deviation 
> 2% were excluded. Correlation analyses were performed in Prism using the 
Spearman rank correlation coefficient. Mean values of surface markers and regulatory 
cytokines in six samples of healthy skin tissue are as follow: CD11c (0.4 ± 0.2%), 
CD123 (0.2 ± 0.2%), CD83 (0.2 ± 0.1%), TLR9 (< 0.01%), TNF-α (0.1 ± 0.1%), IL-6 
(0.1 ± 0.1%) and IL-8 (4.7 ± 5.1%). IFN-α, IFN-γ, IL-10 and IL-12p40 mRNA were 
undetectable.  
Immunohistochemistry 
Tissue samples were fixed overnight in neutral buffered 4% paraformaldehyde, 
embedded in paraffin according to standard protocol and cut into 5 µm sections using 
a microtome. After de-paraffinization, sections were re-hydrated through graded 
Chapter 4.2 
 
152 
 
alcohols and washed in distilled water. Antigen retrieval was performed by 
microwave unmasking technique in 10 mM EDTA pH 8.0. Subsequently, endogenous 
peroxidase was blocked with 0.3% H2O2 for 30 min and unspecific binding prevented 
by incubating with blocking serum for 20 min at room temperature. CD123 
monoclonal antibody (Biosciences, San Diego, CA) was diluted 1:100 in PBS plus 
0.1% Tween-20 and slides incubated in a humid chamber for 1 h at room temperature. 
Sections were than incubated for 30 min at room temperature with the secondary 
antibody biotin labelled (Vector Laboratories; 1:200 in PBS). Slides were then 
labelled with streptavidin horseradish peroxidase conjugate (Vector Laboratories, 
Vectastain Elite ABC kit) for 30 min at room temperature and staining was performed 
by using Vector NovaRed and Hematoxylin (counter stain).  
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Figure 1. Spatial localisation of bacterial load and dendritic cell markers in BU lesions. 
Patients A, B and C excisions with tissue samples: A-N, A-K, A-I; respectively. Relative 
quantity of mRNA for the surface markers CD83 (d-f), CD11c (g-i), CD123 (j-l) and 
intracellular receptor TLR9 (m-o) expressed in percent relative to β-actin gene expression. M. 
ulcerans DNA load and histo-pathological changes of the excisions (a-c) (Rondini et al., 
2006). 
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Figure 2. Distribution of bacterial load and regulatory cytokine mRNA in Buruli ulcer 
excisions. Patient A, B and C excisions with tissue samples: A-N, A-K, A-I; respectively. 
Relative quantity of mRNA for the cytokines IL-8 (a-c), IL-6 (d-f), TNF-α (g-i), IFN-α (j-l), 
IL-10 and IFN-γ (m-o) expressed in percent relative to β-actin gene expression. M. ulcerans 
DNA load and histo-pathological changes of the excisions (a-c) (Rondini et al., 2006). 
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Figure 3. Correlations of dendritic cell markers and cytokine expression. 
Patient A (), B (♦), C (+). Spearman’s correlations of the mRNA spatial distribution in the 
excisions are given.  CD123 vs. CD83 (a); CD11c vs. CD83 (b); IL-6 vs. CD83 (c); TNF-α 
vs. CD83 (d); IL-6 vs. CD123 (e); IL-6 vs. CD11c (f). Spearman’s correlations with an r 
ranging from 0.4 to 0.6 and p value of < 0.05 are moderate positive; with r > 0.6 and p < 0.05 
are positive to strong positive. Each point represents the value of one tissue sample. 
 
 
Innate immunity activation in Buruli ulcer lesions 
 
157 
 
 
 
Figure 4. Immunohistochemical analysis of P-DC recruitment to BU excisions. 
Immunohistochemical stainings in thin sections of tissues samples B and F of patient B. (a, b) 
CD123 staining (original magnification x100, inset original magnification x400) and (c, d) 
TLR9 staining (original magnification x200, inset original magnification x1’000), bars = 40 
µm. 
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5.1 Monitoring cellular immune responses in clinical vaccine 
trials and characterization of host-pathogen interactions 
Based on current knowledge immune protection against malaria and Buruli ulcer is 
not a single variable or single compartment end point, but it is more likely to be a 
mosaic of immune responses comprising innate, adaptive, cellular and humoral 
effector mechanisms. In principle, there is general agreement that immune monitoring 
should guide the development of new vaccines and treatment modalities against 
infectious diseases and cancer [1,2]. Assessment of vaccine potency has become quite 
standard for humoral immune responses. Antibodies can reliably be detected in 
peripheral blood and saliva and, for some pathogens, protective titers have been well 
established [1]. On the other hand, specific parameters of cell mediated immunity are 
more and more needed to evaluate new vaccines: antibody titers are unlikely to 
remain the sole reliable measure of vaccine immunogenicity and protective efficacy 
[3]. However, up to date, the evaluation and standardization of cell-mediated 
immunity is the subject of long debates focusing on the relative merits and 
appropriate use of the various immune cellular monitoring tools [4]. One inherent 
limitation to cellular monitoring is that in the clinical setting, only the peripheral 
blood compartment (PBC) is generally accessible for serial analyses. Additionally, in 
contrast to antibody responses, specific T cell responses may not always be present in 
PBC and their presence in the blood is of undefined relevance for clinical efficacy. In 
humans, only few studies have also monitored T cell responses in the draining lymph 
node at the vaccine site [5]. This complicates the choice of the optimal blood 
sampling time points. Moreover, the consistent amount of blood required for T cell 
analysis limit the allowed blood sampling frequency. Often this decision is the results 
of a compromise. During the described malaria vaccine Phase Ia clinical trial with 
malaria synthetic peptides including optimized B cell epitopes  (Chapter 3.2), the key 
readouts were anti-peptide antibody titers (ELISA) and anti-parasite titers (IFA, 
Western blot analysis) (Genton et al. submitted, Okitsu et al. submitted). The priority 
was therefore given to blood sampling for serum analysis. The cellular analysis was 
an additional readout to extent the understanding of virosomal technology for future 
applications. We received the blood samples prior to the first vaccination and 20 days 
after each immunization (in total 3 immunizations and four blood samplings). Most of 
the positive CD4 T cell responders were detected after the first and second 
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immunization (Chapter 3.2), therefore a unique post immunization sampling after the 
third immunization would have been detrimental for our T cell study.   
A standardization of cellular monitoring is hampered also by the fact that suitable 
animal models are lacking, considering that most preclinical vaccine development is 
assessed in small rodents, which are not appropriate for serial monitoring of cellular 
immune responses in peripheral blood. Protection experiments in mice typically 
evaluate cellular responses in spleen or lymph nodes. Furthermore, different vaccine 
formulations may induce distinctive T cell subsets with diversities in cytotoxic and 
proliferative capacity or long-term memory. This can result in selective accumulation 
of the specific T cells in lymph nodes, PBC or tissues [6].  
Different types of tests have been developed so far with the aim to address and 
overcome the limitations of cellular monitoring. They can be divided into three 
different generations, according to their properties: 
The first generation was developed several decades ago and it includes three different 
assays based on measuring: (i) the overall T-cell proliferation after exposure to the 
target antigen, where the readout is in terms of 3H-thymidine uptake; (ii) the lysis 
induced by cytotoxic cells (readout: 53Cr release from target cells into the supernatant) 
and (iii) the cytokine release in the supernatant (sandwich ELISA). This category of 
assays assesses the T cell response at the whole cell population level, thus requiring 
prior in vitro expansion. The ability to detect T cell responses is based on the 
proliferative potential of the cells, and the results might be influenced by in vitro 
stimulation procedures.   
In the last 10 years, the use of a second generation of assays based on single cell level 
analysis of the T cell properties is increasingly applied. Cytokine production after 
exposure to antigen is measured using either a plate- (ex vivo ELISpot assay) or a 
flow cytometry- readout, which includes intracellular cytokine staining or the capture 
of secreted cytokines by antibodies bound to the cell surface. On the other hand, the 
affinity of the T cell receptor (TCR) to a given epitope is measured by MHC peptide 
tetramers that allow the visualization and quantification of antigen-specific T cells. 
Limitations of the multimer analysis include, required knowledge of a defined epitope 
and availability of suitable tetramers for the respective epitope/HLA allele 
combination.  
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ELISpot and cytokine flow cytometry analyses provide, at the same time, ex vivo 
frequency and functional results. However, only the T cell subset producing the 
respective cytokine is detected. Usually, it is recommended to perform monitoring 
preferentially with two of these second generation assays. ELISpot is highly sensitive 
(detection limit 1/50’000 cells [7,8]) giving therefore the possibility to detect ex vivo 
specific cells [9]. However, ex vivo frequencies of antigen specific T cells in the PBC 
might be below this detection limit due to a complete lack of prior in vitro expansion 
of the specific population [10]. Longer cell-incubation times can increase the 
detection of specific responses, like in the described 5-days or 14-days cultured 
ELISpot [10,11]. Clearly, the mentioned cultured ELISpot assays do not give 
anymore an ex vivo quantification of the specific primed T cell population.  
In both human and mouse the proliferative, IL-2 producing central memory is 
opposed to less proliferative, high IFN-γ producing effector memory [12]. It is 
therefore tempting to speculate that by detecting T cell IFN-γ responses with ex vivo-, 
5-days cultured- and 14-days cultured- ELISpot there is a progressive shift in central 
memory cells [10,11]. Only detailed phenotype studies for the specific diseases and 
analyzed vaccination systems can elucidate these suppositions. We have also to 
consider that a prolonged cell culture time and extensive in vitro manipulations can 
lead to misleading artifacts [13]. During long cultivation periods, beside antigen-
specific T cell stimulation, bystander T cell activation or apoptosis of specific T cells 
can more easily occur. Moreover, the use of different cell culture lengths is 
highlighting cell populations with diverse potential for in vitro growth [13].  
We monitored, in the framework of a Phase Ia clinical trial, AMA-1 derived synthetic 
peptide specific immune responses both by ELISpot and lymphoproliferation 
analysis. Results revealed the detection limits of ex vivo ELISpot and discrepancies 
between assays with short and longer in vitro cultivation (ELISpot vs. 
lymphoproliferation). This underlines the importance of using at least two cellular 
monitoring methods in parallel (Chapter 3.2). On the other side, ex vivo IFN-γ 
ELISpot was appropriate to compare PBMC of Buruli ulcer patients prior to and after 
surgical excisions stimulated with complex antigens and immunostimulators such as 
IPP, PPD, PHA and influenza antigens (Chapter 4.1). 
Although the development of computer-based image-analysis systems has increased 
the accuracy and speed of scoring ELISpot assays [14], there is still a certain degree 
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of subjectivity in the interpretation of the results, as the threshold for the size, 
intensity, and gradient of the spots are user-defined. Moreover, functional tests are 
much more sensitive to variation in assay conditions because the production of 
nonspecific background cytokines may limit the sensitivity of the assays [15]. In this 
respect, the settings for IFN-γ spots analysis (AID-reader system) were defined at the 
beginning of this thesis on the basis of results obtained with PBMC of Caucasian and 
African healthy volunteers stimulated with common antigens (tetanus toxoid, 
influenza antigens). These settings were then used to monitor vaccine related immune 
responses in the Phase Ia clinical trial (Chapter 3.2) and the reactivity recovery of 
systemic cellular immune responses in Buruli ulcer patients after surgery (Chapter 
4.1). To reduce the variation in assay conditions, fresh PBMC were used throughout 
the vaccine trial.  Only cryopreserved PBMC were available for the Buruli ulcer 
study.  
For better comparability of results among different research groups, standardization of 
parameters that define a positive spot across laboratories and readers would be very 
helpful.  
The third-generation of T cell assays is based on a two-step principle: the detection of 
specific T cells based on tetramers or cytokine flow cytometry is associated with a 
phenotypic or functional quantitative characterization. The additional markers 
employed for this purpose can define the cytokine production repertoire, the 
memory/effector phenotype, the cytotoxic capacity, the proliferative capacity, a 
migratory phenotype, a regulatory T cells subtype, the functional TCR affinity or 
avidity and the level of cell maturation. Since it can yield information on many facets 
of the nature of T cell responses, this type of analysis has a great potential for 
monitoring cellular immune responses in clinical vaccine trials and in characterizing 
host-pathogen interactions [16]. But, the specific role of these T cell characteristics 
for clinical vaccine efficacy has not yet been established.  
In conclusion, there are four important levels in cellular immunological monitoring, 
the sampling compartment, the sampling time point, the measured cell features and 
the translation of the obtained results in terms of protective efficacy (clinical trials) or 
in terms of immonopathogenic relevance (characterization of host-pathogen 
interactions).  
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Within the framework of the present thesis, proliferation assays but not ex vivo IFN-γ 
ELISpot turned out to be suitable to monitor the cellular immune response to one 
peptide-based vaccine component (AMA-1 derived synthetic peptide). Attempts to 
characterize the peptide reactive T cells by generating a panel of T cell clones using 
established methods [17,18] failed. Reasons for this may be the low frequency of 
synthetic peptide positive cells (SI ranging from 2 to 4.5) found in the PBC, which is 
probably attributable to a paucity of promiscuous T cell epitopes in the short malaria 
synthetic peptide and/or limited specific T cell recirculation in the PBC. However, 
detailed monitoring of immune responses in trials with at least partially effective 
vaccines may help to develop surrogate markers of protection. In the case of malaria, 
experimental challenge Phase II trials represent a suitable setting for such analysis.  
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5.2 Plasmodium falciparum malaria vaccine development 
The focus of the current research is the development of a multi-component, multi-
stage subunit vaccine against malaria in order to overcome high antigenic variation, 
extensive polymorphism and life stage specific antigen-expression characteristic for 
P. falciparum parasite [19-21]. The goal is to reach greater magnitude, duration, and 
strain-transcendence than naturally acquired immunity and the endpoint in efficacy 
trials is now rather prevention of severe disease than infection (anti-disease vaccine).  
5.2.1 Virosome: novel antigen delivery system for synthetic peptides 
The physico-chemical nature and the spatial organization of antigens influence the 
vaccine immunogenicity. The attenuated or inactivated whole pathogens, the 
paradigms of vaccines, are particulate and immunogenic by definition. The rigid, 
repetitive organization of the antigens strongly promotes B cell receptor cross-linking 
required for optimal B cell activation [22,23]. However, small synthetic components 
(of sugar, protein or lipid origin) are very attractive for vaccine design because they 
overcome many safety problems related to inactivated or attenuated pathogens. But, 
these components do not have an auspicious physico-chemical nature. They are 
soluble, monovalent antigens that are poorly immunogenic, and may even induce 
tolerance [24]. Several attempts have been made to present small defined, purified 
antigens to the immune system in particulate form such as preparation of protein 
aggregates (by denaturation or crystallization), precipitation of the molecules with 
alum, generation of virus-like particles, and incorporation of antigens in liposomes, 
proteosomes, microparticles of immunostimulating complexes (ISCOMs). Still, only 
25% of the vaccines currently in use are subunit-based and none is synthetic peptide-
based. In this thesis we show that the virosomal technology represents an important 
step in this direction (Chapter 3.1-3.2). The CSP and AMA-1 malaria peptide 
candidates (UK39 and AMA49-CPE, respectively) were hooked to virosomes via a 
PE-anchor for non-covalent linking to the virosomal membrane. In the conducted 
Phase Ia clinical trial two immunizations with a 10 µg dose of UK39 and with a 50 µg 
dose of AMA49-CPE were enough to induce high anti-peptide antibody titers (Genton 
et al. submitted, Okitsu et al. submitted). Furthermore a boost of viral HA specific 
antibody-titers were observed after the first immunization. These results are indicative 
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for a suitable spatial arrangement of the malaria synthetic peptides on the virosomal 
surface. Furthermore, in the case of the CSP derived peptide we have shown that 
optimal conformational restriction of the peptide is decisive for the induction of 
parasite binding antibodies in mice. The first generation of peptides with single or 
double loops of NPNA repeats hooked to a rigid template were highly immunogenic 
but only low titer of parasite cross-reactive IgG were induced [25]. Only the internally 
cyclized and more flexible NPNA peptides BP65 [26] and UK39 were good at 
eliciting parasite-binding antibodies (Chapter 3.1). This more flexible type of 
conformation is close to the natural conformation found in CSP on the surface of 
sporozoites, as indicated by NMR and crystallization studies. In this respect a very 
crucial issue was to exclude conformational disturbance caused by the delivery 
system. Alum-adjuvanted formulation of NPNA first generation peptide elicited 
higher anti-peptide but only low parasite cross-reactive antibody titers compared to 
the IRIV formulation [25]. This indicates that the IRIV antigen delivery system does 
not disturb the spatial conformation of the coupled peptides. 
5.2.2 Interaction of the virosome with the immune system 
Further important parameters that can influence vaccine immunogenicity are the 
ability to induce T helper cells and to activate DC [23,27].  
The information about DC activation by the virosome delivery system are still limited 
[28,29]. This is definitively an important issue to be further analyzed because antigens 
and delivery systems that lack the capacity to induce DC maturation may also be 
internalized by DC. However, in the absence of costimulatory molecules expression 
the activation of T helper cells is prevented and may induce antigen-specific tolerance 
by promoting differentiation of the T cells to regulatory/suppressor cells [27,30,31].  
Due to the fusion-mediated activity of HA, the virosomal technology also has the 
potential to mediate efficient CTL induction against foreign encapsuled molecules 
[32-35]. Other delivery systems that do not give to the antigens direct access to the 
cytosol might gain the MHC class I route only through the so-called cross-
presentation process [36].  
The CD4 T cell response against influenza spike proteins (HA, NA) anchored on 
virosomal surface is the result of restimulation of a previously primed response, either 
due to former exposure to natural infection or prior vaccination. The peptide 
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sequences of HA and NA constantly change as a result of the well-described antigenic 
drift and shift [37]. In general, T cell epitopes of influenza proteins, particularly of 
matrix and nucleocapsid proteins, are more conserved across the different influenza 
strains and less influenced by antigenic drift [38]. T cell memory against influenza 
antigens remains therefore a very important issue. In old people presenting impaired T 
cell functions, the influenza vaccination programs are only 40-60% effective [3]. 
Moreover, the growing threat of the development of a new pandemic strain of 
influenza from the circulating avian influenza strains (antigen shift) reinforces the 
importance to promote, by vaccination, cross-species protection [38]. In both humans 
and mice two broad memory T cell subsets have been delineated according to their 
homing capacity and effector function [39-41]. CD4 central memory T cells home to 
the lymph nodes and have a limited effector function, but proliferate and become 
effector cells upon secondary stimulation (CD62LhighCCR7+). By contrast CD4 
effector memory T cells home to peripheral tissues and can rapidly produce effector 
cytokines such as IFN-γ upon antigenic stimulation, but have limited proliferative 
capacity (CD62LlowCCR7-) [12]. The maintenance of memory T cells is dependent on 
the expression of anti-apoptotic molecules, such as BclXL [42], and their capacity to 
respond to homeostatic cytokines (IL-2, IL-7 and IL-15) [43]. Age-related IL-7 
decline corresponds to a failure in optimal maintaining the influenza memory T helper 
cells [44] combined with IL-2 synthesis reduction and a shift toward Th2 cytokines 
[3].  
For most infectious diseases, precise mechanisms for the generation of memory CD4 
T cells their maintenance and delineation into diverse subsets, remain largely 
unknown. Studies in mice suggest that influenza specific CD4 T cells generated in 
secondary organs appear as multiple subsets in terms of numbers of cell division, 
phenotype and function. Thus, progressive stages of differentiation IL-2 and IFN-γ 
production are represented. The effector cells migrating to the lung were found to be 
the most differentiated population acquiring a phenotype of high and stable CD44 and 
CD49d expression, loss of CD62L, down-regulation of CCR7 and markedly reduced 
levels of IL-2 [45]. The memory cells detected in the lung were small resting cells 
expressing low levels of CD62L and CCR7 [46]. The model proposed for effectors 
and memory influenza specific CD4 T cells development, suggest quantitative and 
qualitative regulation affected by factors such as (i) the antigen-dose during the initial 
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T cell interaction with APC (ii) the duration of repeated antigen-interactions and (iii) 
the milieu of inflammatory and growth cytokines; which explains the heterogeneous 
spectrum of influenza CD 4 T cell responses [38].  
In humans, small scale PBMC analysis with DR1-HA306-318 tetramer detected ex vivo 
memory CD4 T cells frequencies ranging from 0.00012 to 0.0061%, characterized by 
a CD62L+ and CCR7+ phenotype, IFN-γ and IL-2 production [47]. Another study 
determined influenza ex vivo frequencies 60 days post-influenza vaccination with 
DR1-HA306-318 tetramers, CFSElowtetramer-positive T cells and ex vivo IFN-γ ELISpot 
and showed comparable frequencies with all assays (0.0033-0.17%) and an 
heterogenous CD62L and CCR7 expression [48]. The CD4 T cell influenza specific 
responses (Chapter 6.1, [49]) that we monitored on a large scale during the described 
Phase Ia clinical trial were indicative for cells with IL-2 and IFN-γ release abilities 
(lymphoproliferation and ex vivo IFN-γ ELISpot assays), which were detected in all 
thirty tested volunteers and all along the trial (Chapter 3.2). The ex vivo frequencies 
were ranging from 0.0093 to 0.11% and oscillation IFN-γ and lymphoproliferative 
abilities were observed during the trial (Chapter 3.2, Chapter 6.1). These data confirm 
a solid anti influenza CD4 T cell memory response in Caucasian healthy adults.  
When using the virosome for antigen delivery, the influence of pre-existing immunity 
to the viral components is an important issue. A general lack of correlation between 
the magnitude of the pre-existing influenza specific T cell response and the 
vaccination-induced AMA49-C1 specific humoral and cellular immune responses was 
found. Thus, these results indicate that between pre-existing influenza immunity and 
the priming of synthetic peptide specific responses there is no interference (Figure 1). 
However, in the perspective of the development of a multi-component vaccine 
exploiting the virosomal technology, dose-combination studies of virosomes and the 
coupled synthetic peptides are recommended to find out which kind of population is 
favored by which dose of synthetic peptide and viral antigens (HA, NA) [50-52]. 
5.2.3 Induction of cellular immunity to anchored peptides 
During this thesis, for the first time, the feasibility to elicit a CD4 T cell response 
against a synthetic peptide anchored on the virosomal surface was proven (Chapter 
3.2, Figure 1). Moreover, all volunteers who developed high titers of parasite cross-
reactive IgG in IFA and Western blot analysis, were positive in the anti-synthetic 
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peptide lymphoproliferation assay. These studies demonstrate that the virosomal 
antigen delivery platform combined with surface-anchored synthetic peptides is 
suitable to elicit specific human CD4 T cell responses. These responses are not 
essential for eliciting target IgG, but may improve the quality of the humoral immune 
response (Chapter 3.2). In children living in regions endemic for malaria, a malaria 
vaccine may boost pre-existing anti-malaria T cell responses. More importantly, 
malaria antigen specific T cells elicited by natural exposure are expected to provide T 
cell help for vaccine induced B cell upon reinfection.  
For an application of the virosomal technology against infections where the elicited 
CD4 T cell response play a crucial role further optimization has to be considered such 
as the detection of an optimal synthetic peptide length, the incorporation of multiple 
promiscuous T cell epitopes, the issue of HLA restriction and the definition of 
markers of protection. An effective CD4 T cell response against synthetic peptides 
might be particularly helpful for vaccinating immunologically naïve adults or target 
population presenting an impaired T cell activity, e.g. old people. Other possible 
applications of this technology are post-infection immunizations during acute 
diseases. For example, the lack of specific Th1 effector cell response within the first 
months of acute hepatitis C virus infection represents an efficacious predictor of viral 
persistence and chronic course of the disease [53,54]. A post-infection vaccination 
during early acute disease might be successful in shifting the balance toward a Th1 
specific response. 
Figure 1 Virosome as delivery system for the synthetic peptide AMA49-CPE. The 
detection of specific AMA49-C1 T helper cells proved the feasibility to use the virosomal 
technology to elicit T helper cells specific for the anchored synthetic peptide. Yellow arrows 
indicate a non-interference relationship in the magnitude between the different immune 
response compartments. 
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5.2.4 Aotus monkeys as malaria vaccine model 
Most investigations of malaria infection are conducted with rodent Plasmodium spp. 
in inbred mouse strains. However, no single rodent model replicates all the features of 
human malaria in terms of either pathology or immune responses [55]. The New 
World primate Aotus is one of the few non-human primate genus that is susceptible to 
infections with the human malaria parasites P. falciparum and P. vivax. Structural 
molecular similarities between the Aotus monkey and the human immune system 
have been analyzed in a series of studies which demonstrated a high degree of gene 
sequence conservation for αβ TCR, Ig κ-light chain, MHC class II molecules, and 
CD1b [56-61]. In our research group the similarities in function and structure of γδ T 
cells were studied [62] and a new panel of cross-reactive mAbs specific for immune 
surface molecules were detected by flow cytometry analysis [63]. Moreover, within 
this thesis the anti-INFγ mAb for ELISpot coating (GZ-4, Mabtech, Sweeden), cross-
reactive for human, rhesus and cynomologous macaques IFN-γ, was found cross-
reactive for A. nancymaae IFN-γ. However, there is still a general shortage of 
reagents tested for Aotus spp. cross-reactivity and a lack of exhaustive information at 
the immunogenetic level. The idea is to bridge this gap to further extent the use of this 
animal model for malaria research as recommended by the WHO [64]. In Chapter 3.3 
the TLR9 Aotus-human homology was analyzed. Our results showed that A. 
nancymaae TLR9 has a 92% identity to human TLR9, whereas rodent TLR9 
displayed only 73% of similarity at the amino acid sequence level.  The high level of 
identity of a TLR9 to human could be very helpful within the context of a malaria 
vaccine using TLR9 ligands as adjuvants. In general, TLR ligands are proposed to 
have a great potential as vaccine-adjuvants due to their capacities to activate the 
immune system in very different ways according to their sequence [65]. Furthermore, 
the virosome technology has been already described as a platform for incorporation of 
additional adjuvant [23,66]. Mice vaccinated with influenza virosomes with an 
incorporated lipopeptide binding to TLR2 showed a 150-fold increase in IgG response 
compared to virosomes without the adjuvant [66]. For a virosomally formulated 
malaria vaccine the use of CpG ODN as immunomodulators may represent an option 
to stimulate the immune system of malaria endemic population, which is under 
constant complex interactions with P. falciparum parasites, in the most suitable way. 
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It is known that TLR ligands are recognized in species-specific manner [67], e.g. 
unmethylated CpG ODN highly active in rodents often showed no effects in primates 
[68,69]. In this respect the high homology we found between human and A. 
nancymaae TLR9 might also be very precious in helping to elucidate the stimulation 
of the innate immune system by P. falciparum in a more suitable animal model. 
Indeed, Coban et al. recently demonstrated an interaction of hemozoin with TLR9 on 
mice DC, by showing impaired TNF-α, IL12p40 and IL-6 release in TLR9-/- and 
MyD88-/- mice DC [70]. Hemozoin is the digestion product of hemoglobin 
metabolized by P. falciparum, which is released into the blood stream. In vitro, 
human RBC infected with P. falciparum schizont-stage lead to upregulation of CD86 
and IFN-α release in P-DC [71,72]. Controversially, recent studies identified 
hemozoin as possible key player in malaria immunosuppression: hemozoin was not 
inducing mice DC maturation, since the levels of MHC class II, CD40 and CD86 
were the same as the levels expressed by unstimulated control DC [73,74]. Evidence 
of immunosuppression in malaria infected patients are given by their higher 
susceptibility to secondary infection and reduced MHC class II levels on DC [75-78]. 
In this respect, the high homology between human and Aotus TLR9 might help 
elucidating the exact role of hemozoin and be the start point to better understand 
immunomodulatory mechanisms of P. falciparum parasite.  
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5.3 Host-pathogen interactions in Buruli ulcer and treatment 
implications 
M. ulcerans bacteria proliferate freely in subcutaneous fatty tissue, where they find an 
optimal temperature for growth and secretion of mycolactone, causing death of 
lipocytes and fibroblasts by apoptosis and immunosuppression in the vicinity. The 
effect of the toxin in causing tissue necrosis and preventing inflammation may be 
confined to the immediate vicinity. In the adjacent tissue, to which mycolactone has 
not diffused, an anti-mycobacterial immune response may develop (Figure 2) [79]. 
Although intact M. ulcerans are rarely seen within cells, macrophages can process 
antigens released by M. ulcerans together with fragments of dead bacteria, initiating 
an inflammatory response where mycolactone has not yet diffused. Individuals 
infected with M. ulcerans may therefore develop a Th1 immune response, but the rate 
at which it develops varies from person to person [79]. 
A direct proof for the presence and the diffusion-pattern of mycolactone in infected 
human tissue does not exist, principally due to difficulties to develop immunological 
reagents suitable for reliable immunostaining against this macrolide toxin. 
Consequently, it is not known if and how mycolactone secretion is terminated in 
lesions that heal spontaneously. Various lines of research including histopathological 
data, cytokine expression profile analyses of punch biopsies, and mycolactone 
immunosuppressive studies both in vitro and in vivo (in mice and guinea pig) are 
indicative for the theory illustrated above [80-83].  
In this study, we took advantage of the exceptional opportunity to investigate, within 
the same lesions, how immune system infiltrates relates with M. ulcerans distribution 
and the tissue damage caused by its presence. This provided a broad picture of the 
host-pathogen interaction in active Buruli ulcer lesions. The mRNA expression data 
obtained with a broad spectrum of innate immune system markers (Chapter 4.2, [84]) 
clearly demonstrated that the presence of immune system components can vary 
considerably both between lesions and within different areas of the same Buruli ulcer 
lesion. TLR9 and CD123 immunohistochemical analysis were indicative for an 
extremely focal localization of the infiltrates even within a single small tissue sample. 
High expression of innate immunity markers and granulocyte infiltrates were 
sometimes found in areas with high bacterial DNA content (Chapter 4.2,[84]). The 
employed IS2404 real-time PCR quantified the entire load of M. ulcerans DNA in a 
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tissue block including live and dead bacteria. Therefore DNA concentrations did not 
necessarily correlate with the presence of mycolactone. These results reinforce the 
assumption of a patchy intercalating picture of Buruli ulcer lesions composed by 
different levels of tissue damage, immunosuppression and inflammatory infiltrates, 
probably determined by the diffusion pattern of mycolactone in the affected tissue.  
Buruli ulcer patients and many healthy household contacts show a specific humoral 
immune response to M. ulcerans antigens [85,86]. These data suggest that, in analogy 
to leprosy and tuberculosis [87], Buruli ulcer disease develops only in a limited 
proportion of the infected people. On the other hand, a lack of swollen lymph nodes 
and a reduced PBMC IFN-γ production in response to stimulation with live or dead 
M. bovis BCG and M. ulcerans has been repeatedly observed in Buruli ulcer affected 
people [80,88-90]. In this thesis, we extended the observation of a T cell anergy 
condition in Buruli ulcer patients to non-mycobacterial antigens (Chapter 4.1).  
The reasons for this systemic immunosuppression are largely unknown and could be 
of different origin (Figure 2). There might be a local constant influx of neutrophils, 
monocytes/macrophages [91] and DC initiated, maintained and exacerbated by the 
presence of necrotic tissue and potential bacteria fragments in the mycolactone free 
spots that can lead to an intralesional chronic condition possibly affecting the 
systemic immune system. Indicative for such an assumption are the presence of high 
IL-8, IL-6 and TNF-α expression, activated P-DC and M-DC, neutrophils and TLR9 
expression in all the analyzed lesions, which often exhibit coexpression profiles 
(Chapter 4.2). All three inflammatory cytokines have been already described as 
potential products released by TLR9 expressing cells after CpG ODN stimulation 
[92]. For example large amount of IL-8 and moderate IL-6 and TNF-α secretion were 
measured in human neutrophil granulocytes after bacterial CpG DNA stimulation 
[93]. IL-8 is one of the key regulators of leukocyte trafficking in inflammation. On 
the other side the Th2-polarizing properties [94] and inhibitory activities of IL-6 
towards an adaptive IFN-γ response have been suggested in M. tuberculosis [95]. The 
presence of high P-DC marker and IL-6 expression in the analyzed Buruli ulcer 
lesions in the absence of IFN-α gene expression raises therefore the issue of induced 
inhibitory responses in the lesions (Chapter 4.2). CpG ODN embodying 
immunosuppressive motifs have been already described [96,97]. Therefore we do not 
exclude the possibility of a further inhibitory effect exerted by DNA or other TLR 
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ligands of M. ulcerans bacteria fragments that may be present in mycolactone free 
spots of the lesions. A direct comparison of immune system activation in antibiotics-
untreated versus antibiotics-treated Buruli ulcer lesions would be very interesting and 
helpful to better evidence possible M. ulcerans key immunomodulators. Recently the 
combination of rifampicin (oral administration) with streptomycin (intramuscular 
administration) prior to surgical treatment has been shown to be useful in containing 
and diminishing the size of Buruli ulcer lesions and in reducing the recurrence rate 
[98]. Some preliminary immunohistochemical data indicate a better organized 
immune response in the treated lesions (Schütte personal communication). Therefore, 
M. ulcerans successful adaptive immune response may develop once an effective 
therapeutic intervention limits the production of mycolactone. 
The reversal of systemic immune suppression after surgical treatment-associated 
(Chapter 4.1) indicates that a local removal or elimination of the M. ulcerans bacteria 
may be sufficient to eradicate the disease. In this respect, topical treatments could be a 
solution that obviates the surgical and post-surgical treatments comprising skin 
grafting and rehabilitation of the affected limb. Creams generating topical nitrogen 
oxides promoted healing in one small controlled trial [99]. Nitric oxide was also 
shown to kill M. ulcerans in vitro [100]. Phenytoin powder probably does not kill the 
organism, but it appeared to promote healing, perhaps through acceleration of 
fibrogenesis [101]. Taking advantage of the temperature sensitivity of M. ulcerans, 
localized application of heat to lesions has been reported to help healing [102]. An 
optimized topical treatment using effective antibiotics or other anti-mycobacterial 
agents [103] could be a solution to avoid the orally administration of antibiotics. 
Disease prevention with an effective vaccine would be the most effective solution. 
From the above arguments, it appears that an effective vaccine for Buruli ulcer should 
prime an individual to mount a strong specific Th1 response to enhance his ability to 
control initial bacilli inoculation. On the other hand, the induction of a neutralizing 
antibody against mycolactone, which is essential for virulence, should in essence 
disarm the pathogen and prevent it from causing disease. Such a strategy will only be 
effective if the toxin can be neutralized by specific antibody responses. Mycolactone, 
which has a polyketide structure, is not ideal for the generation of highly affine mAbs, 
unless chemically modified. Therefore there is still the need to identify highly 
immunogenic M. ulcerans antigens for both vaccine development and serodiagnosis.  
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Figure 2 Various steps in the interaction between humans and mycobacteria. Exposure to 
mycobacteria does not always result in infection. Whether or not an established infection 
develops depends on innate immunity, alone or in conjunction with adaptive immunity. 
Immunological and clinical phenotypes may be detectable once mycobacterial infection is 
established and adaptive immunity to mycobacteria is involved. Each of the three steps in this 
process is under host and environmental control. Host factors may be genetic (e.g., mutation 
in a gene involved in immunity to mycobacteria) or nongenetic (e.g., skin lesion) and may 
have an impact at each stage of the interaction. Environmental factors may be mycobacterial 
(e.g., virulence factors) or related to the mode of exposure (e.g., direct inoculation) and may 
have an impact at each stage of the interaction.  
Casanova and Abel Annu. Rev. Immunol. 2002 
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Phase Ia clinical trial (Chapter 3.2) 
 
In this Chapter we report the protocol optimization, the ensemble of raw and 
processed data of the Phase Ia clinical trial illustrated in Chapter 3.2. Detailed final 
protocols of ex vivo IFNγ ELISpot and lymphoproliferation assays, the vaccine design 
and formulations are described in Chapter 3.2 (section Material and methods and 
Table I) 
 
Ex vivo IFNγ-ELISpot, optimization of the pellet pre-incubation step 
Fresh isolated PBMC were adjusted to 2 x 10 6 cells/ml and pre-incubated for 24 h in 
5 ml polypropylene round-bottom tube (pellet pre-incubation step [1]) at 37 °C, 5 % 
CO2 humified atmosphere with 1µg/ml tetanus toxoid (TT). The stimulated cells were 
transferred on the coated ELISpot plate either directly or by decanting the medium 
after centrifugation, and incubated at 37 °C for further 20 h. Significantly higher 
numbers of spots were obtained by changing the medium. A decanting step was 
therefore adopted for the entire trial with the following antigens: Phytohämagglutinin 
(PHA), TT, influenza antigens, malaria peptides (UK40, AMA49-C1) 
 
 
 
Figure 1 Example of ex vivo IFNγ ELISpot results obtained after decanting- or directly-
transfer to ELISpot plate of pellet pre-incubated PBMC. Fresh isolated PBMC of Volunteer A 
were stimulated with 1 µg/ml TT for 24 h, decanted (Columns 4-6) or transferred directly 
(Columns 7-9) to the IFNγ coated ELISpot plate. Rows: a) 2 x 105 cells/well; b) 1 x 105 
cells/well; c) 0.5 x 105 cells/well; d) 0.25 105 cells/well 
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Ex vivo IFNγ  ELISpot, plate-layout (Phase Ia clinical trial)  
 
 
 1-3 4-6 7-9 10-12 
A 2x105 c/well + IRIV 2x105 c/well + w/o S 2x105 c/well + IRIV 2x105 c/well + w/o S 
B 1x105 c/well + IRIV 1x105 c/well + w/o S 1x105 c/well + IRIV 1x105 c/well + w/o S 
C 0.5x105  c/well + IRIV 0.5x105  c/well + w/o S 0.5x105  c/well + IRIV 0.5x105  c/well + w/o S 
D 0.25x105 c/well+ IRIV 0.25x105  c/well + w/o S 0.25x105 c/well+ IRIV 0.25x105  c/well + w/o S 
E 2x105 c/well + UK40 2x105  c/well + AMA49-C1 2x105 c/well + UK40 2x105  c/well + AMA49-C1 
F 1x105 c/well + UK 40 1x105 c/well+ AMA49-C1 1x105 c/well + UK 40 1x105 c/well+ AMA49-C1 
G 2x105 c/well + TT  2x105 c/well + TT  
H 2x105 c/well+ PHA-P  2x105 c/well+ PHA-P  
 a) 
 
 
 
b) 
 
Figure 2 a) ex vivo IFNγ ELISpot plate-layout used during the Phase Ia clinical trial 
(November 2003-November 2004). Volunteer x (Columns 1-6), Volunteer y (Columns 7-12, 
evidenced in blue). w/o S: PBMC incubated only with cell culture medium, without any Ag-
stimulus. b) Example of a developed ex vivo IFNγ ELISpot plate. Columns 1-6, fresh isolated 
PBMC of Volunteer #42 21 days after the 2nd immunization, vaccine formulation: group 6 
(IRIV). Columns: 7-12, fresh isolated PBMC of Volunteer #39 21 days after the 2nd 
immunization, vaccine formulation: group 5 (AMA49-CPE&UK40). 
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Ex vivo IFNγ  ELISpot assessment with inactivated influenza (H1N1Sing/A) PBMC 
stimulation 
 
The measured influenza specific T cell response was an optimal positive control for 
the validity of the ELISpot assay and the chance to monitor on a large scale the pre-
existing inactivated influenza H1N1Sing/A specific effector memory CD4 T cells 
response in Caucasian healthy volunteers.  
Stimulation of inactivated influenza specific CD8 negative T cells  
Prior to clinical trial begin the stimulation of total PBMC with TT and inactivated 
influenza was compared to CD4 and CD8 depleted cells stimulation. Fresh isolated 
PBMC of Volunteer B were divided in three groups: (i) total PBMC, (ii) CD8 
depleted cells (incubation with anti-human CD8 mAb MicroBeads and depletion of 
labeled cells), (iii) CD4 depleted cells (incubation with anti-human CD4 mAb 
MicroBeads and depletion of labeled cells). Magnetic-labeling and depletion 
procedure were performed according to the manifactures instructions using LD 
columns and MidiMACS separator (Miltenyi Biotec, Germany). By harvesting the 
flow through with unlabeled cells a pure CD8 negative (CD8 depleted) or CD4 
negative (CD4 depleted) population was ready for further Ag-stimulation and in vitro 
cultivation (Figure 3). The cells of the three groups were stimulated with TT and 
inactivated influenza (1 µg/ml and 40 µg/ml, respectively) for 24 h. CD4 depletion 
induced a dramatic decrease in spot numbers; on the contrary CD8 depletion induced 
an increase in spot numbers compared to the whole PBMC (Figure 3c).  These results 
were consistent with published results [2] and were important to evaluate the 
influenza stimulation of the whole PBMC during the trial. 
Optimal concentration of influenza antigens-stimulated cells 
To better assess the ELISpot assay validity, the influenza stimulation was performed 
with four different cell concentrations (2x105, 1x105, 0.5x105 and 0.25x105, 
respectively). The obtained curves of each Volunteer are illustrated in Figures 4-7 
(ordered per vaccine formulation group and immunization time-point). Missing 2 x105 
cells/well values indicate that the wells were not countable by the AID ELISpot-
reader (too many overlapping spots). For further analysis of influenza ELISpot data 
only the 1 x 105 cells/well concentration was considerate because the spot were always 
distinct and countable by the AID reader and the curve plateau was not reached. 
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a) b)  
 
 1-3 4-6 7-9 10-12 
A 2x105 c/well + w/o 2x105 c/well + w/o 2x105 c/well + w/o  
B 1x105 c/well + w/o 1x105 c/well + w/o 1x105 c/well + w/o  
C 2x105  c/well + IRIV 2x105  c/well + IRIV 2x105  c/well + IRIV  
D 1x105 c/well+ IRIV 1x105 c/well+ IRIV 1x105 c/well+ IRIV  
E 2x105  c/well + TT 2x105  c/well + TT 2x105  c/well + TT  
F 1x105 c/well+ TT 1x105 c/well+ TT 1x105 c/well+ TT  
G     
H     
c)      PBMC  CD4 depletion  CD8 depletion 
 
    
d) 
Figure 3 Comparison of inactivated influenza and TT stimulation of total PBMC (black), 
CD4 depleted (green) and CD8 depleted (red) of Volunteer B. a-b) Double staining FACS 
control with FITC-labeled anti-CD4 mAb (FL1) and PE-labeled anti-CD8 mAb (FL2) of a) 
collected CD4 negative cells of CD4 depletion column b) collected CD8 negative of CD8 
depletion column. Total PBMC and the collected cells were further stimulated with 40 µg/ml 
inactivated influenza or 10 µg/ml TT and analysed in ex vivo IFNγ ELISpot c) plate-layout d) 
developed plate. 
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Figure 4. Summary of ex vivo IFNγ ELISpot results of fresh isolated PBMC stimulated with 
inactivated influenza (40 µg/ml); vaccine formulation group 3, 50 µg AMA49-CPE. Each 
point of the curves represents the triplicate- arithmetic mean of each cell concentra tion with 
the correspondent standard error mean (SEM).   
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Figure 5 Summary of ex vivo IFNγ ELISpot results of fresh isolated PBMC stimulated with 
inactivated influenza (40 µg/ml); vaccine formulation group 4, 50 µg UK39. Each point of the 
curves represents the triplicate- arithmetic mean of each cell concentration with the 
correspondent SEM.   
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Figure 6 Summary of ex vivo IFNγ ELISpot results of fresh isolated PBMC stimulated with 
inactivated influenza (40 µg/ml); vaccine formulation group 5, 50 µg AMA49-CPE&UK39 
immunization. Each point of the curves represents the triplicate- arithmetic mean of each cell 
concentration with the correspondent SEM. 
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Figure 7 Summary of ex vivo IFNγ ELISpot results of fresh isolated PBMC stimulated with 
inactivated influenza (40 µg/ml); vaccine formulation group group 6, IRIV (placebo). Each 
point of the curves represents the triplicate- arithmetic mean of each cell concentration with 
the correspondent SEM.  
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Raw data Phase Ia clinical trial 
 
Tables I-IV: ex vivo IFNγ  ELISpot and lymphoproliferation raw data 
 
Arithmetic means of triplicates with the correspondent standard deviation are reported 
in the tables I-IV by volunteer, immunization time-point and vaccine formulation and 
assay.  
Lymphoproliferation data are given in counts per minuts (cpm), (LKB-Wallac 
counter, Sweden) 
[Usually, Background counts (not stimulated cells) can range from 160 to 2’000 cpm. 
Range of counts for immunological recall to complex antigens (for example BCG and 
TT) are 5’000 to 100’000 counts per minute [3]]  
Ex vivo IFNγ ELISpot data are given in spot forming units (SFU) per well (AID-
reader system, Germany) using always the same settings. Only raw data of the 
optimal cell concentration are reported: 
100’000 cells/well for inactivated influenza stimulation 
200’000 cells/well for malaria peptide stimulation 
 
Figures 8-9: ex vivo IFNγ  ELISpot and lymphoproliferation processed data 
Lymphoproliferation (Figure 7): Stimulation Index (SI) was calculated by dividing the 
stimulated vs unstimulated arithmetic mean values.  
A response is typically considered positive when a SI > 2 is found [3]. 
Ex vivo IFNγ ELISpot (Figure 8): The negative control arithmetic mean (not 
stimulated cells) was subtracted from the positive arithmetic mean (stimulated cells).  
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Table 1: Raw data summary of Group 3, PEV 301 (AMA-CPE peptide) 
virosome-formulated vaccine incorporating the AMA-1 derived peptide conjugate AMA49-CPE, (n=8), dosis peptide: 50 µg/ml, dosis HA: 10 µg/ml
All assays were run in triplicate with fresh isolated PBMC
Assay: Proliferation (cpm: counts per minute) IFN-gamma Elispot  (SFU: spot forming units)
cell concentration: 200'000 cells/well 100'000 cells/well 200'000 cells/well
stimulus: stimulus:
Volunteer Immunization w/o SD IRIV SD AMA-1 SD CSP SD w/o SD IRIV SD w/o SD AMA-1 SD CSP SD
21 0 6'154 1'539 86'183 7'872 4'791 188 3'730 821 2 1 52 11 4 2 3 1 38 0
1 8'370 1'066 100'847 981 3'625 926 8'739 1'967 0 0 55 1 1 1 1 1 8 3
2 1'754 590 49'448 2'523 507 150 893 158 1 1 39 7 1 1 1 1 1 1
3 1'851 767 37'780 1'074 781 193 911 26 1 1 54 10 3 3 7 3 6 2
24 0 1'239 341 56'706 1'728 1'076 104 1'753 629 1 2 66 4 1 1 4 2 3 2
1 4'438 637 15'278 2'200 1'543 310 1'831 212 0 0 58 6 0 1 6 0 1 1
2 21'513 31'578 69'724 2'302 1'211 1'496 612 48 1 1 67 7 1 1 0 1 1 1
3 331 30 32'100 1'988 214 9 244 46 1 1 66 6 1 1 7 3 4 2
26 0 3'746 429 85'242 4'786 1'678 140 1'821 180 0 1 49 3 1 2 1 1 3 2
1 4'783 1'516 17'097 3'487 2'032 500 2'080 404 0 0 52 3 0 0 1 1 0 1
2 5'369 4'829 55'107 3'628 2'089 1'897 1'674 683 5 3 41 4 5 1 0 0 1 1
3 1'267 356 49'182 3'059 819 436 1'224 752 1 1 37 3 2 2 7 3 5 2
27 0 9'083 474 82'675 8'949 1'336 196 2'828 469 1 1 42 4 1 1 0 1 1 1
1 2'706 669 35'108 1'560 3'219 181 2'433 1'076 0 0 37 7 1 1 1 1 1 1
2 1'094 121 58'619 4'234 2'576 3'101 685 57 0 0 25 12 1 1 1 1 1 1
3 1'993 354 49'432 3'370 617 183 504 107 0 0 44 8 0 1 0 1 0 1
28 0 6'390 429 61'555 5'070 2'224 1'101 3'781 1'941 5 1 54 6 9 4 5 1 12 4
1 7'483 1'108 60'358 7'570 2'720 978 2'333 824 0 1 62 3 1 1 3 1 9 4
2 1'361 54 37'179 2'861 2'202 322 1'380 396 0 0 44 2 1 1 0 1 0 1
3 1'595 304 48'873 1'123 2'189 439 1'071 312 2 1 76 17 4 2 10 7 8 1
29 0 7'280 2'391 32'126 2'698 1'929 371 3'604 876 3 2 63 6 6 5 4 2 4 1
1 6'859 646 19'400 7'421 5'898 1'243 3'796 1'362 1 1 57 13 1 2 3 2 2 0
2 798 132 49'422 3'679 2860 1624 1'017 357 0 1 76 7 0 0 1 1 0 0
3 4'796 417 44'915 1'965 674 207 1'444 899 1 1 78 7 2 2 4 2 2 1
30 0 3'169 416 106'880 3'949 1907 360 1'864 215 1 1 35 5 1 1 0 0 23 7
1 4'840 306 47'712 8'570 9832 11528 2'689 562 0 1 67 12 1 1 2 1 1 1
2 627 420 55'488 1'608 2538 2383 435 134 0 1 54 12 0 0 4 1 2 1
3 754 205 52'666 2'177 490 229 1'138 606 1 1 76 5 2 2 6 2 1 1
32 0 4'515 1'045 93'031 4'757 1'572 698 1'925 503 0 0 63 10 0 1 1 0 2 2
1 8'184 1'037 55'808 4'934 1'938 268 3'101 315 0 0 44 4 0 0 0 1 0 1
2 5'667 1'728 31'041 7'404 4'127 1'743 3'894 687 2 1 74 15 1 1 1 1 5 2
3 1'128 499 29'769 2'393 788 437 1'591 1'088 1 1 88 14 2 1 4 2 2 2
0 21 days post pre-immunization w/o: PBMC incubated without any stimulus n.d.: not done
1 21 days post 1st immunization IRIV: PBMC incubated with inactivated Influenza A/Sing, 40 µg/ml HA (hemagglutinin) SD: standard deviation
2 21 days post 2nd immunization AMA-1: PBMC incubated with AMA49-C1(AMA49-CPE without lipid anchor, 40 µg/ml *   single
3 21 days post 3rd immunization CSP: PBMC incubated with UK40 (UK39 without lipid anchor), 40 µg/ml ** duplicate
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Table II: Raw data summary of Group 4, PEV 302 (UK39 peptide) 
virosome-formulated vaccine incorporating the CSP derived peptide conjugate UK39, (n=8), dosis peptide: 50 µg/ml, dosis HA: 10 µg/ml
All assays were run in triplicate with fresh isolated PBMC
Assay: Proliferation (cpm: counts per minute) IFN-gamma Elispot  (SFU: spot forming units)
cell concentration: 200'000 cells/well 100'000 cells/well 200'000 cells/well
stimulus: stimulus:
Volunteer Immunization w/o SD IRIV SD AMA-1 SD CSP SD w/o SD IRIV SD w/o SD AMA-1 SD CSP SD
20 0 3'667 615 82'531 9'473 848 152 789 46 1 2 43 6 3 2 2 2 42 9
1 2'256 944 28'167 3'039 1'560 648 1'290 508 0 1 25 2 1 1 2 1 1 1
2 1'121 458 59'725 3'791 568 425 1'122 345 0 1 35 6 1 0 2 3 2 1
3 535 197 37'512 4'230 571 143 446 281 2 1 44 7 1 1 9 2 5 3
22 0 n.d n.d n.d n.d 1 1 87 13 1 1 1 0 1 0
1 1'234 24 16'454 1'560 2'388 1'157 2'390 213 0 1 39 5 1 1 1 1 1 1
2 1'176 811 83'854 6'430 460 153 782 153 0 0 50 3 1 1 7 5 2 1
3 395 31 61'281 2'600 374 27 363 25 1 1 65 7 2 2 4 3 1 1
23 0 **5080 1'009 **43097 4'039 **3221 1'157 **2460 176 2 1 75 8 2 2 6 1 4 3
1 849 43 13'254 1'337 504 26 490 99 0 0 11 7 0 1 0 0 0 0
2 1'016 667 47'057 4'104 548 78 2'341 1'856 1 1 83 8 1 2 3 2 1 1
3 444 143 n.d n.d 1'140 1'352 3 2 85 6 8 1 14 6 15 5
25 0 2'094 165 50'066 2'480 1'217 382 2'225 553 0 1 52 6 0 1 2 1 2 1
1 1'240 397 14'059 2'750 916 125 1'868 431 1 1 47 6 0 0 2 1 1 1
2 2'561 1'378 46'313 3'163 461 102 900 32 1 1 40 2 1 1 1 1 0 1
drop out 3
31 0 1'385 303 54'713 2'102 1'478 896 1'525 513 1 2 55 9 3 2 2 2 1 1
1 1'758 214 75'400 1'439 603 84 1'932 362 0 1 54 1 0 1 2 2 1 1
2 1'017 242 34'017 4'052 732 409 3'661 2'634 0 1 39 9 1 1 1 1 5 2
3 407 30 29'454 6'806 288 49 465 344 3 2 44 4 6 4 5 2 5 3
33 0 5'043 550 38'088 1'017 7'169 1'552 4'667 537 0 1 89 3 1 1 1 1 0 1
1 4'564 624 35'140 1'411 2'520 571 7'341 3'055 0 0 79 3 0 1 6 0 1 1
2 1'754 942 338 313 688 680 499 130 1 1 69 6 1 1 0 1 1 1
3 1'267 416 27'858 345 858 446 809 120 3 1 113 5 8 1 6 2 7 4
35 0 5'173 503 78'142 10'515 4655 366 4'520 605 8 3 66 13 4 2 3 2 42 11
1 773 219 5'810 831 485 25 1'383 366 1 1 15 5 0 0 1 1 1 1
2 3'116 760 59'249 10'190 3970 4703 1'355 103 0 0 53 8 0 1 1 1 0 0
3 384 19 19'942 4'002 388 103 430 81 3 0 40 5 1 2 6 4 4 2
36 0 **4093 600 **12280 1'018 **1504 23 **2815 387 1 1 37 3 1 1 3 2 1 1
1 11'203 632 20'886 8'734 4'932 2'172 2'677 57 0 0 45 6 0 1 1 1 0 0
2 854 302 32'279 4'141 579 72 672 180 0 1 53 3 0 0 0 0 2 1
3 646 226 16'922 1'651 275 59 240 20 1 1 34 12 3 3 9 6 5 6
0 21 days post pre-immunization w/o: PBMC incubated without any stimulus n.d.: not done
1 21 days post 1st immunization IRIV: PBMC incubated with inactivated Influenza A/Sing, 40 µg/ml HA (hemagglutinin) SD: standard deviation
2 21 days post 2nd immunization AMA-1: PBMC incubated with AMA49-C1(AMA49-CPE without lipid anchor, 40 µg/ml *   single
3 21 days post 3rd immunization CSP: PBMC incubated with UK40 (UK39 without lipid anchor), 40 µg/ml ** duplicate
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Table III: Raw data summary of Group 5, PEV 301& PEV 302 (AMA-CPE & UK39- peptides) 
virosome-formulated vaccine incorporating AMA49-CPE & UK39, (n=8), dosis peptide: 50 µg/ml, dosis HA: 20 µg/ml
All assays were run in triplicate with fresh isolated PBMC
Assay: Proliferation (cpm: counts per minute) IFN-gamma Elispot (SFU: spot forming units)
cell concentration: 200'000 cells/well 100'000 cells/well 200'000 cells/well
stimulus: stimulus:
Volunteer Immunization w/o SD IRIV SD AMA-1 SD CSP SD w/o SD IRIV SD w/o SD AMA-1 SD CSP SD
37 0 605 113 56'125 3'069 241 81 444 104 1 2 38 8 2 2 3 1 3 1
1 329 59 60'453 4'735 1'325 1'849 303 45 0 1 60 6 0 0 0 1 0 1
2 648 162 70'543 1'133 598 291 1'223 298 0 1 83 5 0 1 5 5 1 1
3 371 60 **27603 2,7 339 56 308 27 0 0 62 2 0 0 1 1 1 1
38 0 395 63 16'703 3'780 455 352 389 86 0 1 16 4 1 1 4 18 2 2
1 297 18 45'847 4'630 206 31 338 126 0 1 26 3 0 1 1 1 0 0
2 459 11 67'783 2'820 747 456 337 134 0 1 42 1 0 1 1 2 0 1
3 298 39 **16792 708 277 83 266 38 1 1 68 3 0 0 1 1 0 1
39 0 2'842 2'383 38'083 4'815 3'459 4'318 2'526 967 1 1 11 2 3 1 4 3 2 2
1 995 311 53'548 1'128 4'369 2'800 5'731 1'813 1 1 44 7 0 1 1 1 16 11
2 2'262 1'002 42'079 3'676 6'285 3'142 4'324 1'524 1 1 41 5 0 1 5 3 1 1
3 2'778 641 *22779 **5181 1'648 1'204 577 1 2 21 5 1 2 2 1 0 1
41 0 799 385 51'110 8'860 1'195 1'326 386 2 2 1 33 7 2 1 3 5 6 3
1 1'258 443 67'894 2'133 5'176 4'479 2'224 1'254 3 0 108 5 6 2 15 2 17 11
2 1'541 260 70'564 1'211 4'180 1'486 1'574 644 1 1 80 6 1 0 3 2 2 2
3 1'393 49 33'446 2'649 3'537 597 644 69 1 1 67 4 1 1 0 1 0 1
43 0 728 23 78'167 5'137 694 91 542 75 1 1 23 4 0 1 1 1 48 6
1 239 18 45'745 2'857 856 1'170 251 9 0 0 60 6 1 1 1 2 1 1
drop out 2
3
44 0 483 134 53'318 5'847 447 122 434 47 1 1 22 5 3 2 6 5 5 5
1 730 76 65'535 4'330 627 253 1'333 1'077 1 1 68 3 4 5 12 4 8 2
2 1'305 208 61'086 7'129 1'417 682 563 85 2 1 78 4 4 1 7 2 10 5
3 311 39 4'903 399 111 310 68 2 1 34 10 2 1 0 0 0 1
45 0 498 80 41'777 4'107 525 24 441 62 2 1 31 4 6 1 10 12 18 11
1 528 98 43'954 742 378 167 727 363 1 1 46 3 2 2 0 0 1 1
2 560 135 52'611 2'195 940 430 457 50 0 0 44 8 2 3 0 1 1 2
3 742 12 24'300 1'611 1'195 1'172 369 66 1 1 29 3 1 1 0 0 0 1
46 0 2'012 262 56'883 2'966 1'018 87 834 266 14 2 62 6 11 8 24 7 18 11
1 575 102 39'865 2'574 1'352 898 404 27 0 1 90 8 1 1 2 1 1 1
2 1'820 165 52'087 732 4'598 2'835 884 153 2 2 66 3 1 1 2 4 1 0
3 760 65 n.d. 953 669 457 32 2 1 20 4 2 1 2 0 0 1
0
1
2 *   single
3 ** duplicate
21 days post pre-immunization w/o: PBMC incubated without any stimulus n.d.: not done
21 days post 1st immunization IRIV: PBMC incubated with inactivated Influenza A/Sing, 40 µg/ml HA (hemagglutinin) SD: standard deviation
21 days post 2nd immunization AMA-1: PBMC incubated with AMA49-C1(AMA49-CPE without lipid anchor, 40 µg/ml
21 days post 3rd immunization CSP: PBMC incubated with UK40 (UK39 without lipid anchor), 40 µg/ml
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Table IV: Raw data summary of Group 6, IRIV (virosome) 
virosome-formulated vaccine incorporating the AMA-1 derived peptide conjugate AMA49-CPE, (n=8), dosis peptide: 50µg/ml, dosis HA: 10 µg/ml
All assays were run in triplicate with fresh isolated PBMC
Assay: Proliferation (cpm: counts per minute) IFN-gamma Elispot  (SFU: spot forming units)
cell concentration: 200'000 cells/well 100'000 cells/well 200'000 cells/well
stimulus: stimulus:
Volunteer Immunization w/o SD IRIV SD AMA-1 SD CSP SD w/o SD IRIV SD w/o SD AMA-1 SD CSP SD
2 0 6'706 1'378 79'212 16'984 3'278 1'340 4'356 831 3 2 56 3 4 3 51 6 0 1
1 6'045 1'441 73'407 4'291 4'664 236 6'153 899 45 4 96 10 65 13 55 10 82 9
2 2'965 326 64'563 3'792 1'912 122 2'832 944 0 1 27 4 1 2 0 0 0 0
3 3'617 786 63'396 7'518 1'328 402 1'078 159 1 0 83 3 1 1 0 1 1 1
12 0 2'667 594 46'466 15'712 4'229 2'389 3'127 802 2 3 76 6 4 4 43 11 35 8
1 4'284 596 99'329 14'850 2'491 1'162 1'748 489 17 2 67 3 46 17 79 1 50 9
2 3238 645 80'020 1'740 2'505 189 3'395 625 0 1 38 11 0 0 1 1 1 1
3 425 63 39'083 5'891 321 32 330 58 0 1 51 4 3 3 8 2 3 2
19 0 5'600 468 62'376 18'077 4'043 3'618 n.d 2 2 50 2 5 3 5 2 3 2
1 6'248 521 95'683 4'053 1'268 275 1'918 690 1 1 29 4 1 1 1 1 2 2
2 457 144 44'203 4'471 470 49 1'725 1'564 0 0 25 3 1 0 0 0 1 1
3 960 683 43'958 986 2'006 2'767 649 95 1 1 42 14 2 1 4 2 2 2
34 0 4'900 1'359 89'587 5'826 9'669 2'963 3'912 234 0 0 36 0 1 1 0 0 1 0
1 2'519 207 37'800 2'193 1'889 195 4'231 488 1 1 44 12 0 0 0 1 0 1
2 13'364 1'193 74'570 10'821 10'155 6'100 7'632 877 2 1 28 6 1 1 1 1 1 1
3 3'840 749 35'990 2'707 2'462 269 3'703 434 3 2 32 5 2 0 6 6 4 3
40 0 982 1'047 47'739 5'779 2'320 551 406 58 1 1 30 6 1 1 13 12 8 3
1 420 31 54'905 2'428 506 77 440 15 1 0 53 4 0 1 0 0 0 1
2 1'859 233 50'906 2'422 1'290 787 580 61 1 1 42 2 1 1 3 4 2 2
3 653 62 19'552 1'524 543 283 456 65 1 1 34 3 1 1 1 1 0 1
42 0 532 90 62'459 1'660 519 195 537 187 1 1 55 6 3 2 6 2 4 1
1 861 772 50'117 5'437 256 44 305 70 0 0 88 3 0 0 1 2 1 1
2 449 51 55'808 2'858 529 224 1'640 641 1 1 61 3 0 1 0 1 0 1
3 296 11 *17190 269 10 363 89 2 1 60 7 2 1 0 0 0 1
0 21 days post pre-immunization w/o: PBMC incubated without any stimulus n.d.: not done
1 21 days post 1st immunization IRIV: PBMC incubated with inactivated Influenza A/Sing, 40 µg/ml HA (hemagglutinin) SD: standard deviation
2 21 days post 2nd immunization AMA-1: PBMC incubated with AMA49-C1(AMA49-CPE without lipid anchor, 40 µg/ml *   single
3 21 days post 3rd immunization CSP: PBMC incubated with UK40 (UK39 without lipid anchor), 40 µg/ml ** duplicate
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Figure 8 Summary of lymphoproliferation results considering the different immunization groups. Boxes show the distribution of results, the resting line 
indicating median response, upper and lower box boundaries showing 25th and 75th centiles, and the whiskers show adjacent values 
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Figure 8 Summary of lymphoproliferation results considering the different immunization groups
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Figure 9 Summary of ex-vivo IFN-γ Elispot results considering the different immunization groups
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Figure 9 Summary of ex vivo IFN-γ ELISpot results considering the different immunization groups. Boxes show the distribution of results, the resting line 
indicating median response, upper and lower box boundaries showing 25th and 75th centiles, and the whiskers show adjacent values  
     Chapter 6.1 - Appendix 206 
Figure 10 Overview of inactivated influenza lymphoproliferation and ex vivo ELISpot results (y-axes) at a single volunteers level (x-axes) by 
immunization time-point and vaccine formulation group 
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Figure 10 Overview of lymphoproliferation and ex-vivo Elispot results assay at single volunteers level
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Background 
In Chapter 4.2 we showed a local activation of the innate immune system in Buruli 
ulcer lesions. The mRNA of plasmacytoid DC (P-DC) and myeloid DC (M-DC) 
specific surface markers (CD123 and CD11c, respectively) was detected by 
quantitative real time PCR. Their activation was suggested by a positive correlations 
with CD83 and TNF-α mRNA expression. Furthermore, mRNA co-expression of P-
DC marker was observed with IL-6 but not IFN-α and P-DC expressing TLR9 were 
evidenced by immunohistochemistry analysis. IFN-γ mRNA was detected in one of 
the three analysed BU lesions, where it was present in low amount and only in highly 
focal areas mirroring the systemic IFN-γ down-regulation. 
Short term objective 
Investigate the mechanisms of P-DC activation by M. ulcerans 
Long term objective 
Study the consequences of intralesionally M. ulcerans immunopathogenicity on 
systemic IFN-γ immunosuppression.  
A better understanding of the crosstalk between the host and M. ulcerans has the final 
goal to control the disease in a more effective and rational way. 
M. ulcerans genome 
Genetic diversity of Mycobacteria is driven by the activity of mobile DNA such as 
insertion sequences (IS). M. ulcerans has at least two high copy number IS elements: 
IS2404 and IS2606. IS2404 is repeated about 200 times in the entire genome of M. 
ulcerans () and contains large amount of CpG motifs, which are known to activate the 
innate immune response by binding to TLR9 receptors. 
Hypothesis 
The M. ulcerans IS2404 directly activate the P-DC through TLR9  
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Material and Methods 
Figure 1 ODN used for in vitro stimulation assays. Positive and negative Buruli ulcer ODN 
were selected from the AA IS2404 sequence following the CpG criteria described in the 
literature. Positive and negative control ODN (2006, IMT022) were included in the analysis. 
 
Figure 2 In vitro model. First, immature P-DC were positively isolated by magnetic cell 
sorting (MACS) from PBMC with anti-human BDCA4+ MicroBeads. From the BDCA4- 
cells, monocytes were positively isolated with CD14+ MicroBeads and cultured with IL-4 and 
GM-CSF for 6 days to obtain immature M-DC.  Both immature DC subsets were stimulated 
with IL-3, LPS, bacterial- or literature- ODNs, respectively. After 24 h incubation they were 
characterized for CD80 and CD86 expression by flow cytometry and after 3 days, collected 
supernatants were tested by ELISA for cytokine release (IFN-γ, IFN-α, TNF-α, IL-4, IL-6, 
IL-10, IL-12). CD123 (IL-3Rα) 
Buruli ulcer ODN (selected from the M. ulcerans genome IS2404):
– Buruli positive (BU +) 5’-ACG ATC GAG TTG GTT ACT GTT CGT CGT T-3’
– Buruli negative (BU -) 5’-AGC ATG CAG AAG GAA AGA GAA GCA GCA A-3’
Optimized ODN from literature:
– positive (2006)                     5’-TCG TCG TTT TGT CGT TTT GTC GTT-3’
– negative (IMT022) 5’-TGC TGC AAA AGA CGA AAA GAG CAA-3’
(Hartmann and Krieg, Journal of Immunology 2000)
Chapter 6.2 - Appendix 
 
210 
 
Results  
 
Figure 3 Phenotype FACS profiles. Immature P-DC isolated from PBMC were stimulated 
for 24 h with BU + (IS2404 CpG ODN), 2006 (literature positive CpG ODN) and IMT022 
(literature negative ODN) and IL-3 and characterized for CD80 (blue) and CD86 (pink) 
expression by flow cytometry. Black lines indicate the CD80 and CD86 expression of not 
stimulated precursor P-DC. Representative histograms are shown out of four similar 
experiments. 
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Figure 4 Cytokine profiles. The immature M-DC and P-DC were incubated for 3 days with 
the stimuli reported on the y-axes (BU +, IS2404 CpG ODN; 2006, literature positive CpG 
ODN) and BU -, IS2404 negative ODN). The correspondent cytokine release was measured 
by ELISA. The release of IFN-γ, IL-4, IL-6. IL-10, IL-12, TNF-α was measured for both DC 
subsets, IFN-α only for P-DC. Only the cytokines giving a detectable optical density are 
reported. 
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Summary  
An undergoing maturation process of peripheral blood isolated immature P-DC  
stimulated with BU+ ODN is suggested by the upregulation of the CD80 and CD86 
surface markers. Moreover, IL-6 release, but not IFN-γ and IL-12 was detected in all 
tested donors. In contrast, TNF-α and IFN-α were respectively detected only in one 
donor. TNF-α in consistent amount (1585 pg/ml) and IFN-α in relative low amount 
(532 pg/ml). As a negative control, the immature M-DC were stimulated with BU+ 
ODN which, as expected, did not show any CD40, CD80 and CD86 upregulation and 
cytokine release indicating a specific interaction of BU + ODN with TLR9. These 
preliminary results suggest that with the selected M. ulcerans CpG ODN is possible, 
in some extent, to reproduce the local in vivo situation of Buruli ulcer lesions.   
Outlook 
(i) Further characterize the stimulatory properties of the natural encoded BU+ ODN 
by evaluating the P-DC priming capacities of the adaptive immune response after 
undergoing BU+ ODN maturation [1]. Such a well characterized TLR9 ligand could 
represent a new candidate for a group of immunosuppressive agents [1-3]. (ii) 
Compare the P-DC activation employing genomic DNA of different Mycobacteria 
[4]. (iii) Compare the immune system activation in antibiotics treated [5] versus 
antibiotics untreated Buruli ulcer lesions to better evidence M. ulcerans the presence 
of possible key immunomodulators. 
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